{
  "responseHeader":{
    "status":0,
    "QTime":0,
    "params":{
      "q":"(Doc_abstract: melanoma OR Doc_title: melanoma) AND (Doc_abstract: NF1 truncation OR Doc_title: NF1 truncation)"}},
  "response":{"numFound":172,"start":0,"docs":[
      {
        "Doc_abstract":"Desmoplastic melanoma (DM) is a rare variant of melanoma with distinct clinical, histopathologic, and immunohistochemical features. Clinically, DM differs from conventional melanoma by a higher propensity for local recurrence and less frequent metastatic spread to regional lymph nodes. In its pure form, DM has a distinct appearance displaying a low density of fusiform melanocytes in a collagen-rich matrix. Whereas a number of mutations have been identified in primary melanoma, including BRAF, NRAS, GNAQ, GNA11, and KIT, and the occurrence of these mutations has been found to correlate to some extent with the histopathologic features, anatomic site, and/or mode of sun exposure, no distinct set of mutations has so far been reported for DM. To study the potential association of neurofibromin (NF1) mutations with DM, we examined 15 desmoplastic and 20 non-DMs by next-generation sequencing. Mutations of the NF1 gene were found in 14 of 15 (93%) DMs and 4 of 20 (20%) non-DMs. The high frequency of NF1 mutations in DMs suggests an important role for NF1 in the biology of this type of melanoma. ",
        "Doc_title":"NF1 Mutations Are Common in Desmoplastic Melanoma.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"26076063",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;DNA Mutational Analysis;Female;Genes, Neurofibromatosis 1;Genetic Predisposition to Disease;High-Throughput Nucleotide Sequencing;Humans;Male;Melanoma;Middle Aged;Mutation;Phenotype;Skin Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;methods;genetics;pathology;genetics;pathology",
        "_version_":1605746276934090753},
      {
        "Doc_abstract":"A 64-year-old man with neurofibromatosis type 1 (NF1) developed a primary malignant melanoma of the anus. Genetic analysis of the resected tumor confirmed loss of heterozygosity (LOH) of the NF1 gene. Anorectal malignant melanoma in NF1 is extremely rare, and genetic studies of the NF1 gene in such patients have not been reported. The allelic loss detected in the present patient supports the previously raised idea that NF1 can function as a tumor suppressor gene in the development of malignant melanoma in patients with NF1.",
        "Doc_title":"Allelic loss of the NF1 gene in anal malignant melanoma in a patient with neurofibromatosis type 1.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"11706558",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Anus Neoplasms;Genes, Neurofibromatosis 1;Genes, Tumor Suppressor;Humans;Loss of Heterozygosity;Male;Melanoma;Middle Aged;Neurofibromatosis 1",
        "Doc_meshqualifiers":"etiology;genetics;genetics;etiology;genetics;complications;genetics",
        "_version_":1605875632554639360},
      {
        "Doc_abstract":"We report on whole-exome sequencing (WES) of 213 melanomas. Our analysis established NF1, encoding a negative regulator of RAS, as the third most frequently mutated gene in melanoma, after BRAF and NRAS. Inactivating NF1 mutations were present in 46% of melanomas expressing wild-type BRAF and RAS, occurred in older patients and showed a distinct pattern of co-mutation with other RASopathy genes, particularly RASA2. Functional studies showed that NF1 suppression led to increased RAS activation in most, but not all, melanoma cases. In addition, loss of NF1 did not predict sensitivity to MEK or ERK inhibitors. The rebound pathway, as seen by the induction of phosphorylated MEK, occurred in cells both sensitive and resistant to the studied drugs. We conclude that NF1 is a key tumor suppressor lost in melanomas, and that concurrent RASopathy gene mutations may enhance its role in melanomagenesis. ",
        "Doc_title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.",
        "Journal":"Nature genetics",
        "Do_id":"26214590",
        "Doc_ChemicalList":"AZD 6244;Antineoplastic Agents;Benzimidazoles;Neurofibromin 1;ras Proteins",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzimidazoles;DNA Mutational Analysis;Drug Resistance, Neoplasm;Exome;Genetic Association Studies;Genetic Predisposition to Disease;Humans;Inhibitory Concentration 50;Kaplan-Meier Estimate;Loss of Heterozygosity;Male;Melanoma;Mutation, Missense;Neurofibromin 1;Sequence Analysis, RNA;Skin Neoplasms;Sunlight;Tumor Cells, Cultured;ras Proteins",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;etiology;genetics;genetics;drug therapy;etiology;genetics;adverse effects;genetics",
        "_version_":1605756688982343680},
      {
        "Doc_abstract":"Neurofibromatosis type 1 (NF1) is the most common hereditary neurocutaneous disorder and it is associated with an elevated risk for malignant tumors of tissues derived from neural crest cells. The NF1 gene is considered a tumor suppressor gene and inactivation of both copies can be found in NF1-associated benign and malignant tumors. Melanocytes also derive from neural crest cells but melanoma incidence is not markedly elevated in NF1. In this study we could analyze a typical superficial spreading melanoma of a 15-year-old boy with NF1 for loss of heterozygosity (LOH) within the NF1 gene. Neurofibromatosis in this patient was transmitted by the boy's farther who carried the mutation NF1 c. 5546 G/A.;Melanoma cells were isolated from formalin-fixed tissue by liquid coverslip laser microdissection. In order to obtain statistically significant LOH data, digital PCR was performed at the intragenic microsatellite IVS27AC28 with DNA of approx. 3500 melanoma cells. Digital PCR detected 23 paternal alleles and one maternal allele. Statistical analysis by SPRT confirmed significance of the maternal allele loss.;To our knowledge, this is the first molecular evidence of inactivation of both copies of the NF1 gene in a typical superficial spreading melanoma of a patient with NF1. The classical double-hit inactivation of the NF1 gene suggests that the NF1 genetic background promoted melanoma genesis in this patient.",
        "Doc_title":"Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR.",
        "Journal":"Molecular cancer",
        "Do_id":"16961930",
        "Doc_ChemicalList":"DNA, Neoplasm;Neurofibromin 1",
        "Doc_meshdescriptors":"Adolescent;Alleles;Chromosomes, Human, Pair 17;DNA Mutational Analysis;DNA, Neoplasm;Gene Deletion;Humans;Loss of Heterozygosity;Male;Melanoma;Microsatellite Repeats;Neurofibromatosis 1;Neurofibromin 1;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;chemistry;genetics;genetics;complications;pathology;genetics;complications;genetics;genetics;methods",
        "_version_":1605823986017501184},
      {
        "Doc_abstract":"NF1 is a tumour suppressor gene, germline mutations of which lead to neurofibromatosis type 1 syndrome. Patients develop benign tumours from several types of cells including neural crest-derived cells. NF1 somatic mutations also occur in 15% of sporadic melanoma, a cancer originating from melanocytes. Evidence now suggests the involvement of NF1 mutations in melanoma resistance to targeted therapies. Although NF1 is ubiquitously expressed, genetic links between NF1 and genes involved in melanocyte biology have been described, implying the lineage-specific mechanisms. In this review, we summarize and discuss the latest advances related to the roles of NF1 in melanocyte biology and in cutaneous melanoma. ",
        "Doc_title":"Multiple roles of NF1 in the melanocyte lineage.",
        "Journal":"Pigment cell & melanoma research",
        "Do_id":"27155159",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605842348577652736},
      {
        "Doc_abstract":"Neurofibromatosis 1 (NF1) occurs in 1:2000 births. The main diagnostic signs are visible on the skin and this opens several interesting aspects for dermatological point of view. The NF1 syndrome is caused by mutations in the NF1 gene which encodes the tumor suppressor protein neurofibromin. Neurofibromin functions as a Ras-GTPase activating protein (RasGAP), and NF1 mutations lead to over-activation of the Ras signaling pathway. The NF1 gene and neurofibromin have intriguing functions in keratinocytes and melanocytes. Neurofibromin regulates melanin synthesis and keratinocyte differentiation in a currently unknown manner. The NF1 gene has also an important but poorly understood role in tumorigenesis and cancer. Compared to the general population, NF1 patients have a fivefold risk for cancer and a more than 2000-fold risk for neurogenic malignancies. Mutations of the NF1 gene are common in numerous cancer types in patients without NF1, and this suggests a more general role for the NF1 gene in oncogenesis. In melanoma, NF1 mutations seem to drive tumorigenesis and contribute to drug resistance. In this article we review the literature on neurofibromin with special attention to keratinocytes, melanocytes, NF1 related tumors, and melanoma. This article is protected by copyright. All rights reserved.",
        "Doc_title":"Neurofibromatosis type 1 (NF1) gene: Beyond cafÃ© au lait spots and dermal neurofibromas.",
        "Journal":"Experimental dermatology",
        "Do_id":"27622733",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746311678656512},
      {
        "Doc_abstract":"Neurofibromatosis 1 (NF1) is a genetically transmitted disease occurring approximately once in 3000 live births and resulting from mutations of the NF1 gene that encodes a protein named neurofibromin, a negative regulator of the ras-dependent pathway. An excess of neoplasia especially tumours of neuroectodermal origin is classically observed. The occurrence of malignant melanoma in patients with NF1 has already been described in scattered clinical reports but little is known as to the characteristics of melanoma arising in NF1 patients. A multicentric retrospective study was conducted on a panel of French referring centres for a period of 13 years to identify patients with both melanoma and NF1. Patients with mucosal or ocular melanoma were excluded. The diagnosis of malignant melanoma was based on specific histology whereas NF1 was identified according to the criteria proposed by the NIH Consensus Conference. All patient fulfilling criteria for both melanoma and NF1 were investigated using a common procedure recording clinical and histological data along with prognostic factors for the two diseases. Eleven patients were identified with both diseases. The clinical pattern of NF1 was quite similar to the classical form of the disease, but some unusual features were present as regards to the melanoma: a sex-ratio of 10 women for one man and an average age lower than expected (median age=33 years) for melanoma occurrence. Among prognostic factors, median thickness was high compared to large series of melanoma in the literature (3.20 versus 1.5 mm). Another neoplasia occurred in three patients. An increase in melanoma incidence in patients with NF1 remains hypothetical but our small series of malignant melanoma arising in NF1 patients displays a large female preponderance, a higher thickness than expected and a frequent association with a second neoplasia. The peculiar female proneness for cancer whatever its localization and the risk of multiple neoplasias have already been reported in NF1 patients and could be true for malignant melanoma as well.",
        "Doc_title":"Cutaneous malignant melanoma and neurofibromatosis type 1.",
        "Journal":"Melanoma research",
        "Do_id":"15057048",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Female;Follow-Up Studies;Humans;Male;Melanoma;Middle Aged;Neoplasm Staging;Neurofibromatosis 1;Retrospective Studies;Sex Distribution;Skin Neoplasms",
        "Doc_meshqualifiers":"complications;diagnosis;complications;diagnosis;complications;diagnosis",
        "_version_":1605818711232479233},
      {
        "Doc_abstract":"Studies on cytogenetic abnormalities and cell lines have implicated chromosome 1p32 as being important in the pathogenesis of melanoma. Genetic linkage studies have also mapped a melanoma-susceptibility locus to chromosome 1p. The gene TAL1 is present on chromosome 1p32, and deletions within it are the commonest chromosomal abnormality in T-acute lymphoblastic leukaemia (T-ALL). A melanoma cell line harbouring a 1p32 deletion involving the TAL1 gene and the presence of TAL1 protein in developing mouse melanocytes led us to investigate whether TAL1 deletions and/or TAL1 protein expression occur in sporadic melanomas. DNA extracted from 32 fresh melanomas was amplified by standard polymerase chain reaction for the four common deletions of the TAL1 gene that occur in T-ALL. In addition, frozen and paraffin-embedded sections of these melanomas were stained with monoclonal antibodies that detect full-length and truncated TAL1 protein. The results of the study show that deletions of TAL1 do not occur in melanoma. Indeed, full and truncated TAL1 protein also could not be detected immunohistochemically in the paraffin-embedded and frozen sections of the melanomas. We conclude that the TAL1 gene and its protein are probably not directly involved in the oncogenesis of melanomas.",
        "Doc_title":"TAL1 gene deletions and TAL1 protein expression in sporadic melanoma.",
        "Journal":"Melanoma research",
        "Do_id":"7496160",
        "Doc_ChemicalList":"Basic Helix-Loop-Helix Transcription Factors;DNA-Binding Proteins;Proto-Oncogene Proteins;Tal1 protein, mouse;Transcription Factors;TAL1 protein, human",
        "Doc_meshdescriptors":"Base Sequence;Basic Helix-Loop-Helix Transcription Factors;Chromosomes, Human, Pair 1;DNA-Binding Proteins;Frozen Sections;Gene Deletion;Humans;Immunohistochemistry;Melanoma;Molecular Sequence Data;Paraffin Embedding;Proto-Oncogene Proteins;Transcription Factors",
        "Doc_meshqualifiers":"analysis;biosynthesis;genetics;genetics;metabolism;pathology",
        "_version_":1605811946790060032},
      {
        "Doc_abstract":"The gene responsible for neurofibromatosis type 1 (NF1) has sequence homology to the GTPase-activating protein (GAP) and demonstrates GAP activity against ras p21. To study tissue-specific and/or tumor-specific expression of the NF1 gene product, now called neurofibromin, immunostaining and immunoblotting were applied to the N-nitroso-N-ethylurea (ENU)-induced Syrian hamster neurofibromatosis model using polyclonal antibodies against the NF1 fusion protein and a synthetic peptide. Strong expression was observed specific to the Schwann cells of the normal peripheral nerves by immunostaining. Neoplastic Schwann cells showed specific binding of anti-NF1; however, the frequency of positive cells was diminished. Immunoblotting also revealed positive expression of the 250-kd NF1 gene product in the brain, the normal peripheral nerves, and 7 of 14 ENU-induced neurofibromas. Although ENU-induced melanoma and Wilms' tumor were negative for neurofibromin, foci of Schwannian differentiation in both primary and transplanted melanomas were positive. These results suggest that neurofibromin plays some role in differentiation and growth regulation of the Schwann cell.",
        "Doc_title":"Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell.",
        "Journal":"The American journal of pathology",
        "Do_id":"8129040",
        "Doc_ChemicalList":"Glial Fibrillary Acidic Protein;Laminin;Neurofibromin 1;Proteins;DNA",
        "Doc_meshdescriptors":"Animals;Brain Chemistry;Cell Differentiation;Cricetinae;DNA;Gene Expression;Genes, Neurofibromatosis 1;Glial Fibrillary Acidic Protein;Immunoblotting;Immunohistochemistry;Laminin;Melanoma;Neurofibroma;Neurofibromatosis 1;Neurofibromin 1;Peripheral Nerves;Proteins;Schwann Cells;Sequence Homology, Nucleic Acid;Wilms Tumor",
        "Doc_meshqualifiers":"analysis;genetics;genetics;genetics;analysis;genetics;metabolism;analysis;genetics;metabolism;genetics;pathology;genetics;pathology;genetics;pathology;chemistry;pathology;analysis;genetics;metabolism;chemistry;metabolism;pathology;genetics;pathology",
        "_version_":1605759809195343872},
      {
        "Doc_abstract":"RAF inhibitors such as vemurafenib and dabrafenib block BRAF-mediated cell proliferation and achieve meaningful clinical benefit in the vast majority of patients with BRAF(V600E)-mutant melanoma. However, some patients do not respond to this regimen, and nearly all progress to therapeutic resistance. We used a pooled RNA interference screen targeting more than 16,500 genes to discover loss-of-function events that could drive resistance to RAF inhibition. The highest ranking gene was NF1, which encodes neurofibromin, a tumor suppressor that inhibits RAS activity. NF1 loss mediates resistance to RAF and mitogen-activated protein kinase (MAPK) kinase kinase (MEK) inhibitors through sustained MAPK pathway activation. However, cells lacking NF1 retained sensitivity to the irreversible RAF inhibitor AZ628 and an ERK inhibitor. NF1 mutations were observed in BRAF-mutant tumor cells that are intrinsically resistant to RAF inhibition and in melanoma tumors obtained from patients exhibiting resistance to vemurafenib, thus showing the clinical potential for NF1-driven resistance to RAF/MEK-targeted therapies.",
        "Doc_title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
        "Journal":"Cancer discovery",
        "Do_id":"23288408",
        "Doc_ChemicalList":"Neurofibromin 1;Protein Kinase Inhibitors;BRAF protein, human;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Cell Line, Tumor;Cell Proliferation;Drug Resistance, Neoplasm;Humans;MAP Kinase Signaling System;Melanoma;Mutation;Neurofibromin 1;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf;RNA Interference",
        "Doc_meshqualifiers":"drug therapy;genetics;metabolism;deficiency;genetics;pharmacology;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605799352743231488},
      {
        "Doc_abstract":"Truncating germline mutations in the tumor suppressor gene BRCA-1 associated protein-1 (BAP1) have been reported in families predisposed to developing a wide range of different cancer types including uveal melanoma and cutaneous melanoma. There has also been an association between amelanotic tumor development and germline BAP1 mutation suggesting a possible phenotypic characteristic of BAP1 mutation carriers. Though there have been many types of cancer associated with germline BAP1 mutation, the full spectrum of disease association is yet to be ascertained. Here we describe a Danish family with predominantly uveal melanoma but also a range of other tumor types including lung, neuroendocrine, stomach, and breast cancer; as well as pigmented skin lesions. Whole-exome sequencing identified a BAP1 splice mutation located at c.581-2A>G, which leads to a premature truncation of BAP1 in an individual with uveal melanoma. This mutation was carried by several other family members with melanoma or various cancers. The finding expands on the growing profile of BAP1 as an important uveal and cutaneous melanoma tumor suppressor gene and implicates its involvement in the development of lung, and stomach cancer. ",
        "Doc_title":"A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.",
        "Journal":"PloS one",
        "Do_id":"23977234",
        "Doc_ChemicalList":"Protein Isoforms;RNA Splice Sites;Tumor Suppressor Proteins;BAP1 protein, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"Adult;Aged;Amino Acid Sequence;Base Sequence;Case-Control Studies;DNA Mutational Analysis;Denmark;Female;Frameshift Mutation;Genetic Association Studies;Genetic Predisposition to Disease;Humans;Loss of Heterozygosity;Male;Melanoma;Middle Aged;Molecular Sequence Data;Pedigree;Protein Isoforms;RNA Splice Sites;Tumor Suppressor Proteins;Ubiquitin Thiolesterase;Uveal Neoplasms;Young Adult",
        "Doc_meshqualifiers":"enzymology;genetics;genetics;genetics;genetics;enzymology;genetics",
        "_version_":1605807293428924416},
      {
        "Doc_abstract":"Whole-exome sequencing of 213 tumor samples shows that NF1 is mutated in 13.1% of melanomas. The gene is usually mutated in tumors that don't carry mutations in BRAF or NRAS, and it may be a cancer driver. However, loss of the gene didn't predict whether RAS activity increased or whether cell lines responded to inhibitors of the MAP kinase pathway, which RAS activates. ",
        "Doc_title":"NF1 Mutations Prevalent but Not Clinically Relevant.",
        "Journal":"Cancer discovery",
        "Do_id":"26283687",
        "Doc_ChemicalList":"Neurofibromin 1",
        "Doc_meshdescriptors":"Humans;Melanoma;Mutation;Neurofibromin 1;Precision Medicine",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism",
        "_version_":1605893856333660160},
      {
        "Doc_abstract":"Cadherins comprise Ca(2+)-dependent homophilic cell-cell adhesion molecules which are responsible for correct location of cells and for tissue integrity. They are crucial factors for the development and maintenance of epithelial architecture. Aberrantly expressed cadherins are known to be involved in malignant transformation of different types of tissues. In a previous study, we determined the expression of a short truncated 50 kDa form of P-cadherin only consisting of the N-terminal part in malignant melanoma. Further analysis revealed that this short 50 kDa form of P-cadherin representing the N-terminal, extracellular region, is secreted by melanoma cells in contrast to the membrane bound form in melanocytes. In order to define the functional relevance of expression of the 50 kDa P-cadherin variant in malignant melanoma, antisense P-cadherin cell clones were generated. The clones in which P-cadherin expression is reduced show no changes in proliferation or in attachment-independent growth when compared to controls. However, a strong reduction of migratory and invasive properties was observed in these cells, suggesting that truncated P-cadherin promotes melanoma cell invasion and migration and therefore has an important role in the progression of malignant melanoma. Functionally, the secreted form of P-cadherin could play a role as regulator of the homophilic interaction between P-cadherin molecules by antagonizing their biological role acting as a dominant negative form to interrupt cell-cell attachment.",
        "Doc_title":"Functional implication of truncated P-cadherin expression in malignant melanoma.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"16919267",
        "Doc_ChemicalList":"Cadherins;Extracellular Matrix Proteins;RNA, Antisense;RNA, Messenger",
        "Doc_meshdescriptors":"Animals;Cadherins;Dimerization;Extracellular Matrix Proteins;Gene Expression Regulation, Neoplastic;Humans;Melanoma;Mice;Neoplasm Metastasis;RNA, Antisense;RNA, Messenger;Transfection;Wound Healing",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;pathology;metabolism;genetics;metabolism;physiology",
        "_version_":1605749799679688704},
      {
        "Doc_abstract":"To identify mechanisms whereby activating transcription factor 2 (ATF2) alters the radiation resistance of human melanoma cells, we examined the possible role of ATF2 in UVC-induced apoptosis. Forced expression of full-length or truncated (Delta1-195 amino acids) forms of ATF2 in LU1205, a late-stage human melanoma cell line, elevated the levels of UVC-induced apoptosis. At the same time, either truncated or full-length forms of ATF2 reduced UVC-induced activation of the tumor necrosis factor-alpha (TNFalpha) promoter and decreased expression of TNFalpha. Forced expression of c-Jun in ATF2-expressing melanoma cells restored TNFalpha expression, suggesting that both forms of ATF2 sequestered transcription factors that positively regulate TNFalpha expression in response to UV irradiation. Antagonistic antibodies to Fas, but not to TNFR1, efficiently suppressed UVC-induced apoptosis, suggesting that the Fas pathway mediates the primary apoptotic signal in melanoma cells whereas the TNFR1 pathway elicits a survival signal. Indeed, treatment of melanoma cells with TNFalpha before UVC irradiation partially suppressed UVC-induced apoptosis, further supporting the protective role of TNFalpha in UVC-treated melanoma cells. Taken together, our findings suggest that ATF2 contributes to UVC-induced apoptosis through transcriptional silencing of TNFalpha, which balances Fas-mediated cell death in melanoma.",
        "Doc_title":"Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"10318823",
        "Doc_ChemicalList":"ATF2 protein, human;Activating Transcription Factor 2;Cyclic AMP Response Element-Binding Protein;Protein Synthesis Inhibitors;Transcription Factors;Tumor Necrosis Factor-alpha;Dactinomycin;Cycloheximide",
        "Doc_meshdescriptors":"Activating Transcription Factor 2;Apoptosis;Cyclic AMP Response Element-Binding Protein;Cycloheximide;Dactinomycin;Down-Regulation;Gene Expression Regulation;Humans;Leucine Zippers;Melanoma;Protein Synthesis Inhibitors;Radiation Tolerance;Transcription Factors;Transfection;Tumor Cells, Cultured;Tumor Necrosis Factor-alpha;Ultraviolet Rays",
        "Doc_meshqualifiers":"drug effects;radiation effects;physiology;pharmacology;pharmacology;radiation effects;physiopathology;pharmacology;drug effects;physiology;biosynthesis;genetics",
        "_version_":1605818640388587521},
      {
        "Doc_abstract":"PALB2 is a breast and pancreas cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate gene for susceptibility to BRCA2-related cancers such as melanoma. The purpose of this study was to screen for the presence of germline mutations in PALB2 in familial melanoma cases. We sequenced the exons and intron-exon boundaries of PALB2 in probands from 53 families with familial melanoma where CDKN2A mutations were absent. A number of previously reported coding and non-coding variants were observed. However, no truncating mutations were identified. These results indicate that deleterious PALB2 mutations are unlikely to play a significant role in familial melanoma.",
        "Doc_title":"Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma.",
        "Journal":"Familial cancer",
        "Do_id":"21153565",
        "Doc_ChemicalList":"Nuclear Proteins;PALB2 protein, human;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Female;Genetic Predisposition to Disease;Humans;Melanoma;Middle Aged;Mutation;Nuclear Proteins;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605747562455760899},
      {
        "Doc_abstract":"CDKN2A is thought to be the main candidate gene for melanoma susceptibility. Deletion or mutations in the CDKN2A gene may produce an imbalance between functional p16 and cyclin D, causing abnormal cell growth. We here describe a novel mutation consisting of a 1 bp deletion at nucleotide position 201 (codon 67) (CACGGcGCG) resulting in a truncated protein (stop codon 145). The patient, a female subject from a melanoma-prone family, presented at the age of 47 years with a superficial spreading melanoma of the trunk. Her father had colon cancer at the age of 43 years and melanoma at 63 years, her uncle suffered from gastric cancer, and her grandfather had laryngeal cancer.",
        "Doc_title":"CDKN2A novel mutation in a patient from a melanoma-prone family.",
        "Journal":"Melanoma research",
        "Do_id":"11595880",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Base Sequence;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Databases, Nucleic Acid;Female;Genetic Predisposition to Disease;Heteroduplex Analysis;Humans;Male;Melanoma;Middle Aged;Mutation;Pedigree;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605802065584455680},
      {
        "Doc_abstract":"Recent experiments have revealed that aberrant functionality of the chromatin remodeling complex is related to tumorigenicity in various malignant tumors. Skeletrophin is an actin-binding cytoskeleton-related molecule, which is induced by the overexpression of truncated human SWI1 (SMARCF1). Human SWI1 is a sub-unit of the chromatin remodeling complex and binds chromatin through its ARID (AT-rich interactive domain). Truncated SWI1 lacks one of the two glucocorticoid-receptor binding domains and inhibits the intact human SWI1 in a dominant negative manner. Skeletrophin, was therefore identified as a candidate molecule for the indication of change to a malignant phenotype due to the aberrant function of the chromatin remodeling complex. Surprisingly, the skeletrophin gene is located in 1p36.32, where the putative tumor suppressor gene of cutaneous malignant melanoma has long been postulated to be on. Cutaneous malignant melanoma is a highly aggressive tumor. To overcome the clinical problem of malignant melanoma and highly invasive and metastatic activity, it is important to unravel the molecular mechanism responsible for melanoma progression. Recent studies including those from our laboratories have elucidated that skeletrophin is a novel RING-HC type ubiquitin ligase and that the ubiquitin ligase pathway mediated by skeletrophin acts to oppose melanoma cell invasion. Here, we summarize the characterization of skeletrophin, with emphasis on its biological activity, the disruption of which is linked with melanoma progression.",
        "Doc_title":"Skeletrophin, a novel RING molecule controlled by the chromatin remodeling complex, is downregulated in malignant melanoma.",
        "Journal":"DNA and cell biology",
        "Do_id":"15869411",
        "Doc_ChemicalList":"Chromatin;Microfilament Proteins;Neoplasm Proteins;RNA, Messenger;MIB2 protein, human;Ubiquitin-Protein Ligases",
        "Doc_meshdescriptors":"Chromatin;Chromosomes, Human, Pair 1;Down-Regulation;Genes, Tumor Suppressor;Humans;Melanoma;Microfilament Proteins;Neoplasm Proteins;Point Mutation;Protein Structure, Tertiary;RNA, Messenger;Ubiquitin-Protein Ligases",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;genetics;metabolism;chemistry;genetics;metabolism;metabolism",
        "_version_":1605818624980811776},
      {
        "Doc_abstract":"High levels of beta-catenin and activating mutations in the beta-catenin gene (CTNNB1) have been demonstrated in malignant melanomas, implicating dysregulated Wnt signalling in the pathogenesis of this malignancy. We systematically examined melanoma cell lines for activating CTNNB1 mutations as well as genetic and epigenetic alterations of the adenomatous polyposis coli gene (APC), another key component of the Wnt signalling transduction pathway. Of 40 cell lines tested, one carried a truncating APC mutation and loss of the corresponding wild-type allele, and one carried a CTNNB1 missense mutation. Hypermethylation of APC promoter 1A was present in five of the cell lines (13%) and in nine of 54 melanoma biopsies (17%). Cells with truncating APC or activating CTNNB1 mutations showed increased transcription from endogenous and ectopic beta-catenin/T-cell factor (Tcf)-responsive target genes, consistent with the known effects of these alterations on beta-catenin stability and Tcf transactivation. In contrast, cell lines with APC promoter 1A hypermethylation did not show increased Wnt signalling, probably due to residual APC activity expressed from promoter 1B. Suppression of APC transcripts in melanoma cells by stable expression of short hairpin RNAs led to a Wnt signalling-independent increase in cell proliferation, but also reduced the invasive growth in collagen type I. Collectively, our data suggest that the tumour-suppressive function of APC in melanocytic cells is dose dependent. We propose that epigenetic silencing of promoter 1A may contribute to the development of malignant melanoma by reducing the expression of APC to a level that promotes cell proliferation without compromising the invasive capacity.",
        "Doc_title":"Genetic and epigenetic alterations of the APC gene in malignant melanoma.",
        "Journal":"Oncogene",
        "Do_id":"15133491",
        "Doc_ChemicalList":"Adenomatous Polyposis Coli Protein;CTNNB1 protein, human;Collagen Type I;Cytoskeletal Proteins;Proto-Oncogene Proteins;Trans-Activators;Wnt Proteins;beta Catenin;Luciferases",
        "Doc_meshdescriptors":"Adenomatous Polyposis Coli Protein;Alleles;Biopsy;Cell Division;Cell Line, Tumor;Cells, Cultured;Collagen Type I;Cytoskeletal Proteins;DNA Methylation;DNA Mutational Analysis;Epistasis, Genetic;Gene Expression Regulation, Neoplastic;Genes, APC;Genes, Reporter;Genetic Variation;Humans;Luciferases;Melanocytes;Melanoma;Mutation, Missense;Neoplasm Invasiveness;Promoter Regions, Genetic;Proto-Oncogene Proteins;RNA Interference;Sequence Analysis, DNA;Sequence Deletion;Trans-Activators;Transcription, Genetic;Transcriptional Activation;Wnt Proteins;beta Catenin",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;pathology;genetics;metabolism;pathology;metabolism",
        "_version_":1605910279134117888},
      {
        "Doc_abstract":"Known melanoma predisposition genes only account for around 40% of high-density melanoma families. Other rare mutations are likely to play a role in melanoma predisposition. RAD51B plays an important role in DNA repair through homologous recombination, and inactivation of RAD51B has been implicated in tumorigenesis. Thus RAD51B is a good candidate melanoma susceptibility gene, and previously, a germline splicing mutation in RAD51B has been identified in a family with early-onset breast cancer. In order to find genetic variants associated with melanoma predisposition, whole-exome sequencing was carried out on blood samples from a three-case cutaneous melanoma family. We identified a novel germline RAD51B nonsense mutation, and we demonstrate reduced expression of RAD51B in melanoma cells indicating inactivation of RAD51B. This is only the second report of a germline truncating RAD51B mutation. While this case report is consistent with melanoma being part of the RAD51B cancer spectrum further population-based screening of large case-control sample series will be needed to definitively establish if this is the case.",
        "Doc_title":"Germline RAD51B truncating mutation in a family with cutaneous melanoma.",
        "Journal":"Familial cancer",
        "Do_id":"25600502",
        "Doc_ChemicalList":"DNA-Binding Proteins;RAD51B protein, human",
        "Doc_meshdescriptors":"DNA-Binding Proteins;Germ-Line Mutation;Humans;Immunohistochemistry;Melanoma;Middle Aged;Skin Neoplasms",
        "Doc_meshqualifiers":"analysis;genetics;genetics;genetics",
        "_version_":1605827253644558336},
      {
        "Doc_abstract":"The CDKN2A gene that encodes the cell cycle inhibitor p16 shows mutations in many but not all 9p21-linked melanoma families. Most Dutch melanoma families segregate for a unique founder mutation (p16-Leiden), encoding a truncated nonfunctional p16 protein. The highly variable risk for p16-Leiden carriers to develop melanoma suggests a role for other genetic and/or environmental factors. We hypothesized that a 9p21 gene other than CDKN2A may be relevant in the remaining 9p21-linked melanoma families without p16 mutations but may also act as a risk modifier in p16-Leiden carriers. Haplotype analysis for 9p21 was performed using microsatellite markers in six p16-Leiden families originating from a founder population. p16-Leiden carriers in two families shared an unexpectedly large founder haplotype ( approximately 20-cM) around CDKN2A, mostly in proximal direction. Melanoma-positive p16-Leiden carriers from these families showed this extensive proximal haplotype compared with melanoma-negative p16-Leiden carriers from the same families. Additional p16-Leiden families less heavily affected with melanoma showed shorter haplotypes sharing, excluding the region proximally of CDKN2A. The presence of a gene involved in melanoma susceptibility proximal of CDKN2A is corroborated by somatic deletions of 9p in tumors, which frequently do not include CDKN2A but a more proximal chromosomal area instead. Our results provide a candidate region for further gene mapping in p16-negative 9p21-linked melanoma families and guide the search for risk modifiers in melanoma development.",
        "Doc_title":"A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.",
        "Journal":"Genome research",
        "Do_id":"10400925",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Genetic Markers",
        "Doc_meshdescriptors":"Alleles;Alternative Splicing;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Dysplastic Nevus Syndrome;Female;Genetic Linkage;Genetic Markers;Heterozygote Detection;Humans;Male;Middle Aged;Netherlands;Pedigree;Risk Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605897369858080768},
      {
        "Doc_abstract":"Allelic loss in human cutaneous melanoma has been detected on chromosomes 1p, 6q, 9p, 10q, and 11q. Chromosome 17 contains important tumor suppressor genes such as p53, NM23, and neurofibromatosis type 1 (NF1), which have been implicated in melanoma tumorigenesis. The role of p53 has already been studied by a number of laboratories, showing contrasting results. In the present study, two restriction fragment length polymorphism (RFLP) probes for the NM23 and NF1 genes, together with five other RFLP and four variable number of tandem repeat chromosome 17 probes, were investigated at the loss of heterozygosity (LOH) level in a Southern blot-based assay. The NF1 gene was also tested for LOH by a polymerase chain reaction (PCR)-based approach in two different experiments, using a dinucleotide repeat polymorphic probe at locus D17S250 (17q11.2-q12), and an Alu probe intragenic to the NF1 gene (17q11.2). A PCR single-strand conformation polymorphism assay was included in the study for mutation detection at the NF1-GTPase-activating protein-related domain (GRD). A total of 68 melanocytic tumors were analyzed. LOH was detected in 9 of 87 informative cases (10%). LEW301 (17p11.2-pcen) presented the highest LOH frequency (22%). NM23 showed LOH in 17% of the informative cases, while NF1 did not show either LOH in the Southern blot- and PCR-based experiments or mutations at the NF1-GRD. These results are in concordance with those of previous smaller studies, but when compared with higher LOH frequencies obtained from other chromosomes, these findings indicate that the LOH values found in our study can most likely be attributed to background effect. Thus, chromosome 17 LOH is likely to play and unimportant role as a genetic event in melanoma tumorigenesis. Nevertheless, NF1 merits further study, since homozygous deletions have been detected at this locus in melanoma cell lines.",
        "Doc_title":"Chromosome 17 allelic loss and NF1-GRD mutations do not play a significant role as molecular mechanisms leading to melanoma tumorigenesis.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"8648172",
        "Doc_ChemicalList":"DNA, Neoplasm;GTPase-Activating Proteins;Proteins",
        "Doc_meshdescriptors":"Alleles;Chromosomes, Human, Pair 17;DNA, Neoplasm;GTPase-Activating Proteins;Genes, Neurofibromatosis 1;Heterozygote;Humans;Melanoma;Mutation;Point Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proteins",
        "Doc_meshqualifiers":"genetics;genetics;etiology;genetics;genetics",
        "_version_":1605750648801853440},
      {
        "Doc_abstract":"MSH-PE38KDEL is a chimeric molecule composed of MSH, and fused to a truncated mutant form of Pseudomonas exotoxin (PE38KDEL). Our study aims to evaluate the specific cytotoxicity of recombinant immunotoxin MSH-PE38KDEL on melanoma cells A875 and B16 in vitro, as well as its inhibition of metastatic melanoma in vivo. MSH-PE38KDEL was expressed in Escherichia coli, and greater than 90% purity was obtained. The purified MSH-PE38KDEL was found to be selectively cytotoxic to MSH receptor-positive melanoma cells in vitro. The specific cytotoxicity of recombinant MSH-PE38KDEL to A875 and B16 was over 85% by cell viability assay; however, MSH-PE38KDEL had no cytotoxicity to the human 2BS cells. The anti-tumor activity of MSH-PE38KDEL was evaluated in mice with induced melanoma through intra-tumor or intravenous administration. The results showed that 90% melanoma growths were inhibited, and 40% of the tumors were disappeared completely. Histopathology results showed MSH-PE38KDEL can effectively inhibit intrahepatic metastasis. In conclusion, MSH-PE38KDEL had cytotoxic effects on MSH receptor-positive melanoma cells, and causes significant tumor growth inhibition. These results support a possible new approach for the treatment of melanoma.",
        "Doc_title":"In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.",
        "Journal":"Neoplasma",
        "Do_id":"25027740",
        "Doc_ChemicalList":"Antineoplastic Agents;Bacterial Toxins;Exotoxins;Immunotoxins;Recombinant Fusion Proteins;Virulence Factors;Melanocyte-Stimulating Hormones;ADP Ribose Transferases;toxA protein, Pseudomonas aeruginosa",
        "Doc_meshdescriptors":"ADP Ribose Transferases;Animals;Antineoplastic Agents;Bacterial Toxins;Exotoxins;Female;Humans;Immunoenzyme Techniques;Immunotoxins;In Vitro Techniques;Liver Neoplasms;Melanocyte-Stimulating Hormones;Melanoma, Experimental;Mice;Mice, Nude;Recombinant Fusion Proteins;Tumor Cells, Cultured;Virulence Factors",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;drug therapy;immunology;secondary;immunology;drug therapy;immunology;pathology;therapeutic use;therapeutic use",
        "_version_":1605746793474162689},
      {
        "Doc_abstract":"PREX2 is a PTEN interacting protein that is significantly mutated in melanoma and pancreatic ductal adenocarcinoma. Recently, we reported the mechanistic basis of melanomagenesis by PREX2 mutations. Truncating PREX2 mutations activate its guanine nucleotide exchange factor activity for its substrate RAC1. This leads to increased PI3K/AKT signaling associated with reduced DNA methylation and increased cell proliferation in NRAS-mutant melanoma. Here, we provide additional data that indicates a reciprocal regulation of PREX2 by PTEN whereby loss of PTEN results in a dramatic increase in expression of PREX2 at the protein level. Pharmacologic studies revealed destabilization of PREX2 by inhibition of PI3K/AKT signaling. Additionally, we provide data to show a selective decrease in a particular histone mark, H4 Lys20 trimethylation, in cells expressing PREX2 (E824*) truncating mutation globally and at the imprint control region of CDKN1C (also known as p57) and IGF2. The decrease in H4K20 trimethylation coupled with DNA hypomethylation at this particular locus is associated with genomic imprinting and regulation of expression of p57 and IGF2. Taken together, these results demonstrate the complex signaling mechanisms that involve PREX2, PI3K/AKT/PTEN and downstream epigenetic machinery to deregulate expression of key cell cycle regulators. ",
        "Doc_title":"Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.",
        "Journal":"Small GTPases",
        "Do_id":"27111337",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818593442791424},
      {
        "Doc_abstract":"Germ-line mutations in the CDKN2A tumor-suppressor gene (also known as p16, p16INK4a, and MTS1) have been linked to the development of melanoma in some families with inherited melanoma. Whether mutations in CDKN2A confer a predisposition to sporadic (nonfamilial) melanoma is not known. In some patients with sporadic melanoma, one or more additional primary lesions develop, suggesting that some of these patients have an underlying genetic susceptibility to the cancer. We hypothesized that this predisposition might be due to germ-line CDKN2A mutations.;We used the polymerase chain reaction, single-strand conformation polymorphism analysis, and direct DNA sequencing to identify germ-line mutations in the CDKN2A gene in patients with multiple primary melanomas who did not have family histories of the disease. A quantitative yeast two-hybrid assay was used to evaluate the functional importance of the CDKN2A variants.;Of 33 patients with multiple primary melanomas, 5 (15 percent; 95 percent confidence interval, 4 percent to 27 percent) had germ-line CDKN2A mutations. These included a 24-bp insertion at the 5' end of the coding sequence, three missense mutations (Arg24Pro, Met53Ile, and Ser56Ile), and a 2-bp deletion at position 307 to 308 (resulting in a truncated CDKN2A protein). In three families, CDKN2A mutations identical to those in the probands were found in other family members. In two families with mutations, we uncovered previously unknown evidence of family histories of melanoma.;Some patients with multiple primary melanomas but without family histories of the disease have germ-line mutations of the CDKN2A gene. The presence of multiple primary melanomas may signal a genetic susceptibility to melanoma not only in the index patient but also in family members, who may benefit from melanoma-surveillance programs.",
        "Doc_title":"CDKN2A mutations in multiple primary melanomas.",
        "Journal":"The New England journal of medicine",
        "Do_id":"9516223",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;DNA Mutational Analysis;Female;Genes, p16;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Male;Melanoma;Middle Aged;Neoplasms, Multiple Primary;Pedigree;Skin Neoplasms",
        "Doc_meshqualifiers":"methods;genetics;genetics;genetics;genetics",
        "_version_":1605760045207781376},
      {
        "Doc_abstract":"The p16 gene (CDKN2) which is localized on chromosome 9p21, is deleted in a significant number of sporadic cancers. Moreover, germline mutations identified in some melanoma-prone kindreds last year suggested that CDKN2 is identical to the 9p21-linked melanoma susceptibility gene (MLM); however, failure to identify p16 mutations in all melanoma kindreds putatively linked to 9p21 left some doubts. We have analysed CDKN2 coding sequences in 15 Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome pedigrees, and identified a 19 basepair (bp) germline deletion in 13 of them. All 13 families originate from an endogamous population. The deletion causes a reading frame shift, predicted to result in a severely truncated p16 protein. Interestingly, two family members are homozygous for the deletion, one of whom shows no obvious signs of disease. This surprising finding demonstrates that homozygotes for this CDKN2 mutation are viable, and suggests the presence of a genetic mechanism that can compensate for the functional loss of p16. Our results also greatly strengthen the notion that p16 is indeed MLM.",
        "Doc_title":"Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.",
        "Journal":"Nature genetics",
        "Do_id":"7670475",
        "Doc_ChemicalList":"DNA Primers",
        "Doc_meshdescriptors":"Amino Acid Sequence;Chromosomes, Human, Pair 9;DNA Primers;Female;Germ-Line Mutation;Homozygote;Humans;Male;Melanoma;Molecular Sequence Data;Neoplasms, Multiple Primary;Netherlands;Pedigree;Phenotype;Polymerase Chain Reaction;Sequence Deletion;Syndrome",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605755254919397376},
      {
        "Doc_abstract":"Reports suggest that a subset of uveal melanoma is familial. The association of uveal melanoma with breast and ovarian cancer and the increased risk in BRCA2-linked families implicates germline BRCA2 mutations as the cause of a subset of uveal melanomas. Similarly, the association between cutaneous and uveal melanomas in some families, coupled with the high frequency of somatic deletions of the INK4A-ARF locus in uveal melanomas, strongly suggests that mutations in P16(INK4A) and P15 account for a proportion of uveal melanomas.;To examine this proposition, a systematically ascertained series of 385 patients with uveal melanoma were screened for germline mutations in BRCA2, P16(INK4A), P14(ARF), and P15.;One patient was found to harbor a Gly35Ala substitution in exon 1alpha of P16(INK4A), which has previously been reported to be pathogenic. No mutations were detected in P14(ARF) or P15. None of the patients harbored germline nucleotide changes that lead to truncation or that create or disrupt consensus splice sites of BRCA2 or missense variants with clear pathogenic potential.;These findings suggest that less than 2% of cases of uveal melanoma can be ascribed to germline mutations in BRCA2, P16(INK4A), P14(ARF), or P15. It is likely that mutations in other genes contribute to an inherited predisposition to uveal melanoma.",
        "Doc_title":"Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.",
        "Journal":"Investigative ophthalmology & visual science",
        "Do_id":"12556369",
        "Doc_ChemicalList":"BRCA2 Protein;CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;BRCA2 Protein;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Female;Germ-Line Mutation;Humans;Incidence;Male;Melanoma;Middle Aged;Polymerase Chain Reaction;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;Uveal Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605755773752705024},
      {
        "Doc_abstract":"In the last 2 years, it has become apparent that the p53-family members p53 and p73 play fundamentally different roles in human malignancies. In contrast to p53, many studies on cancer patients failed to detect mutational inactivation of p73 and reported overexpression of wild-type p73 instead. A possible explanation was provided by the recent discovery of N-terminal truncated isoforms of p73 (DeltaTA-p73) that act as dominant-negative inhibitors of wild-type p53 and TA-p73 and result in tumor growth in nude mice. We investigated the role of DeltaTA-p73 in the development and progression of human melanomas, which lack p53 mutations. We analyzed 8 benign melanocytic nevi, 8 primary melanomas and 19 melanoma metastases for alterations of TA-p73 and DeltaTA-p73 expression using isoform-specific real-time RT-PCR. Based on our results, p73Deltaex2 and Deltaex2/3 spliced transcripts derived from the first promoter were significantly up-regulated in melanoma metastases, whereas DeltaN-p73 generated from the second promoter was the predominant isoform in benign nevi. Moreover, increased expression of p73Deltaex2 and p73Deltaex2/3 correlated with high-levels of both TA-p73 and E2F1. Our data suggest a potential function of DeltaTA-p73 splice isoforms in melanoma progression.",
        "Doc_title":"Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression.",
        "Journal":"International journal of cancer",
        "Do_id":"14618632",
        "Doc_ChemicalList":"DNA-Binding Proteins;Nuclear Proteins;Protein Isoforms;Trp73 protein, mouse;Tumor Protein p73;Tumor Suppressor Proteins;p73 protein, human",
        "Doc_meshdescriptors":"DNA-Binding Proteins;Genes, Tumor Suppressor;Humans;Melanoma;Mutation;Nevus, Pigmented;Nuclear Proteins;Protein Isoforms;Tumor Protein p73;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;secondary;genetics;genetics",
        "_version_":1605756720288628736},
      {
        "Doc_abstract":"UV radiation-induced mutation of the p53 gene is suggested as a causative event in skin cancer, including melanoma. We have analyzed here p53 mutations in melanoma cell lines and studied its stabilization, DNA-binding activity, and target gene activation by UVC. p53 was mutated in three of seven melanoma cell lines. However, high levels of p53 were detected in all cell lines, including melanoma cells with wild-type p53, with the exception of one line with a truncated form. Upon UV induction, p53 accumulated in lines with wild-type p53, and p53 target genes p21Cip1/Waf1, GADD45, and mdm2 were induced, but the induction of p21Cip1/Waf1 was significantly delayed as compared with the increase in p53 DNA-binding activity. However, despite p53 target gene induction, p53 DNA-binding activity was absent in one melanoma line with wild-type p53, and p53 target genes were induced also in cells with mutant p53. In response to UV, DNA replication ceased in all cell lines, and apoptosis ensued in four lines independently of p53 but correlated with high induction of GADD45. The results suggest that in melanoma, several p53 regulatory steps are dislodged; its basal expression is high, its activation in response to UV damage is diminished, and the regulation of its target genes p21Cip1/Waf1 and GADD45 are dissociated from p53 regulation.",
        "Doc_title":"Human melanoma cell line UV responses show independency of p53 function.",
        "Journal":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research",
        "Do_id":"10099830",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;GADD45 protein;Intracellular Signaling Peptides and Proteins;Nuclear Proteins;Nucleic Acid Synthesis Inhibitors;Proteins;Proto-Oncogene Proteins;RNA, Messenger;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;Bromodeoxyuridine",
        "Doc_meshdescriptors":"Blotting, Northern;Bromodeoxyuridine;Cell Division;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Gene Expression;Humans;Immunoblotting;Intracellular Signaling Peptides and Proteins;Melanoma;Mutagenesis;Nuclear Proteins;Nucleic Acid Synthesis Inhibitors;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;RNA, Messenger;Time Factors;Tumor Cells, Cultured;Tumor Suppressor Protein p53;Ultraviolet Rays;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;drug effects;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605893035221057536},
      {
        "Doc_abstract":"A local gene therapy scheme for the delivery of type I interferons could be an alternative for the treatment of melanoma. We evaluated the cytotoxic effects of interferon-Î² (IFNÎ²) gene lipofection on tumor cell lines derived from three human cutaneous and four canine mucosal melanomas. The cytotoxicity of human IFNÎ² gene lipofection resulted higher or equivalent to that of the corresponding addition of the recombinant protein (rhIFNÎ²) to human cells. IFNÎ² gene lipofection was not cytotoxic for only one canine melanoma cell line. When cultured as monolayers, three human and three canine IFNÎ²-lipofected melanoma cell lines displayed a remarkable bystander effect. As spheroids, the same six cell lines were sensitive to IFNÎ² gene transfer, two displaying a significant multicell resistance phenotype. The effects of conditioned IFNÎ²-lipofected canine melanoma cell culture media suggested the release of at least one soluble thermolabile cytotoxic factor that could not be detected in human melanoma cells. By using a secretion signal-free truncated human IFNÎ², we showed that its intracellular expression was enough to induce cytotoxicity in two human melanoma cell lines. The lower cytoplasmatic levels of reactive oxygen species detected after intracellular IFNÎ² expression could be related to the resistance displayed by one human melanoma cell line. As IFNÎ² gene transfer was effective against most of the assayed melanomas in a way not limited by relatively low lipofection efficiencies, the clinical potential of this approach is strongly supported. ",
        "Doc_title":"Interferon-Î² gene transfer induces a strong cytotoxic bystander effect on melanoma cells.",
        "Journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie",
        "Do_id":"26054674",
        "Doc_ChemicalList":"Culture Media, Conditioned;Reactive Oxygen Species;Recombinant Proteins;Interferon-beta;beta-Galactosidase",
        "Doc_meshdescriptors":"Animals;Bystander Effect;Cell Death;Cell Line, Tumor;Cell Survival;Culture Media, Conditioned;Dogs;Gene Transfer Techniques;Humans;Interferon-beta;Intracellular Space;Melanoma;Reactive Oxygen Species;Recombinant Proteins;Temperature;Transfection;Transgenes;beta-Galactosidase",
        "Doc_meshqualifiers":"drug effects;drug effects;pharmacology;genetics;metabolism;genetics;metabolism;genetics;genetics",
        "_version_":1605742659634200577},
      {
        "Doc_abstract":"A single-chain Fv (scFv) fusion phage library derived from random combinations of VH and VL (variable heavy and light chains) domains in the antibody repertoire of a vaccinated melanoma patient was previously used to isolate clones that bind specifically to melanoma cells. An unexpected finding was that one of the clones encoded a truncated scFv molecule with most of the VL domain deleted, indicating that a VH domain alone can exhibit tumor-specific binding. In this report a VH fusion phage library containing VH domains unassociated with VL domains was compared with a scFv fusion phage library as a source of melanoma-specific clones; both libraries contained the same VH domains from the vaccinated melanoma patient. The results demonstrate that the clones can be isolated from both libraries, and that both libraries should be used to optimize the chance of isolating clones binding to different epitopes. Although this strategy has been tested only for melanoma, it is also applicable to other cancers. Because of their small size, human origin and specificity for cell surface tumor antigens, the VH and scFv molecules have significant advantages as tumor-targeting molecules for diagnostic and therapeutic procedures and can also serve as probes for identifying the cognate tumor antigens.",
        "Doc_title":"Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"9256470",
        "Doc_ChemicalList":"Antibodies, Neoplasm;Cancer Vaccines;Immunoglobulin Fragments;Immunoglobulin Heavy Chains;Immunoglobulin Variable Region;Recombinant Proteins;immunoglobulin Fv",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antibodies, Neoplasm;Bacteriophages;Cancer Vaccines;Gene Library;Humans;Immunoglobulin Fragments;Immunoglobulin Heavy Chains;Immunoglobulin Variable Region;Melanoma;Molecular Sequence Data;Recombinant Proteins",
        "Doc_meshqualifiers":"genetics;immunology;genetics;immunology;genetics;immunology;genetics;immunology;immunology;genetics;immunology",
        "_version_":1605756914130485248},
      {
        "Doc_abstract":"There have been suggestions that mortality from cutaneous malignant melanoma (CMM) is starting to level off in the European Union.;To analyse changes in CMM mortality trends in Spain during 1975-2001 using joinpoint regression models.;Mortality data were obtained from the National Statistics Institute. For each gender, age group-specific and standardized (overall and truncated) rates were calculated by the direct method (using the world standard population). The joinpoint analysis was used to identify the best-fitting points where a statistically significant change in the trend occurred.;In women, there was a marked increase from 1975 to 1994 in age-adjusted (overall and truncated) CMM mortality rates [estimated annual percentage change (EAPC) 6.6% and 7.0%, respectively; P < 0.05], followed by a levelling off (EAPC - 0.3% and - 1.3%, respectively; not significant). In men, age-adjusted (35-64 years) mortality rates increased steadily from 1975 to 1991 (EAPC 9.1%, P < 0.05) and then levelled off.;We confirmed that CMM mortality rates in Spain rose dramatically from the mid-1970s to the beginning of the 1990s, but we also found that mortality rates are now levelling off in middle-aged adults (35-64 years), following a similar tendency to that observed in other countries.",
        "Doc_title":"Has mortality from malignant melanoma stopped rising in Spain? Analysis of trends between 1975 and 2001.",
        "Journal":"The British journal of dermatology",
        "Do_id":"15888159",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Age Distribution;Aged;Aged, 80 and over;Female;Humans;Male;Melanoma;Middle Aged;Mortality;Sex Distribution;Skin Neoplasms;Spain",
        "Doc_meshqualifiers":"mortality;trends;mortality;epidemiology",
        "_version_":1605830822240190464},
      {
        "Doc_abstract":"Î±-Actinin-4 (ACTN4), a key regulator of the actin cytoskeleton, is up-regulated in melanoma, though its role in melanoma remains speculative. We have discovered that in WM1158, a highly aggressive melanoma cell line, down-regulation of ACTN4 by shRNA induces a collagen I-dependent amoeboidal-to-mesenchymal transition. Re-expression of low levels of WT ACTN4 but not similar expression levels of ACTN1 successfully restores the amoeboidal morphology and limits collagen I gel compaction. A truncated ACTN4 mutant 1-890, which lacks the C-terminal tail, fails to rescue the amoeboidal morphology and to compact collagen I gel. Interestingly, in three-dimensional collagen I gels, ACTN4 KD cells are more polarized compared with cells in which scrambled shRNA is expressed. Surprisingly, ACTN4 KD cells migrate faster than the ones expressing the scrambled shRNA on a collagen I gel (two-dimensional) although these two cell lines migrate similarly on tissue culture. Most importantly, down-regulation of ACTN4 significantly reduced invasion of WM1158 cells into the three-dimensional collagen I gel, a representative of the dermis. Taken together, these findings suggest that ACTN4 plays an important role in maintaining the amoeboidal morphology of invasive melanoma and thus promoting dissemination through collagen-rich matrices. ",
        "Doc_title":"Î±-Actinin-4 is required for amoeboid-type invasiveness of melanoma cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"25296750",
        "Doc_ChemicalList":"ACTN4 protein, human;Collagen Type I;Actinin",
        "Doc_meshdescriptors":"Actinin;Cell Line, Tumor;Cell Movement;Cells, Cultured;Collagen Type I;Humans;Immunoblotting;Melanoma;Microscopy, Fluorescence;Neoplasm Invasiveness;RNA Interference;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605812200094564352},
      {
        "Doc_abstract":"The relationship between telomeres, nevi and melanoma is complex. Shorter telomeres have been found to be associated with many cancers and with number of nevi, a known risk factor for melanoma. However, shorter telomeres have also been found to decrease melanoma risk. We performed a systematic analysis of telomere-related genes and tagSNPs within these genes, in relation to the risk of melanoma, dysplastic nevi, and nevus count combining data from four studies conducted in Italy. In addition, we examined whether telomere length measured in peripheral blood leukocytes is related to the risk of melanoma, dysplastic nevi, number of nevi, or telomere-related SNPs. A total of 796 cases and 770 controls were genotyped for 517 SNPs in 39 telomere-related genes genotyped with a custom-made array. Replication of the top SNPs was conducted in two American populations consisting of 488 subjects from 53 melanoma-prone families and 1,086 cases and 1,024 controls from a case-control study. We estimated odds ratios for associations with SNPs and combined SNP P-values to compute gene region-specific, functional group-specific, and overall P-value using an adaptive rank-truncated product algorithm. In the Mediterranean population, we found suggestive evidence that RECQL4, a gene involved in genome stability, RTEL1, a gene regulating telomere elongation, and TERF2, a gene implicated in the protection of telomeres, were associated with melanoma, the presence of dysplastic nevi and number of nevi, respectively. However, these associations were not found in the American samples, suggesting variable melanoma susceptibility for these genes across populations or chance findings in our discovery sample. Larger studies across different populations are necessary to clarify these associations.",
        "Doc_title":"On the interplay of telomeres, nevi and the risk of melanoma.",
        "Journal":"PloS one",
        "Do_id":"23300679",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Case-Control Studies;Disease Progression;Dysplastic Nevus Syndrome;Environmental Exposure;Female;Genetic Predisposition to Disease;Humans;Male;Melanoma;Middle Aged;Nevus;Pigmentation;Polymorphism, Single Nucleotide;Risk Factors;Skin Neoplasms;Sunlight;Telomere;Young Adult",
        "Doc_meshqualifiers":"complications;pathology;adverse effects;statistics & numerical data;genetics;complications;epidemiology;ethnology;genetics;complications;pathology;complications;pathology;adverse effects;genetics",
        "_version_":1605795112864972800},
      {
        "Doc_abstract":"Vaccines based on melanoma-associated antigens (MAGEs) present a promising strategy for tumor immunotherapy, albeit with weak immunogenicity. In this study, the xenoantigen L-rhamnose (Rha) was chemically conjugated with truncated MAGE-A3 (tMAGE-A3) to generate Rha-tMAGE-A3. The product showed good antigenicity with anti-Rha antibodies purified from human serum. FITC-labeled Rha-tMAGE-A3 was detected in THP-1 human macrophage cells via the anti-Rha antibody-dependent antigen uptake process. Furthermore, peripheral blood mononuclear cells (PBMCs) stimulated with Rha-tMAGE-A3 in the presence of anti-Rha antibodies showed better cytotoxicity toward A375 human melanoma cells surfaced by MAGE-A3 antigen compared to PBMCs stimulated with tMAGE-A3. All data reveal that linking of Rha epitopes to MAGE enhances the immunogenicity of MAGE by harnessing the immune effector functions of human naturally existing anti-Rha antibodies. Rha epitopes could become immunogenicity enhancers of tumor associated antigens in the development of tumor immunotherapies.",
        "Doc_title":"L-Rhamnose Enhances the Immunogenicity of Melanoma-Associated Antigen A3 for Stimulating Antitumor Immune Responses.",
        "Journal":"Bioconjugate chemistry",
        "Do_id":"26978574",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605897114376732672},
      {
        "Doc_abstract":"Anorectal melanoma is a rare disease that carries a poor prognosis. To date, limited genetic analyses confirmed KIT mutations as a recurrent genetic event similar to other mucosal melanomas, occurring in up to 30% of anorectal melanomas. Importantly, a subset of tumors harboring activating KIT mutations have been found to respond to c-Kit inhibitor-based therapy, with improved patient survival at advanced tumor stages. We performed comprehensive targeted exon sequencing analysis of 467 cancer-related genes in a larger series of 15 anorectal melanomas, focusing on potentially actionable variants based on gain- and loss-of-function mutations. We report the identification of oncogenic driver events in the majority (93%) of anorectal melanomas. These included variants in canonical MAPK pathway effectors rarely observed in cutaneous melanomas (including an HRAS mutation, as well as a BRAF mutation resulting in duplication of threonine 599), and recurrent mutations in the tumor suppressor NF1 in 20% of cases, which represented the second-most frequently mutated gene after KIT in our series. Furthermore, we identify SF3B1 mutations as a recurrent genetic event in mucosal melanomas. Our findings provide an insight into the genetic diversity of anorectal melanomas, and suggest significant potential for alternative targeted therapeutics in addition to c-Kit inhibitors for this melanoma subtype.Modern Pathology advance online publication, 14 October 2016; doi:10.1038/modpathol.2016.179.",
        "Doc_title":"Identification of recurrent mutational events in anorectal melanoma.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"27739435",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746798692925441},
      {
        "Doc_abstract":"Mel-cell adhesion molecule (CAM), also known as MUC18 and CD146, is a novel member of the immunoglobulin supergene family. Mel-CAM was first identified as an integral membrane glycoprotein in human melanoma and is also abundantly expressed by endothelial cells of various origins. In a previous study (I. M. Shih et al., Cancer Res., 54: 2514-2520, 1994), we showed that Mel-CAM is a cell-cell adhesion molecule with a possible role in melanoma invasion and metastasis. Here, we define the molecular mechanism responsible for cell-cell adhesion of Mel-CAM and demonstrate its role in melanoma-endothelial cell interactions. Most of human melanoma cells, including Mel-CAM-negative SBcl-2 cells, adhered to nitrocellulose-immobilized Mel-CAM produced by baculovirus recombinants. This adhesion can be blocked by full-length Mel-CAM or polyclonal antiserum against Mel-CAM. Adhesion is not affected by the presence of EDTA, truncated Mel-CAM extracellular domain, or heparan sulfate proteoglycan. In cell aggregation assays, Mel-CAM-negative SBcl-2 cells cluster with U937TM cells (U937 transfected with Mel-CAM cDNA) but not with control nontransfectants, suggesting that SBcl-2 cells express the ligand for Mel-CAM. SBcl-2 cells also form heterotypic aggregates with Mel-CAM-positive human endothelial cells but not with Mel-CAM-negative but ligand-positive smooth muscle cells. Taken together, our results show that Mel-CAM mediates cell-cell adhesion through heterophilic adhesion to an as yet unidentified ligand present on melanoma but not on endothelial cells. Thus, melanoma-endothelial interactions during metastasis may occur through this novel mechanism.",
        "Doc_title":"Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion.",
        "Journal":"Cancer research",
        "Do_id":"9288796",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD146;Cell Adhesion Molecules;Heparan Sulfate Proteoglycans;MCAM protein, human;Membrane Glycoproteins;Neoplasm Proteins;Neural Cell Adhesion Molecules;Proteoglycans;Recombinant Proteins;Heparitin Sulfate",
        "Doc_meshdescriptors":"Antigens, CD;Antigens, CD146;Cell Adhesion Molecules;Cell Aggregation;Cell Communication;Heparan Sulfate Proteoglycans;Heparitin Sulfate;Humans;Melanoma;Membrane Glycoproteins;Neoplasm Proteins;Neural Cell Adhesion Molecules;Proteoglycans;Recombinant Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;physiology;drug effects;physiology;metabolism;metabolism;pathology;physiopathology;metabolism;physiology;metabolism;physiology;metabolism",
        "_version_":1605785175766073344},
      {
        "Doc_abstract":"Inactivating germ line BRCA1-associated protein-1 (BAP1) mutations have recently been reported in families with uveal or cutaneous malignant melanoma (UMM, CMM), mesothelioma, and meningioma. Although apparently predisposing to a wide range of tumors, the exact tumor spectrum associated with germ line BAP1 mutations has yet to be established. Here, we report a novel germ line BAP1 splice mutation, c.1708C>G (p.Leu570fs*40), in a multiple-case Danish UMM family with a spectrum of other tumors. Whole-exome sequencing identified an apparent missense mutation of BAP1 in UMM, CMM, as well as paraganglioma, breast cancer, and suspected mesothelioma cases in the family. Bioinformatic analysis and splicing assays demonstrated that this mutation creates a strong cryptic splice donor, resulting in aberrant splicing and a truncating frameshift of the BAP1 transcript. Somatic loss of the wild-type allele was also confirmed in the UMM and paraganglioma tumors. Our findings further support BAP1 as a melanoma susceptibility gene and extend the potential predisposition spectrum to paraganglioma.",
        "Doc_title":"A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.",
        "Journal":"Pigment cell & melanoma research",
        "Do_id":"22889334",
        "Doc_ChemicalList":"RNA Splice Sites;RNA, Messenger;Tumor Suppressor Proteins;BAP1 protein, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"Base Sequence;Chromosome Segregation;Family;Female;Humans;Male;Melanoma;Molecular Sequence Data;Mutation, Missense;Paraganglioma;Pedigree;RNA Splice Sites;RNA Splicing;RNA, Messenger;Skin Neoplasms;Tumor Suppressor Proteins;Ubiquitin Thiolesterase;Uveal Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;metabolism;genetics;genetics;genetics;genetics",
        "_version_":1605896485182898176},
      {
        "Doc_abstract":"Uveal melanomas are molecularly distinct from cutaneous melanomas and lack mutations in BRAF, NRAS, KIT, and NF1. Instead, they are characterized by activating mutations in GNAQ and GNA11, two highly homologous Î± subunits of GÎ±q/11 heterotrimeric G proteins, and in PLCB4 (phospholipase C Î²4), the downstream effector of GÎ±q signaling. We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes. The Leu129Gln CysLT2R mutant protein constitutively activates endogenous GÎ±q and is unresponsive to stimulation by leukotriene. Expression of Leu129Gln CysLT2R in melanocytes enforces expression of a melanocyte-lineage signature, drives phorbol ester-independent growth in vitro, and promotes tumorigenesis in vivo. Our findings implicate CYSLTR2 as a uveal melanoma oncogene and highlight the critical role of GÎ±q signaling in uveal melanoma pathogenesis. ",
        "Doc_title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.",
        "Journal":"Nature genetics",
        "Do_id":"27089179",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747501452754945},
      {
        "Doc_abstract":"In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanomas develop resistance to the BRAF inhibitor vemurafenib by expressing truncated forms of BRAF(V600E) that can dimerize in the absence of activated RAS. Will it be possible to block this with improved BRAF inhibitor design?",
        "Doc_title":"How to fool a wonder drug: truncate and dimerize.",
        "Journal":"Cancer cell",
        "Do_id":"22264784",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605846404757979136},
      {
        "Doc_abstract":"Progression of human cutaneous primary melanoma is, among others, accompanied by de novo expression of activated leukocyte cell adhesion molecule (ALCAM/CD166) and enhanced activity of proteolytic cascades in the invasive, vertical growth phase (VGP) of lesions. The homophilic cell adhesion function of wild-type ALCAM mediates homotypic clustering of melanoma cells and would, thus, antagonize cell release from the primary tumor, an early prerequisite for metastasis. Stable transfection of a transmembrane, amino-terminally truncated ALCAM (DeltaN-ALCAM) into metastatic cells diminished cell clustering mediated by wild-type ALCAM. We have addressed the biological effects of DeltaN-ALCAM on tumorigenicity and found that the relief of cell clustering constraints promoted motility in vitro and the transition from expansive tumor growth to tissue invasion in reconstructed skin in culture. In a transplant tumor model, the changes were reflected in reduced subcutaneous tumor growth and in accelerated, spontaneous lung metastasis. These data indicate that the intact cell adhesion function of ALCAM may both favor primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma. ALCAM induction could, thus, provide an attractive target for proteolysis as a part of a more complex cellular program that couples growth and migration and facilitates dissemination.",
        "Doc_title":"Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"15140234",
        "Doc_ChemicalList":"Activated-Leukocyte Cell Adhesion Molecule",
        "Doc_meshdescriptors":"Activated-Leukocyte Cell Adhesion Molecule;Animals;Cell Adhesion;Cell Line, Tumor;Female;Humans;Lung Neoplasms;Melanoma;Mice;Mice, Inbred BALB C;Mice, Nude;Neoplasm Transplantation;Skin Neoplasms;Transfection;Transplantation, Heterologous",
        "Doc_meshqualifiers":"genetics;metabolism;secondary;metabolism;physiopathology;secondary;metabolism;pathology;physiopathology",
        "_version_":1605798167682482176},
      {
        "Doc_abstract":"Familial atypical multiple mole melanoma syndrome (FAMMM) is characterised by dysplastic naevi, malignant melanoma and pancreatic cancer. Given that large deletions involving CDKN2A (cyclin-dependent kinase inhibitor 2A) account for only 2% of cases, we describe a family that highlights the co-occurrence of both melanoma and neural system tumours to aid clinical recognition and propose a management strategy. A patient with multiple neurofibromas was referred with a provisional diagnosis of neurofibromatosis type 1 (NF1). Prior molecular testing, though, had failed to identify an NF1 mutation by sequencing and multiplex ligation-dependent probe amplification. His family history was significant for multiple in situ/malignant melanomas at young ages and several different cancers reminiscent of an underlying syndrome. A search of the Familial Cancer Database, FaCD Online, highlighted several families with cutaneous melanoma and nervous system tumours who were subsequently identified to have large deletions spanning CDKN2A. Although sequencing of CDKN2A and TP53 failed to identify a mutation, a heterozygous CDKN2A deletion was identified by targeted array comparative genomic hybridisation (CGH). Whole-genome oligonucleotide array CGH and SNP analysis identified an interstitial deletion of at least 1.5 Mb within 9p21.3 and spanning approximately 25 genes. Identification of the underlying molecular abnormality permits predictive testing for at-risk relatives. Given the young cancer diagnoses, a surveillance regimen was developed and a clinical team organised for ongoing management so that genetic testing could be offered to both adults and minor children. Surveillance recommendations addressed cancer risks associated with FAMMM, and other cancers exhibited by this family with a large contiguous gene deletion.",
        "Doc_title":"An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies.",
        "Journal":"Journal of medical genetics",
        "Do_id":"26794401",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605790689216430080},
      {
        "Doc_abstract":"Although the induction of indoleamine 2, 3-dioxygenase (IDO) by several agents is well established, the mechanisms of its transcriptional regulation and those regulating its function as apoptotic mediator seem to be complex, agent-dependent, and cell type-specific. Besides their pro-apoptotic activity in melanoma cells, both anti-Fas agonist antibody (CH11) and the tumor necrosis factor (TNF)-alpha were found to induce IDO gene expression, the activation of apoptosis signal-regulating kinase (ASK1), and the activation of both c-Jun N-terminal kinase (JNK) and NF-kappaB pathways. In addition, the treatment of melanoma cells with CH11 or TNF-alpha induced the loss of mitochondrial membrane potential (Deltapsim), the accumulation of reactive oxygen species (ROS), the phosphorylation of Fas-associated domain (FADD), the cleavage of caspase-8, and truncation of Bid. Using RNA interference and pharmacological inhibitors, we could confirm the pro-apoptotic activity of IDO and address the mechanisms, which are responsible for its transcriptional regulation and the modulation of its pro-apoptotic activity during death receptor activation in melanoma cells. Thus, our data confirm the pro-apoptotic activity of IDO and provide an insight into the molecular mechanism of TNF-alpha and CH11-induced IDO expression, and the mechanism whereby IDO induces apoptosis of melanoma cells.",
        "Doc_title":"Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation.",
        "Journal":"Cellular signalling",
        "Do_id":"19799997",
        "Doc_ChemicalList":"BH3 Interacting Domain Death Agonist Protein;Fas-Associated Death Domain Protein;Indoleamine-Pyrrole 2,3,-Dioxygenase;NF-kappa B;Reactive Oxygen Species;Receptors, Death Domain;Tumor Necrosis Factor-alpha;JNK Mitogen-Activated Protein Kinases;MAP Kinase Kinase Kinase 5;Caspase 8",
        "Doc_meshdescriptors":"Apoptosis;BH3 Interacting Domain Death Agonist Protein;Caspase 8;Cell Line, Tumor;Fas-Associated Death Domain Protein;Humans;Indoleamine-Pyrrole 2,3,-Dioxygenase;JNK Mitogen-Activated Protein Kinases;MAP Kinase Kinase Kinase 5;Melanoma;Membrane Potential, Mitochondrial;NF-kappa B;RNA Interference;Reactive Oxygen Species;Receptors, Death Domain;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;enzymology;metabolism;drug effects;metabolism;metabolism;metabolism;pharmacology",
        "_version_":1605752549007163392},
      {
        "Doc_abstract":"Thioredoxin (Trx) is an intracellular multifunctional 12-kDa protein with a reduction/oxidation (redox) active disulfide constitutively expressed by most cells of the human body. Trx can also be released by cells such as lymphocytes upon activation or oxidative stress exposure and exert a cocytokine and cytoprotective activity. In addition, a truncated 10-kDa form of Trx has been reported. In order to better understand the function of full-length and truncated Trx, we have produced, for the first time, specific monoclonal antibodies, which can discriminate between the two forms. Using these novel antibodies, designated alpha Trx1 to alpha Trx4, a panel of cell lines derived from human B and T lymphocytes, monocytes, granulocytes, and melanomas was analyzed by immunochemical techniques. The cellular distribution differed between the two forms. All lines contained full-length Trx, also located to a minor extent on the cell surface. One exception was the melanoma cell line FM28.4, which did not show any Trx expression. Truncated Trx was present in most cells in minimal amounts only, whereas the monocytic cell lines THP-1 and U-937 expressed high amounts on the cell surface, as shown by flow cytometric analysis of living cells and confocal laser-scanning microscopy. The biological importance and function of the short versus long forms of Trx as detected by the antibodies are discussed.",
        "Doc_title":"Thioredoxin expression and localization in human cell lines: detection of full-length and truncated species.",
        "Journal":"Experimental cell research",
        "Do_id":"9344598",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antigens, Surface;Thioredoxins",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Antibodies, Monoclonal;Antibody Specificity;Antigens, Surface;Blotting, Western;Cell Membrane;Enzyme-Linked Immunosorbent Assay;Female;Flow Cytometry;Gene Expression;Humans;Intracellular Membranes;Mice;Mice, Inbred BALB C;Microscopy, Confocal;Molecular Sequence Data;Molecular Weight;Thioredoxins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;genetics;immunology;chemistry;physiology;chemistry;chemistry;genetics;immunology;chemistry;physiology",
        "_version_":1605892606220304384},
      {
        "Doc_abstract":"Desmoplastic melanoma is an uncommon variant of melanoma with sarcomatous histology, distinct clinical behavior and unknown pathogenesis. We performed low-coverage genome and high-coverage exome sequencing of 20 desmoplastic melanomas, followed by targeted sequencing of 293 genes in a validation cohort of 42 cases. A high mutation burden (median of 62 mutations/Mb) ranked desmoplastic melanoma among the most highly mutated cancers. Mutation patterns strongly implicate ultraviolet radiation as the dominant mutagen, indicating a superficially located cell of origin. Newly identified alterations included recurrent promoter mutations of NFKBIE, encoding NF-ÎºB inhibitor É (IÎºBÉ), in 14.5% of samples. Common oncogenic mutations in melanomas, in particular in BRAF (encoding p.Val600Glu) and NRAS (encoding p.Gln61Lys or p.Gln61Arg), were absent. Instead, other genetic alterations known to activate the MAPK and PI3K signaling cascades were identified in 73% of samples, affecting NF1, CBL, ERBB2, MAP2K1, MAP3K1, BRAF, EGFR, PTPN11, MET, RAC1, SOS2, NRAS and PIK3CA, some of which are candidates for targeted therapies.",
        "Doc_title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.",
        "Journal":"Nature genetics",
        "Do_id":"26343386",
        "Doc_ChemicalList":"I-kappa B Proteins;NFKBIE protein, human;Proto-Oncogene Proteins",
        "Doc_meshdescriptors":"Exome;Humans;I-kappa B Proteins;MAP Kinase Signaling System;Melanoma;Mutation;Promoter Regions, Genetic;Proto-Oncogene Proteins",
        "Doc_meshqualifiers":"genetics;enzymology;genetics;pathology;genetics",
        "_version_":1605797922056699904},
      {
        "Doc_abstract":"To report a choroidal melanoma in a 7-year-old child treated by trans-scleral local resection and adjuvant brachytherapy with a family history of neurofibromatosis type I (NF1) and cutaneous melanoma.;A 7-year-old child was referred for treatment of a choroidal tumor in her left eye with a differential diagnosis of melanoma, neurilemmoma, leiomyoma, and neurofibroma. Trans-scleral local resection and, subsequently, adjuvant brachytherapy were performed.;Histopathology and immunohistochemistry of the specimen diagnosed an amelanotic melanoma of spindle cell type, with a moderately high number of mitoses (7/40 HPF). Multiplex ligation-dependent probe amplification (MLPA) analysis showed two copies of chromosome 3, three copies of the short arm of chromosome 6, and two copies of chromosome 8, strongly suggesting a good prognosis. Postoperative ophthalmic evaluation at 6 months showed no visible tumor and flat retina with visual acuity (VA) of 6/60.;Trans-scleral local resection with adjuvant brachytherapy in children is possible using the same techniques as for adults. Although the follow-up is short, our patient retained the eye with good vision and our cytogenetic studies allowed us to reassure the mother.",
        "Doc_title":"Choroidal melanoma in a 7-year-old child treated by trans-scleral local resection.",
        "Journal":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie",
        "Do_id":"20143236",
        "Doc_ChemicalList":"Ruthenium Radioisotopes",
        "Doc_meshdescriptors":"Brachytherapy;Child;Choroid Neoplasms;Combined Modality Therapy;Female;Humans;Melanoma;Ophthalmologic Surgical Procedures;Radiotherapy, Adjuvant;Ruthenium Radioisotopes;Sclera",
        "Doc_meshqualifiers":"pathology;radiotherapy;surgery;pathology;radiotherapy;surgery;therapeutic use;surgery",
        "_version_":1605759895184867328},
      {
        "Doc_abstract":"Pmel17 is a approximately 100 kDa pigment cell specific glycoprotein that plays a crucial part in the morphogenesis of melanosome precursors. Anti-Pmel17 immunoprecipitates from metabolically pulse labeled melanoma cells and melanocytes contain, in addition to full-length Pmel17, a glycoprotein that migrates with a lower relative molecular weight. Here we show that this glycoprotein is encoded by an mRNA that results from alternative splicing of the human Pmel17 gene from which a cryptic intron is excised. Immunoprecipitation recapture experiments showed that this glycoprotein contained both the N- and C-termini of full-length Pmel17. Sequence analysis of cDNA corresponding to the alternatively spliced form reveals the loss of three of 10 imperfect direct repeats from the central region of the lumenal domain. The product of the splice variant is processed with similar kinetics to full-length Pmel17, and localizes similarly to late endosomes when expressed ectopically in nonpigment cells. We speculate that truncation of the repeat region within Pmel17 alters either fibrillogenic activity or the interaction of Pmel17 with melanin intermediates. The expression of an alternatively spliced product may furthermore affect the cohort of peptides generated for recognition of melanoma cells by tumor-directed T lymphocytes.",
        "Doc_title":"A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"14632201",
        "Doc_ChemicalList":"Epitopes;Melanins;Membrane Glycoproteins;PMEL protein, human;Proteins;RNA, Messenger;gp100 Melanoma Antigen",
        "Doc_meshdescriptors":"Amino Acid Sequence;Base Sequence;Cell Line, Tumor;Epitopes;Humans;Melanins;Melanocytes;Melanoma;Melanosomes;Membrane Glycoproteins;Molecular Sequence Data;Protein Structure, Tertiary;Proteins;RNA Splicing;RNA, Messenger;Skin Neoplasms;T-Lymphocytes;Tandem Repeat Sequences;gp100 Melanoma Antigen",
        "Doc_meshqualifiers":"metabolism;cytology;physiology;physiology;chemistry;genetics;immunology;genetics;immunology",
        "_version_":1605764962257469440},
      {
        "Doc_abstract":"The human monoclonal antibody (HuMAb) L92 reacts to an M(r) 43,000 protein associated with human melanoma. To identify the gene encoding its antigenic epitope, a complementary DNA expression library constructed from the human melanoma cell line UCLASO M14 was screened with HuMAb L92. DNA sequence analysis of the isolated clone revealed that the immunoreactive peptide was composed of 10 amino acids (QDLT-MKYQIF). The peptide was expressed in Escherichia coli with beta-galactosidase as a fused protein. There is no homology between the cloned sequence and other reported DNA sequences. Western blot analysis showed that the fused protein had specific binding to HuMAb L92. An antigen-encoding peptide with 10 amino acids was synthesized and tested for its immunoreactivity in vitro. HuMAb L92 reacted specifically to the 10-amino acid peptide in both an antibody-binding inhibition to the M(r) 43,000 protein and a solid-phase enzyme-linked immunosorbent assay. Using several truncated fusion proteins, we found the minimum number of amino acids required for the antibody binding to be 4 (KYQI). These results suggest that the identified peptide sequence encodes the antigenic epitope of the M(r) 43,000 protein.",
        "Doc_title":"Human monoclonal antibody identified an immunoreactive tetrapeptide sequence (Lys-Tyr-Gln-Ile) in M(r) 43,000 protein of human melanoma.",
        "Journal":"Cancer research",
        "Do_id":"8012974",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antigens, Neoplasm;tumor-associated antigen, gp43",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antibodies, Monoclonal;Antigens, Neoplasm;Base Sequence;Blotting, Western;Humans;Melanoma;Molecular Sequence Data;Molecular Weight;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"immunology;analysis;chemistry;immunology;chemistry;immunology",
        "_version_":1605909757231628288},
      {
        "Doc_abstract":"Histocompatibility leukocyte antigen (HLA)-A2 is used as a restricting element to present several melanoma-associated antigen (MAA)-derived peptides to cytotoxic T lymphocytes (CTLs). HLA-A2 antigen is selectively lost in primary melanoma lesions and more frequently in metastases. Only scanty information is available about the molecular mechanisms underlying this abnormality, in spite of its potentially negative impact on the clinical course of the disease and on the outcome of T cell-based immunotherapy. Therefore, in this study we have shown that the selective HLA-A2 antigen loss in melanoma cells 624MEL28 is caused by a splicing defect of HLA-A2 pre-mRNA because of a base substitution at the 5' splice donor site of intron 2 of the HLA-A2 gene. As a result, HLA-A2 transcripts are spliced to two aberrant forms, one with exon 2 skipping and the other with intron 2 retention. The latter is not translated because of an early premature stop codon in the retained intron. In contrast, the transcript with exon 2 skipping is translated to a truncated HLA-A2 heavy chain without the alpha(1) domain. Such a polypeptide is synthesized in vitro but is not detectable in cells, probably because of the low steady state level of the corresponding mRNA and the low translation efficiency. These results indicate that a single mutational event in an HLA class I gene is sufficient for loss of the corresponding allele. This may account, at least in part, for the high frequency of selective HLA class I allele loss in melanoma cells. Our conclusion emphasizes the need to implement active specific immunotherapy with a combination of peptides presented by various HLA class I alleles. This strategy may counteract the ability of melanoma cells with selective HLA class I allele loss to escape from immune recognition.",
        "Doc_title":"Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"10432284",
        "Doc_ChemicalList":"DNA Primers;DNA, Complementary;DNA, Neoplasm;HLA-A2 Antigen;RNA Precursors;RNA, Neoplasm",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Base Sequence;DNA Primers;DNA, Complementary;DNA, Neoplasm;Gene Expression;Genes, MHC Class I;HLA-A2 Antigen;Humans;Immunotherapy;Introns;Melanoma;Molecular Sequence Data;Mutation;RNA Precursors;RNA, Neoplasm;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;biosynthesis;genetics;genetics;immunology;therapy;genetics;metabolism;genetics;metabolism",
        "_version_":1605808715541250048},
      {
        "Doc_abstract":"The activation of plasminogen at the cell surface is a crucial step in cell migration and invasion. In the present study, the effect of membrane-bound melanotransferrin (mMTf), also known as human melanoma antigen p97, on cell surface plasminogen binding and activation was investigated by using Chinese Hamster Ovary (CHO) cells transfected with full-length melanotransferrin (MTf) cDNA and SK-MeL-28 melanoma cells. The expression of mMTf in CHO increased cell surface plasminogen binding by about 2-fold. In addition, application of the monoclonal antibody L235 against MTf as well as truncated, soluble MTf (sMTf) abolished plasminogen binding to MTf-transfected and SK-MeL-28 cells, indicating that mMTf is a potential cell surface plasminogen receptor. Moreover, mMTf expression in CHO cells stimulates plasminogen activation at the cell surface by about 2.5-fold. In addition to the induced binding and activation of plasminogen, cell motility, migration and invasion were about 3-fold higher in CHO cells expressing mMTf. Both monoclonal antibody L235 and truncated sMTf inhibited mMTf-stimulated CHO cell motility, migration and invasion. Overall, our results indicate a key role for mMTf in cell surface plasminogen binding and in activation processes involved during cell migration and invasion.",
        "Doc_title":"Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion.",
        "Journal":"Experimental cell research",
        "Do_id":"15936756",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antigens, Neoplasm;DNA, Complementary;Melanoma-Specific Antigens;Neoplasm Proteins;PLAUR protein, human;Receptors, Cell Surface;Receptors, Urokinase Plasminogen Activator;Plasminogen;Plasminogen Activators",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antigens, Neoplasm;CHO Cells;Cell Membrane;Cell Movement;Cricetinae;DNA, Complementary;Humans;Melanoma-Specific Antigens;Neoplasm Invasiveness;Neoplasm Proteins;Plasminogen;Plasminogen Activators;Protein Binding;Receptors, Cell Surface;Receptors, Urokinase Plasminogen Activator;Transfection;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;metabolism;physiology;genetics;physiopathology;antagonists & inhibitors;genetics;metabolism;metabolism;metabolism;physiology;genetics;metabolism;physiology",
        "_version_":1605806259940884480},
      {
        "Doc_abstract":"Cadherins belong to a family of homophilic cell-cell adhesion proteins that are responsible for the establishment of a precise cell architecture and tissue integrity. Moreover, experimental data suggest that loss of intercellular adhesion is inversely correlated with cellular differentiation. Furthermore, dedifferentiation is closely linked to tumor progression. Recently, we have shown that a secreted 50 kDa N-terminal fragment of P-cadherin plays a role in the progression of malignant melanoma. In this study, we have detected both the full-length and the truncated versions of P-cadherin in cell lysates of differentiated head and neck oral squamous cell carcinoma cell lines, whereas in cell lysates of dedifferentiated cell lines, we detected only the truncated 50 kDa version of P-cadherin. Treatment of the cell lines with a recombinantly expressed biotinylated, soluble 50 kDa form of the N-terminal part of P-cadherin revealed a major effect on cell aggregation and migration of oral squamous cell carcinoma cells. However, the 50 kDa N-terminal fragment of P-cadherin did not show any influence on cell proliferation in 2D and 3D cell culture. These results suggest that generation of truncated P-cadherin during the progression of oral squamous carcinoma attenuates tissue integrity, facilitates cellular separation, and leads to the acquisition of a more migratory phenotype.",
        "Doc_title":"Truncated P-cadherin is produced in oral squamous cell carcinoma.",
        "Journal":"The FEBS journal",
        "Do_id":"18637117",
        "Doc_ChemicalList":"Cadherins",
        "Doc_meshdescriptors":"Cadherins;Carcinoma, Squamous Cell;Cell Differentiation;Cell Line, Tumor;Cell Movement;Humans;Male;Mouth Neoplasms;Sequence Deletion",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605756422508773376},
      {
        "Doc_abstract":"To evaluate risk factors for lymphoedema development in the upper and lower limbs and to propose a model that predicts risk of lymphoedema after lymphadenectomy.;We studied 84 patients who had undergone radical lymphadenectomies for cutaneous melanoma from 1990 to 2008.;The patients included underwent an evaluation that consisted of measurement of limb volume using perimetry, application of the manually acquired perimetric data to the truncated-cone formula, and data from medical records.;Using multivariate analysis, we obtained the following risk factors for the development of lymphoedema: reconstruction with graft (p = 0.013), Breslow depth >4mm (p = 0.029), ilioinguinal lymphadenectomy (p = 0.037) and wound infection (p = 0.036). We assigned points to each factor as dictated by the value of the regression coefficient, as follows: infection (1 point), ilioinguinal lymphadenectomy and Breslow >4mm (2 points each) and reconstruction with graft (3 points). The mathematical model for predicting lymphoedema risk in the limb ipsilateral to the lymphadenectomy was based on risk groups, defined by score: low risk = 0 point (for which we calculated an 8.3% chance of developing lymphoedema), intermediate risk = 1-2 points (26.8%), high risk = 3 points (52.9%) and very high risk = 4 or more points (88.9%).;This study identified a melanoma thickness >4mm, graft reconstruction, ilioinguinal lymphadenectomy and infection as risk factors for lymphoedema. From these factors, we constructed a mathematical model that successfully predicted risk of post-lymphadenectomy lymphoedema. The combined presence of these risk factors increased the chance of developing lymphoedema.",
        "Doc_title":"Mathematical model to predict risk for lymphoedema after treatment of cutaneous melanoma.",
        "Journal":"International journal of surgery (London, England)",
        "Do_id":"21276878",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Axilla;Child;Child, Preschool;Extremities;Female;Humans;Inguinal Canal;Lymph Node Excision;Lymphedema;Male;Melanoma;Middle Aged;Models, Biological;Multivariate Analysis;Postoperative Complications;Risk Assessment;Risk Factors;Skin Neoplasms;Young Adult",
        "Doc_meshqualifiers":"epidemiology;surgery;epidemiology;methods;surgery",
        "_version_":1605929021292412928},
      {
        "Doc_abstract":"The treatment of melanoma has been revolutionized over the past decade with the development of effective molecular and immune targeted therapies. The great majority of patients with melanoma have mutations in oncogenes that predominantly drive signaling through the mitogen activated protein kinase (MAPK) pathway. Analytic tools have been developed that can effectively stratify patients into molecular subsets based on the identification of mutations in oncogenes and/or tumor suppressor genes that drive the MAPK pathway. At the same time, potent and selective inhibitors of mediators of the MAPK pathway such as RAF, MEK, and ERK have become available. The most dramatic example is the development of single-agent inhibitors of BRAF (vemurafenib, dabrafenib, encorafenib) and MEK (trametinib, cobimetinib, binimetinib) for patients with metastatic BRAFV600-mutant melanoma, a subset that represents 40% to 50% of patients with metastatic melanoma. More recently, the elucidation of mechanisms underlying resistance to single-agent BRAF inhibitor therapy led to a second generation of trials that demonstrated the superiority of BRAF inhibitor/MEK inhibitor combinations (dabrafenib/trametinib; vemurafenib/cobimetinib) compared to single-agent BRAF inhibitors. Moving beyond BRAFV600 targeting, a number of other molecular subsets--such as mutations in MEK, NRAS, and non-V600 BRAF and loss of function of the tumor suppressor neurofibromatosis 1 (NF1)--are predicted to respond to MAPK pathway targeting by single-agent pan-RAF, MEK, or ERK inhibitors. As these strategies are being tested in clinical trials, preclinical and early clinical trial data are now emerging about which combinatorial approaches might be best for these patients.",
        "Doc_title":"Achievements and challenges of molecular targeted therapy in melanoma.",
        "Journal":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting",
        "Do_id":"25993155",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Animals;Drug Discovery;Drug Resistance, Neoplasm;Genomics;Humans;Melanoma;Molecular Diagnostic Techniques;Molecular Targeted Therapy;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf",
        "Doc_meshqualifiers":"genetics;methods;diagnosis;etiology;therapy;pharmacology;therapeutic use;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605757772744359936},
      {
        "Doc_abstract":"The loss of chromosome 1p and chromosome 3 is associated with metastatic disease and decreased survival of uveal melanoma (UM) patients. The p53 homologues, p73 and p63, are located on chromosomes 1p and 3q, respectively. Both are able to activate p53 target genes, resulting in growth arrest, apoptosis and differentiation. N-terminally truncated isoforms of these genes may act as dominant negative inhibitors of wild-type p53 and transactivating activity. Although, p53 is frequently involved in several malignancies it does not play a major role in UM. Altered expression has been reported for both p63 and p73 in various malignancies. In this study, fluorescent in-situ hybridization was performed to identify gains or losses of p63 and p73 loci in UM. The expression of the different p63 and p73 isoforms was evaluated by reverse transcriptase PCR followed by Southern blot analysis. Furthermore, the expression pattern of the various DeltaTAp73 transcripts was analysed in seven primary UMs and 11 UM-derived cell lines using isoform-specific real-time PCR. Our results indicated that the isoform p73Deltaex2/3 was abundantly expressed and a relative loss of the p73 locus was associated with the upregulation of p73Deltaex2 and TAp73 transcripts. N-terminal transactivation forms of both p73 and p63 were observed in primary and metastasis-derived cell lines, as well as in primary melanomas, but in only one of the cell lines a DeltaNp63 mRNA transcript was observed. Our data suggest a potential function of p73 deletion transcripts in UM progression.",
        "Doc_title":"Increased expression of p73Deltaex2 transcript in uveal melanoma with loss of chromosome 1p.",
        "Journal":"Melanoma research",
        "Do_id":"18477895",
        "Doc_ChemicalList":"DNA-Binding Proteins;Nuclear Proteins;Protein Isoforms;RNA, Messenger;Tumor Protein p73;Tumor Suppressor Proteins;p73 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Chromosome Deletion;Chromosomes, Human, Pair 1;DNA-Binding Proteins;Disease Progression;Female;Gene Dosage;Humans;Male;Melanoma;Middle Aged;Nuclear Proteins;Protein Isoforms;RNA, Messenger;Tumor Protein p73;Tumor Suppressor Proteins;Up-Regulation;Uveal Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605841222590529536},
      {
        "Doc_abstract":"Membrane-type-1 matrix metalloproteinase (MT1-MMP) has transmembrane and cytoplasmic domains, which target it to invasive fronts. We analyzed the role of the cytoplasmic tail by expressing wild type MT1-MMP and three mutants with progressively truncated C termini in human Bowes melanoma cells. We examined gelatinase A activation and the localization and processing of recombinant proteins in stable cell clones using gelatin zymography, immunoblotting, and immunofluorescence. Cell invasion was analyzed in vitro by Matrigel invasion assays. Gelatinase A was activated in all cell clones. However, the localization of MT1-MMP to the leading edge of migrating cells and cell invasion through Matrigel were strongly enhanced only in cells expressing either wild type or truncated MT1-MMP lacking 6 C-terminal amino acid residues (Delta577). Truncations of 10 or 16 amino acid residues in the cytoplasmic domain (Delta567 and Delta573, respectively) disturbed MT1-MMP localization. The expression of wild type and Delta577 MT1-MMPs induced also their cleavage to 43-kDa cell surface forms and the release of soluble, approximately 20-kDa N-terminal fragments containing the catalytic center. A synthetic MMP inhibitor but not a gelatinase inhibitor prevented the processing, suggesting that autocatalytic cleavage occurs. Purified soluble MT1-MMP was also autoproteolytically processed to 43- and 20-kDa forms in vitro. Our results indicate that the cytoplasmic domain has an important role in cell invasion by controlling both the targeting and degradation/turnover of MT1-MMP.",
        "Doc_title":"Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"10748199",
        "Doc_ChemicalList":"Drug Combinations;Laminin;Protease Inhibitors;Proteoglycans;Recombinant Proteins;matrigel;Collagen;Matrix Metalloproteinases, Membrane-Associated;Metalloendopeptidases;Matrix Metalloproteinase 2",
        "Doc_meshdescriptors":"Cloning, Molecular;Collagen;Cytoplasm;Drug Combinations;Enzyme Activation;Humans;Laminin;Matrix Metalloproteinase 2;Matrix Metalloproteinases, Membrane-Associated;Melanoma;Metalloendopeptidases;Neoplasm Invasiveness;Protease Inhibitors;Proteoglycans;Recombinant Proteins;Sequence Deletion;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"enzymology;metabolism;chemistry;genetics;metabolism;pharmacology;chemistry;metabolism",
        "_version_":1605877047162306560},
      {
        "Doc_abstract":"Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder, affecting approximately 1 in 3500 individuals. The most commonly seen tumors in NF1 patients are the (sub)cutaneous neurofibromas. However, individuals with NF1 typically present in childhood with well-defined pigmentary defects, including cafe-au-lait macules (CALMs), intertriginous freckling and iris Lisch nodules. NF1 is considered a neurocristopathy, primarily affecting tissues derived from the neural crest. Since the pigment producing melanocyte originates in the neural crest, the presence of (hyper)pigmentary lesions in the NF1 phenotype because of changes in melanocyte cell growth and differentiation is to be expected. We want to discuss the pigmentary cutaneous manifestations of NF1 represented by CALMs and intertriginous freckles and the pigmentary non-cutaneous manifestations represented by iris Lisch nodules. Several hypotheses have been suggested in explaining the poorly understood etiopathogenesis of CALMs. Whether other pigmentary manifestations might share similar etiopathogenic mechanisms remains obscure. Additional attention will be drawn to a readily seen phenomenon in NF1: hyperpigmentation overlying (plexiform) neurofibromas, which could suggest common etiopathogenetic-environmental cues or mechanisms underlying CALMs and neurofibromas. Finally, we want to address the relationship between malignant melanoma and NF1.",
        "Doc_title":"Pigment cell-related manifestations in neurofibromatosis type 1: an overview.",
        "Journal":"Pigment cell research",
        "Do_id":"15649148",
        "Doc_ChemicalList":"Neurofibromin 1",
        "Doc_meshdescriptors":"Cafe-au-Lait Spots;Cell Differentiation;Cell Proliferation;Humans;Melanocytes;Melanoma;Melanosis;Neural Crest;Neurofibromatosis 1;Neurofibromin 1",
        "Doc_meshqualifiers":"etiology;physiopathology;genetics;physiology;pathology;physiology;etiology;physiopathology;etiology;physiopathology;physiopathology;complications;genetics;physiopathology;genetics;metabolism",
        "_version_":1605764206657798144},
      {
        "Doc_abstract":"Glycoprotein NMB (GPNMB), a transmembrane glycoprotein highly expressed in high-grade gliomas (HGGs), is an attractive target in cancer immunotherapy. We isolated a GPNMB-specific scFv clone, G49, from a human synthetic phage-display library. To obtain mutant single-chain variable-fragment antibodies (scFvs) with improved affinity and immunotoxins with increased activity, we subjected G49 to in vitro affinity maturation by a complementarity-determining-region (CDR) random-mutagenesis technique. Using light-chain CDR3 mutagenesis, cell-based panning by phage display, subsequent heavy-chain CDR1 mutagenesis, and flow-cytometric selection by yeast-surface display, we generated the mutant scFv clone 902V, with an overall 11-fold increase in affinity for GPNMB. Clone 902V was further randomized throughout the whole scFv by error-prone PCR, and one mutant, F6V, was selected by yeast-surface display. F6V scFv, differing from 902V by one amino-acid change in the light-chain CDR2, exhibited an affinity for GPNMB of 0.30 nM. The F6V mutant scFv clone was fused with a truncated form of Pseudomonas exotoxin A to form the immunotoxin F6V-PE38. F6V-PE38 demonstrated significant protein-synthesis-inhibition activity on GPNMB-expressing glioma and malignant melanoma cells (IC(50) = 0.5 ng/ml [8 pM]), a 60-fold improvement over G49 activity, but no cytotoxicity on GPNMB-negative cells. Furthermore, F6V-PE38 exhibited significant antitumor activity against subcutaneous malignant glioma xenografts in two nude-mouse models and a melanoma neoplastic meningitis model in athymic rats. These GPNMB-specific scFv antibodies and immunotoxins hold promise as reagents in targeted therapy for HGGs and other GPNMB-expressing malignancies.",
        "Doc_title":"Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.",
        "Journal":"International journal of cancer",
        "Do_id":"20824708",
        "Doc_ChemicalList":"GPNMB protein, human;Immunotoxins;Membrane Glycoproteins;Recombinant Fusion Proteins",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Chromatography, Affinity;Flow Cytometry;Glioma;Humans;Immunotoxins;Melanoma;Membrane Glycoproteins;Mice;Mice, Nude;Recombinant Fusion Proteins;Surface Plasmon Resonance",
        "Doc_meshqualifiers":"pathology;chemistry;isolation & purification;pharmacology;pathology;chemistry;isolation & purification;pharmacology;chemistry;isolation & purification;pharmacology",
        "_version_":1605746400234045441},
      {
        "Doc_abstract":"With the recent discovery of recurrent mutations in the TERT promoter in melanoma, identification of other somatic causal promoter mutations is of considerable interest. Yet, the impact of sequence variation on the regulatory potential of gene promoters has not been systematically evaluated. This study assesses the impact of promoter mutations on promoter activity in the whole-genome sequenced malignant melanoma cell line COLO-829. Combining somatic mutation calls from COLO-829 with genome-wide chromatin accessibility and histone modification data revealed mutations within promoter elements. Interestingly, a high number of potential promoter mutations (n = 23) were found, a result mirrored in subsequent analysis of TCGA whole-melanoma genomes. The impact of wild-type and mutant promoter sequences were evaluated by subcloning into luciferase reporter vectors and testing their transcriptional activity in COLO-829 cells. Of the 23 promoter regions tested, four mutations significantly altered reporter activity relative to wild-type sequences. These data were then subjected to multiple computational algorithms that score the cis-regulatory altering potential of mutations. These analyses identified one mutation, located within the promoter region of NDUFB9, which encodes the mitochondrial NADH dehydrogenase (ubiquinone) 1 beta subcomplex 9, to be recurrent in 4.4% (19 of 432) of TCGA whole-melanoma exomes. The mutation is predicted to disrupt a highly conserved SP1/KLF transcription factor binding motif and its frequent co-occurrence with mutations in the coding sequence of NF1 supports a pathologic role for this mutation in melanoma. Taken together, these data show the relatively high prevalence of promoter mutations in the COLO-829 melanoma genome, and indicate that a proportion of these significantly alter the regulatory potential of gene promoters.;Genomic-based screening within gene promoter regions suggests that functional cis-regulatory mutations may be common in melanoma genomes, highlighting the need to examine their role in tumorigenesis.",
        "Doc_title":"Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"26082173",
        "Doc_ChemicalList":"Chromatin;Sp1 Transcription Factor;NDUFB9 protein, human;NADH Dehydrogenase",
        "Doc_meshdescriptors":"Cell Line, Tumor;Chromatin;Genes, Reporter;Genetic Techniques;Genome, Human;Humans;Melanoma;Models, Genetic;Mutation;NADH Dehydrogenase;Promoter Regions, Genetic;Regulatory Elements, Transcriptional;Skin Neoplasms;Sp1 Transcription Factor;Transcription, Genetic",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605759357788618752},
      {
        "Doc_abstract":"To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer.;A total of 53 unrelated UM patients with high risk for hereditary cancer and five additional family members of one proband were studied. Mutational screening was carried out by direct sequencing.;Of the 53 UM patients studied, a single patient was identified with a germline BAP1 truncating mutation, c. 799 CâT (p.Q267X), which segregated in several family members and was associated with UM and other cancers. Biallelic inactivation of BAP1 and decreased BAP1 expression were identified in the UM, lung adenocarcinoma and meningioma tumours from three family members with this germline BAP1 mutation. Germline BAP1 variants of uncertain significance, likely non-pathogenic, were also identified in two additional UM patients.;This study reports a novel hereditary cancer syndrome caused by a germline BAP1 mutation that predisposes patients to UM, lung carcinoma, meningioma, and possibly other cancers. The results indicate that BAP1 is the candidate gene in only a small subset of hereditary UM, suggesting the contribution of other candidate genes.",
        "Doc_title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.",
        "Journal":"Journal of medical genetics",
        "Do_id":"21941004",
        "Doc_ChemicalList":"Tumor Suppressor Proteins;BAP1 protein, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Chromosomes, Human, Pair 3;DNA Mutational Analysis;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Genetic Diseases, Inborn;Genetic Predisposition to Disease;Genetic Testing;Germ-Line Mutation;Humans;Loss of Heterozygosity;Lung Neoplasms;Male;Melanoma;Meningeal Neoplasms;Meningioma;Microsatellite Repeats;Middle Aged;Pedigree;Tumor Suppressor Proteins;Ubiquitin Thiolesterase;Uveal Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pathology;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605873796304076800},
      {
        "Doc_abstract":"Human MHC class I molecules are encoded by three different loci (HLA-A, -B, and -C), which are regulated at the transcriptional level through several conserved cis-acting promoter elements. The presence of locus-specific residues throughout the entire promoter region strongly suggests that the various HLA class I loci are differentially regulated. To identify regulatory sequences involved in locus-specific HLA class I gene transcription, a series of truncated HLA-A2 and HLA-B7 promoter-reporter constructs were transfected into melanoma cell lines expressing high and low levels of endogenous HLA-B, but comparable levels of HLA-A. These experiments showed that differential regulation of HLA-B expression in melanoma cell lines is mediated by a previously unidentified co-operative action of enhancer A, located 175 bp upstream of the transcription initiation site (+1), and a specific region of 20 nucleotides located at +13 to +33 bp downstream of the transcription initiation site. Furthermore, we demonstrated binding of transcription factor Yin Yang 1 to the HLA-A +13/+33 bp region, but not to the equivalent HLA-B region. Based on these results, we present a model suggesting that YY1 displaces either activating or repressing transcription factors, thereby making the HLA-A gene resistant to differential regulation.",
        "Doc_title":"HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site.",
        "Journal":"Immunogenetics",
        "Do_id":"11132148",
        "Doc_ChemicalList":"DNA-Binding Proteins;Erythroid-Specific DNA-Binding Factors;HLA-A2 Antigen;HLA-B Antigens;HLA-B7 Antigen;Transcription Factors;YY1 Transcription Factor;YY1 protein, human",
        "Doc_meshdescriptors":"Binding Sites;DNA-Binding Proteins;Down-Regulation;Enhancer Elements, Genetic;Erythroid-Specific DNA-Binding Factors;HLA-A2 Antigen;HLA-B Antigens;HLA-B7 Antigen;Humans;Melanoma;Promoter Regions, Genetic;Transcription Factors;Transcription, Genetic;Tumor Cells, Cultured;YY1 Transcription Factor",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;genetics;genetics;immunology;metabolism",
        "_version_":1605810194848153600},
      {
        "Doc_abstract":"Interleukin-6 (IL-6)-type cytokines lead to growth arrest of human A375 melanoma cells. The present study demonstrates that this effect depends on the activation of STAT transcription factors. We observed a correlation between the extent of growth inhibition exerted by IL-6, IL-6 plus soluble IL-6 receptor or oncostatin M (OSM) and the intensities of STAT3 and STAT1 signals. A truncated chimeric receptor retaining only the membrane-proximal region of gp130, the common signal transducer of IL-6-type cytokines, did neither activate STATs nor mediate growth arrest of stable transfectants. These functions were restored by the addition of short STAT recruitment modules comprising critical tyrosine residues from gp130 (Y767, Y814). A receptor carrying tyrosine module Y759 of gp130 effectively mediated activation of the phosphatase SHP-2 but did not alter cell growth. Overexpression of dominant negative forms of STAT3 but not STAT1 abrogated the inhibitory effect of OSM and IL-6 in A375 cells. In addition, we have identified the cyclin-dependent kinase inhibitor p27/Kipl as a novel target to be regulated by IL-6-type cytokines. Stimulation-dependent upregulation of p27 mRNA occurred STAT3-dependently. Also p27 protein accumulated which coincided with the disappearance of hyperphosphorylated retinoblastoma protein in three human melanoma cell lines sensitive to IL-6-type cytokines.",
        "Doc_title":"Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.",
        "Journal":"Oncogene",
        "Do_id":"10391682",
        "Doc_ChemicalList":"Antigens, CD;Cell Cycle Proteins;DNA-Binding Proteins;IL6ST protein, human;Interleukin-6;Intracellular Signaling Peptides and Proteins;Membrane Glycoproteins;Microtubule-Associated Proteins;Neoplasm Proteins;OSM protein, human;Peptides;RNA, Messenger;RNA, Neoplasm;Receptors, Erythropoietin;Recombinant Fusion Proteins;Retinoblastoma Protein;STAT1 Transcription Factor;STAT1 protein, human;STAT3 Transcription Factor;STAT3 protein, human;Trans-Activators;Tumor Suppressor Proteins;Oncostatin M;Cytokine Receptor gp130;Cyclin-Dependent Kinase Inhibitor p27;PTPN11 protein, human;PTPN6 protein, human;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Protein Tyrosine Phosphatase, Non-Receptor Type 6;Protein Tyrosine Phosphatases",
        "Doc_meshdescriptors":"Antigens, CD;Cell Cycle Proteins;Cell Division;Cyclin-Dependent Kinase Inhibitor p27;Cytokine Receptor gp130;DNA-Binding Proteins;Enzyme Activation;Gene Expression Regulation, Neoplastic;Humans;Interleukin-6;Intracellular Signaling Peptides and Proteins;Melanoma;Membrane Glycoproteins;Microtubule-Associated Proteins;Neoplasm Proteins;Oncostatin M;Peptides;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Protein Tyrosine Phosphatase, Non-Receptor Type 6;Protein Tyrosine Phosphatases;RNA, Messenger;RNA, Neoplasm;Receptors, Erythropoietin;Recombinant Fusion Proteins;Retinoblastoma Protein;STAT1 Transcription Factor;STAT3 Transcription Factor;Signal Transduction;Trans-Activators;Transfection;Tumor Cells, Cultured;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;physiology;drug effects;physiology;drug effects;pharmacology;pathology;genetics;physiology;biosynthesis;genetics;physiology;biosynthesis;genetics;physiology;pharmacology;physiology;biosynthesis;biosynthesis;genetics;physiology;physiology;metabolism;drug effects;physiology",
        "_version_":1605742151986053120},
      {
        "Doc_abstract":"The overexpression of the Xmrk oncogene (ONC-Xmrk) in pigment cells of certain Xiphophorus hybrids has been found to be the primary change that results in the formation of malignant melanoma. Spontaneous mutant stocks have been isolated that have lost the ability to induce tumor formation when crossed with Xiphophorus helleri. Two of these loss-of-function mutants were analyzed for genetic defects in ONC-Xmrk's. In the lof-1 mutant a novel transposable element, TX-1, has jumped into ONC-Xmrk, leading to a disruption of the gene and a truncated protein product lacking the carboxyterminal domain of the receptor tyrosine kinase. TX-1 is obviously an active LTR-containing retrotransposon in Xiphophorus that was not found in other fish species outside the family Poeciliidae. Surprisingly, it does not encode any protein, suggesting the existence of a helper function for this retroelement. In the lof-2 mutant the entire ONC-Xmrk gene was found to be deleted. These data show that ONC-Xmrk is indeed the tumor-inducing gene of Xiphophorus and thus the critical constituent of the tumor (Tu) locus.",
        "Doc_title":"Melanoma loss-of-function mutants in Xiphophorus caused by Xmrk-oncogene deletion and gene disruption by a transposable element.",
        "Journal":"Genetics",
        "Do_id":"10545466",
        "Doc_ChemicalList":"DNA Transposable Elements;Fish Proteins;Proto-Oncogene Proteins;Recombinant Proteins;Receptor Protein-Tyrosine Kinases;Xmrk protein, Xiphophorus",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Crosses, Genetic;Cyprinodontiformes;DNA Transposable Elements;Fish Diseases;Fish Proteins;Gene Deletion;Melanoma;Molecular Sequence Data;Mutation;Oncogenes;Polymerase Chain Reaction;Protein Biosynthesis;Proto-Oncogene Proteins;Receptor Protein-Tyrosine Kinases;Recombinant Proteins;Restriction Mapping;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;veterinary;genetics;biosynthesis;chemistry;genetics;biosynthesis",
        "_version_":1605907966448369664},
      {
        "Doc_abstract":"The neurofibromatosis type I gene encodes a protein, neurofibromin, which may function as a tumor suppressor gene product. Recent studies have demonstrated loss of neurofibromin in tumors from NF1 and non-NF1 patients, including neurofibrosarcomas, neuroblastomas and malignant melanomas. Since neurofibromin is expressed in the adrenal gland, six pheochromocytomas and one adrenal cortical tumor were examined for neurofibromin expression. In all seven tumors, no neurofibromin could be detected. Furthermore, loss of heterozygosity (LOH) analysis demonstrated that in one of the pheochromocytomas, reduction to homozygosity was observed for both 17p and 17q markers while the adrenal cortical tumor demonstrated LOH for only 17q markers. The frequent LOH surrounding the NF1 locus and lack of neurofibromin expression in these tumors suggest that NF1 gene mutations may contribute to the development of adrenal gland neoplasms in patients with NF1.",
        "Doc_title":"Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"7519874",
        "Doc_ChemicalList":"DNA Primers;Neurofibromin 1;Proteins",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Adult;Base Sequence;Chromosome Deletion;Chromosomes, Human, Pair 17;DNA Primers;Female;Heterozygote;Humans;Molecular Sequence Data;Neurofibromatosis 1;Neurofibromin 1;Pheochromocytoma;Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605905769979445248},
      {
        "Doc_abstract":"Tyrosinase has been suggested as a prodrug-converting enzyme for the treatment of melanoma. We hypothesized that tyrosinase expression in transfected nonmelanotic cells can be used in a gene therapy paradigm of prodrug activation. To verify our hypothesis, we used the following tyrosinase variants: (a) a full-length human tyrosinase clone (T); (b) a mutant lacking the COOH-terminal cytoplasmic domain (TdeltaC); (c) a mutant lacking the COOH-terminal transmembrane and cytoplasmic domains (TdeltaTC); and (d) a fusion with the eight COOH-terminal amino acids of lysosome-associated membrane protein-1 (TL). Expression of mutant and wild-type tyrosinases was induced by transfection in nontumorigenic human cells of epithelial origin (293HEK, MCF-10A adenoma, and NHDF-Ad human dermal fibroblasts) as well as in tumor cells (9L gliosarcoma, MCF7 adenocarcinoma, and HT-1080 fibrosarcoma). When compared with the wild-type tyrosinase transfectants, truncated mutant expression resulted in higher mRNA levels that paralleled higher enzyme activity of the truncated mutants. Two model tyrosinase prodrugs, hydroxyphenyl-propanol (HPP) and N-acetyl-4-S-cysteaminylphenol (NAcSCAP) inhibited proliferation and caused cell death of transfected cells in a dose-dependent manner. Effects of prodrug treatment were compared for tumorigenic cells and their nontumorigenic counterparts. Two truncated mutants (TdeltaC and TdeltaTC) showed low endogenous cytotoxicity and efficiently suppressed proliferation and induced cytotoxicity in transfected tumor cells in the presence of NAcSCAP. Overall, these results indicate that the developed tyrosinase mutants hold promise as prodrug activation systems for tumoral gene therapy.",
        "Doc_title":"Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells.",
        "Journal":"Cancer research",
        "Do_id":"11118049",
        "Doc_ChemicalList":"3-(4-hydroxyphenyl)propanol;Antineoplastic Agents;Melanins;Phenols;Prodrugs;Propanols;RNA, Messenger;Cysteamine;N-acetyl-4-S-cysteaminylphenol;Monophenol Monooxygenase",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Antineoplastic Agents;Biotransformation;Cell Division;Cell Line;Cysteamine;Fibrosarcoma;Gliosarcoma;Humans;Kidney;Melanins;Monophenol Monooxygenase;Mutation;Phenols;Prodrugs;Propanols;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug therapy;enzymology;genetics;pharmacokinetics;pharmacology;drug effects;analogs & derivatives;pharmacokinetics;pharmacology;drug therapy;enzymology;genetics;drug therapy;enzymology;genetics;cytology;enzymology;biosynthesis;genetics;metabolism;pharmacokinetics;pharmacology;pharmacokinetics;pharmacokinetics;pharmacology;genetics;metabolism",
        "_version_":1605750143670288384},
      {
        "Doc_abstract":"Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans. To the best of our knowledge, the current report of MM in a two-and-a-half-year-old Nigerian who had a pre-existing congenital giant hairy nevus is probably the first (in an accessible literature) in a black African child. Primary neoplastic transformation and metastatic spread were suggested by the appearance of multiple swellings over the \"garment\" precursor nevus at the posterior trunk, multiple ipsilateral axillary nodal enlargement, and fresh occipital swellings postadmission. Smaller-sized hyperpigmented lesions with irregular, nonlobulated, and frequently hairy surfaces were also discernible over the upper and lower extremities, but the face, anterior trunk, and mucosal surfaces were relatively spared. A diagnosis of MM was confirmed by the subsequent histopathologic findings from the fine-needle aspirate and biopsy specimens. Chemotherapy was initiated but was truncated shortly after by parent-pressured discharge. Despite the rarity of MM in a tropical African setting where management options are few, the current case underscores the need for a high clinical index of diagnostic suspicion, an early pursuit of investigative confirmation, and prophylactic excision in children with the predisposing skin lesions, like congenital giant hairy nevus. An expounded discourse of the possible precursors and management options of MM is provided. We emphasize the need for institutional cost subsidy for anticancer care in tropical children.",
        "Doc_title":"Malignant melanoma in a black child: predisposing precursors and management.",
        "Journal":"Journal of the National Medical Association",
        "Do_id":"15540891",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"African Continental Ancestry Group;Causality;Child, Preschool;Dysplastic Nevus Syndrome;Female;Humans;Lymph Nodes;Melanoma;Nigeria;Risk Factors;Skin Neoplasms;Skin Pigmentation",
        "Doc_meshqualifiers":"genetics;complications;congenital;ethnology;pathology;diagnosis;drug therapy;ethnology;etiology;complications;congenital;genetics",
        "_version_":1605746968805507072},
      {
        "Doc_abstract":"CD4(+) T cells play a critical role in generating and maintaining immune responses against pathogens and alloantigens, and evidence suggests an important role for them in antitumor immunity as well. Although major histocompatibility complex class II-restricted human CD4(+) T cells with specific antitumor reactivities have been described, no standard method exists for cloning the recognized tumor-associated antigen (Ag). In this study, biochemical protein purification methods were used in conjunction with novel mass spectrometry sequencing techniques and molecular cloning to isolate a unique melanoma Ag recognized by a CD4(+) tumor-infiltrating lymphocyte (TIL) line. The HLA-DRbeta1*0101-restricted Ag was determined to be a mutated glycolytic enzyme, triosephosphate isomerase (TPI). A C to T mutation identified by cDNA sequencing caused a Thr to Ile conversion in TPI, which could be detected in a tryptic digest of tumor-derived TPI by mass spectrometry. The Thr to Ile conversion created a neoepitope whose T cell stimulatory activity was enhanced at least 5 logs compared with the wild-type peptide. Analysis of T cell recognition of serially truncated peptides suggested that the mutated amino acid residue was a T cell receptor contact. Defining human tumor Ag recognized by T helper cells may provide important clues to designing more effective immunotherapies for cancer.",
        "Doc_title":"Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"10049939",
        "Doc_ChemicalList":"Antigens, Neoplasm;Epitopes;HLA-DR1 Antigen;Triose-Phosphate Isomerase",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antigens, Neoplasm;CD4-Positive T-Lymphocytes;Cell Line;Epitopes;HLA-DR1 Antigen;Humans;Lymphocytes, Tumor-Infiltrating;Male;Melanoma;Middle Aged;Molecular Sequence Data;Mutation;Triose-Phosphate Isomerase",
        "Doc_meshqualifiers":"genetics;immunology;immunology;genetics;immunology;immunology;enzymology;immunology;genetics;immunology",
        "_version_":1605747009027833857},
      {
        "Doc_abstract":"Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.;Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete response (CR) on BRAF and/or MEK inhibitors was analyzed using next generation sequencing (NGS) assay. Genomic libraries were captured for 3230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to average median depth of 734X with 99% of bases covered >100X.;Three of the ten patients (median number of prior therapiesâ=â2) attained prolonged CR (durationâ=â23.6+ to 28.7+ months); seven patients achieved either a PR or a short-lived CR. One patient who achieved CR ongoing at 28.7+ months and had tissue available close to the time of initiating BRAF inhibitor therapy had only a BRAF mutation. Abnormalities in addition to BRAF mutation found in other patients included: mutations in NRAS, APC and NF1; amplifications in BRAF, aurora kinase A, MYC, MITF and MET; deletions in CDKN2A/B and PAX5; and, alterations in RB1 and ATM. Heterogeneity between patients and molecular evolution within patients was noted.;NGS identified potentially actionable DNA alterations that could account for resistance in patients with BRAF mutation-positive advanced melanoma who achieved a PR or CR but whose tumors later progressed. A subset of patients with advanced melanoma may harbor only a BRAF mutation and achieve a durable CR on BRAF pathway inhibitors.",
        "Doc_title":"Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.",
        "Journal":"BMC cancer",
        "Do_id":"25886620",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;BRAF protein, human;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Adult;Drug Resistance, Neoplasm;Female;High-Throughput Nucleotide Sequencing;Humans;Male;Melanoma;Middle Aged;Mutation;Pilot Projects;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf;Skin Neoplasms;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"methods;drug therapy;genetics;therapeutic use;genetics;drug therapy;genetics",
        "_version_":1605794987016978432},
      {
        "Doc_abstract":"Bias in estimates of familial cancer may result if population-based registers fail to identify relatives as affected when disease occurs before the start-up of registration (ie, \"left-truncation\" of family history).;Apparent familial relative risks (among offspring of parents with cancer) of colorectal, lung, breast, and prostate cancers and melanoma in a Swedish cohort were compared with relative risks in a simulated population. The study cohort (approximately 7 million individuals) was based on the Swedish MultiGenerational Register linked to the Swedish Cancer Register for the period 1961-2002. A similar population of related individuals (approximately 7 million) with complete family information was simulated by using the R-package PopLab and used to estimate the sensitivity of the observed family history. This sensitivity was then used to calculate corrected age group-specific and overall risks, which were compared with the apparent familial risks of cancer in the cohort.;The apparent familial risks for colorectal, lung, breast, and prostate cancers and melanoma were 1.99 (95% confidence interval [CI] = 1.85 to 2.14), 2.05 (95% CI = 1.86 to 2.26), 1.84 (95% CI = 1.76 to 1.92), 2.33 (95% CI = 2.19 to 2.48), and 2.68 (95% CI = 2.35 to 3.07), with corresponding absolute rates of 3.69, 2.59, 16.05, 10.38, and 2.96 per 10 000 person-years, among offspring of parents diagnosed with the same cancer. Corrected age group-specific and overall estimates of the familial risks were close to these apparent risks for all studied cancers (all approximately 2.0), except for melanoma. For melanoma, the corrected estimate of 3.18 (95% CI = 2.73 to 3.64) was somewhat larger than the apparent estimate and was not included in the confidence interval for the apparent estimate. When the exposure of interest was a parent affected at a younger age, this bias was more pronounced; the apparent estimate for melanoma changed from 4.07 (95% CI = 3.21 to 5.16) to 5.67 (95% CI = 4.51 to 6.83) after correction.;For common cancers, risk estimates from the Swedish MultiGenerational cohort do not generally appear to be biased by left-truncation.",
        "Doc_title":"Evaluation of bias in familial risk estimates: a study of common cancers using Swedish population-based registers.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"18780865",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Bias (Epidemiology);Breast Neoplasms;Child;Child, Preschool;Colorectal Neoplasms;Confounding Factors (Epidemiology);Female;Genetic Predisposition to Disease;Humans;Incidence;Lung Neoplasms;Male;Melanoma;Middle Aged;Neoplasms;Prevalence;Prostatic Neoplasms;Registries;Risk Assessment;Risk Factors;Sensitivity and Specificity;Skin Neoplasms;Sweden",
        "Doc_meshqualifiers":"epidemiology;genetics;epidemiology;genetics;epidemiology;genetics;epidemiology;genetics;epidemiology;genetics;epidemiology;genetics;epidemiology;genetics;epidemiology",
        "_version_":1605818577828446209},
      {
        "Doc_abstract":"Desmoplastic melanoma (DM) is a variant of melanoma, which typically affects chronically sun-damaged skin of elderly patients. Pure DM displays a low density of fusiform melanocytes in a collagen-rich matrix. In mixed DM, tumor cell density is higher, and parts of the tumor lack abundant stromal fibrosis. Both pure and mixed DMs usually express S100 protein homogenously. We report herein an unusual biphenotypic tumor characterized by the association of a pure DM with an undifferentiated solid spindle cell nodule. It occurred on the scalp of a 66-year-old man. A biopsy of the undifferentiated spindle cell nodule was initially interpreted at a commercial laboratory as atypical fibroxanthoma. The pure DM was seen only in the excisional specimen. All cells of the pure DM stained for S100 protein and SOX10. The adjacent solid sarcomatoid spindle cell nodule lacked expression of S100 protein, SOX10, as well as melan-A, gp100, and microphthalmia-associated transcription factor in >95% of its tumor cells. Although focal expression of melanocyte differentiation antigens in the solid tumor component made us favor a combined DM with sarcomatoid dedifferentiation, we also considered the possibility of a collision scenario, that is, a pleomorphic dermal sarcoma incidentally colliding with a DM. To further assess a possible relationship of the sarcomatoid nodule with the DM, we performed next-generation sequencing analysis on each component separately. The analysis revealed shared chromosomal copy number changes and a high number of common mutations, thereby supporting the concept of a DM with a dedifferentiated sarcomatoid component. An interesting finding is the presence of mutations of the neurofibromin 1 (NF1) gene in both tumor components. ",
        "Doc_title":"Desmoplastic melanoma with sarcomatoid dedifferentiation.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"24618614",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Biopsy;Cell Dedifferentiation;Head and Neck Neoplasms;Humans;Immunohistochemistry;Male;Melanoma;Neoplasms, Complex and Mixed;Phenotype;Sarcoma;Scalp;Skin Neoplasms",
        "Doc_meshqualifiers":"analysis;genetics;chemistry;genetics;pathology;surgery;chemistry;genetics;pathology;surgery;chemistry;genetics;pathology;surgery;chemistry;genetics;pathology;surgery;chemistry;pathology;surgery;chemistry;genetics;pathology;surgery",
        "_version_":1605879859352961024},
      {
        "Doc_abstract":"Cutaneous malignant melanoma (CMM) morbidity and mortality rates have increased over the past several decades all around the world, but some developed countries have experienced recent declines in mortality from CMM among the young and middle-aged and even a reversal in the long-term increase in deaths attributable to CMM.;To describe CMM mortality trends, by age and gender, in Spain between 1975 and 1998.;Crude, age-adjusted, truncated, cumulative, age-specific and potential years of life lost rates of CMM mortality were calculated by gender. Age and period Poisson regression models were fitted to gender- and age-specific CMM mortality rates.;In males there were marked increases in all CMM mortality rates between 1975 and 1994, followed by their decrease during 1995-98. In contrast, rates rose in females between 1975 and 1998. There were annual increases of 13% in the risk of dying among males and 33% among females. Relative risks of CMM mortality increased with age in both genders: (i) 21.75 (95% confidence interval, CI 17.32-27.30) in males, and (ii) 28.27 (95% CI 24.99-31.97) in females in the > or = 70-year-old group, when compared with those < 35 years.;CMM mortality rates continue to rise in females while males have experienced a recent reversal of this trend in Spain. Emphasizing the danger of overexposure to ultraviolet radiation may be especially important in females.",
        "Doc_title":"Gender differences in rising trends in cutaneous malignant melanoma in Spain, 1975-98.",
        "Journal":"The British journal of dermatology",
        "Do_id":"12534603",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Distribution;Aged;Aged, 80 and over;Child;Child, Preschool;Female;Humans;Infant;Male;Melanoma;Middle Aged;Registries;Regression Analysis;Sex Distribution;Sex Factors;Skin Neoplasms;Spain;Survival Rate",
        "Doc_meshqualifiers":"mortality;mortality;epidemiology",
        "_version_":1605880347855159296},
      {
        "Doc_abstract":"Long-term treatment of mouse cancer cells with interferon-alpha (IFN-alpha) converts parental B16 melanoma cells to B16alpha vaccine cells. Inoculation of syngeneic mice with B16alpha vaccine cells triggers immunity to the parental B16 tumor that is mediated by host macrophages, T cells, and natural killer (NK) cells. Lymph node cells from mice inoculated with irradiated B16alpha vaccine cells, but not with irradiated parental cells, proliferate when cultured in vitro, suggesting long-term in vivo activation of lymphoid cells. Long-term IFN-alpha treatment of B16alpha vaccine cells induced both interleukin-15 (IL-15) mRNA and IL-15 protein. The bulk of the induced IL-15 remained cell associated, either cytoplasmic or associated with the cell membrane. Immunofluorescence microscopy studies showed that the cell-associated IL-15 was broadly distributed throughout the cytoplasm. These observations suggest that long-term IFN-alpha treatment may induce primarily the truncated isoform of IL-15. Vaccination with irradiated B16alpha vaccine cells may promote tumor immunity by releasing high levels of cell-associated IL-15 when spontaneously lysed or directly killed by innate immune cells. The release of accumulated cell-associated IL-15 may then trigger a host T cell response to tumor antigens and cause host development of immunity to the B16 tumor cells.",
        "Doc_title":"IFN-alpha-induced murine B16 melanoma cancer vaccine cells: induction and accumulation of cell-associated IL-15.",
        "Journal":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research",
        "Do_id":"17266439",
        "Doc_ChemicalList":"Cancer Vaccines;Interferon-alpha;Interleukin-15",
        "Doc_meshdescriptors":"Animals;Cancer Vaccines;Cell Line, Tumor;Cell Proliferation;Interferon-alpha;Interleukin-15;Lymph Nodes;Lymphocyte Activation;Melanoma, Experimental;Mice;T-Lymphocytes",
        "Doc_meshqualifiers":"immunology;physiology;biosynthesis;metabolism;secretion;cytology;immunology;immunology;immunology;metabolism;pathology;immunology;metabolism",
        "_version_":1605850607547056128},
      {
        "Doc_abstract":"The polycomb repressive complex 2 (PRC2) exerts oncogenic effects in many tumour types. However, loss-of-function mutations in PRC2 components occur in a subset of haematopoietic malignancies, suggesting that this complex plays a dichotomous and poorly understood role in cancer. Here we provide genomic, cellular, and mouse modelling data demonstrating that the polycomb group gene SUZ12 functions as tumour suppressor in PNS tumours, high-grade gliomas and melanomas by cooperating with mutations in NF1. NF1 encodes a Ras GTPase-activating protein (RasGAP) and its loss drives cancer by activating Ras. We show that SUZ12 loss potentiates the effects of NF1 mutations by amplifying Ras-driven transcription through effects on chromatin. Importantly, however, SUZ12 inactivation also triggers an epigenetic switch that sensitizes these cancers to bromodomain inhibitors. Collectively, these studies not only reveal an unexpected connection between the PRC2 complex, NF1 and Ras, but also identify a promising epigenetic-based therapeutic strategy that may be exploited for a variety of cancers. ",
        "Doc_title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.",
        "Journal":"Nature",
        "Do_id":"25119042",
        "Doc_ChemicalList":"(+)-JQ1 compound;Azepines;BRD4 protein, human;Chromatin;Neurofibromin 1;Nuclear Proteins;SUZ12 protein, human;Suz12 protein, mouse;Transcription Factors;Triazoles;Tumor Suppressor Proteins;Polycomb Repressive Complex 2;Mitogen-Activated Protein Kinase Kinases;ras Proteins",
        "Doc_meshdescriptors":"Animals;Azepines;Cell Death;Chromatin;Disease Models, Animal;Epigenesis, Genetic;Gene Expression Regulation, Neoplastic;Glioma;Humans;Melanoma;Mice;Mitogen-Activated Protein Kinase Kinases;Neoplasms;Nerve Sheath Neoplasms;Neurofibromin 1;Nuclear Proteins;Polycomb Repressive Complex 2;Transcription Factors;Transcription, Genetic;Triazoles;Tumor Suppressor Proteins;ras Proteins",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;drug effects;genetics;metabolism;drug effects;drug effects;drug therapy;genetics;pathology;drug therapy;genetics;pathology;antagonists & inhibitors;drug therapy;genetics;pathology;drug therapy;genetics;pathology;deficiency;genetics;antagonists & inhibitors;deficiency;genetics;metabolism;deficiency;genetics;metabolism;antagonists & inhibitors;deficiency;genetics;metabolism;drug effects;pharmacology;therapeutic use;deficiency;genetics;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605836404496007168},
      {
        "Doc_abstract":"Cellular invasion depends on cooperation between adhesive and proteolytic mechanisms. Evidence is provided that the matrix metalloproteinase MMP-2 can be localized in a proteolytically active form on the surface of invasive cells, based on its ability to bind directly integrin alpha v beta 3. MMP-2 and alpha v beta 3 were specifically colocalized on angiogenic blood vessels and melanoma cells in vivo. Expression of alpha v beta 3 on cultured melanoma cells enabled their binding to MMP-2 in a proteolytically active form, facilitating cell-mediated collagen degradation. In vitro, these proteins formed an SDS-stable complex that depended on the noncatalytic C-terminus of MMP-2, since a truncation mutant lost the ability to bind alpha v beta 3. These findings define a single cell-surface receptor that regulates both matrix degradation and motility, thereby facilitating directed cellular invasion.",
        "Doc_title":"Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.",
        "Journal":"Cell",
        "Do_id":"8646777",
        "Doc_ChemicalList":"Receptors, Vitronectin;Vitronectin;Gelatinases;Metalloendopeptidases;Matrix Metalloproteinase 2",
        "Doc_meshdescriptors":"Animals;Cell Adhesion;Cell Membrane;Chick Embryo;Cricetinae;Gelatinases;Humans;Matrix Metalloproteinase 2;Melanoma, Experimental;Metalloendopeptidases;Neoplasm Invasiveness;Neovascularization, Pathologic;Receptors, Vitronectin;Solubility;Tumor Cells, Cultured;Vitronectin",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;pathology;secondary;metabolism;metabolism;metabolism",
        "_version_":1605763521512996864},
      {
        "Doc_abstract":"Dok-1 (p62(Dok)) is a multiple-site docking protein that acts downstream of receptor and nonreceptor tyrosine kinases. Although it has been proposed to contribute to the control of cell growth and migration through association with the Ras GTPase-activating protein and the adapter protein Nck, the role of Dok-1 remains largely unknown. The functions of Dok-1 have now been investigated by the generation of two different COOH-terminal truncation mutants of this protein: one (DokPH+PTB) containing the pleckstrin homology and phosphotyrosine-binding domains, and the other (DokPH) composed only of the pleckstrin homology domain. Both of these mutant proteins were shown to act in a dominant negative manner. Overexpression of each of the mutants in highly metastatic B16F10 mouse melanoma cells thus both inhibited the tyrosine phosphorylation of endogenous Dok-1 induced by cell adhesion as well as reduced the association of the endogenous protein with cellular membranes and the cytoskeleton. Overexpression of DokPH+PTB in these cells also markedly reduced both the rates of cell spreading, migration, and growth as well as the extent of Ras activation. The effects of DokPH on these processes were less pronounced than were those of DokPH+PTB, indicating the importance of the phosphotyrosine-binding domain. These results suggest that at least in B16F10 cells, Dok-1 positively regulates not only cell spreading and migration but also cell growth and Ras activity.",
        "Doc_title":"Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"11463826",
        "Doc_ChemicalList":"DNA-Binding Proteins;Dok1 protein, mouse;GAP-associated protein p62;Phosphoproteins;RNA-Binding Proteins",
        "Doc_meshdescriptors":"Animals;Cell Movement;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Melanoma, Experimental;Mice;Mutation;Phosphoproteins;RNA-Binding Proteins;Signal Transduction;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;genetics",
        "_version_":1605784189805789184},
      {
        "Doc_abstract":"The cutaneous malignant melanoma (CMM) incidence rate in most affluent countries has increased over the last three or four decades. Despite specific attention, evidence for a role of factors other than sun and ultraviolet exposure is weak.;To update time trends of CMM in Israel.;A population-based cancer registry data base of CMM among Jews and non-Jews by age and gender was analyzed. A quality control survey was conducted to insure complete coverage and data validation for the period 1960-1989.;The incidence rate of CMM in All Jews increased throughout the study period, with a monotonic annual increase of 4.8% for males and 4.3% for females. There was a steep increase in incidence until the mid-1970s, with an a posteriori levelling-off. Also, incidence was higher in females than in males. There were variations in incidence among Jewish subpopulations. Israel-born Jews are the highest incidence subgroup (average age-adjusted incidence rate (AAIR) 7.8 and 9.4 per 100,000 for males and females, respectively), followed by Jews born in Europe and America (AAIR, 6.1 and 7.3 per 100,000 for males and females, respectively). The lowest rate was for Jews born in Africa and Asia (AAIR, 1.3 per 100,000 for both males and females). Analysis of age-truncated rates reveals that Jews born in Europe, America, and Israel, mainly at age 45-64, have increasing CMM incidence. Non-Jews have a stable rate which could either be real or an artifact of underdiagnosis.;The different time trend incidence patterns between subpopulations could be due to differing cumulative sun exposure over the last 40-50 years, mainly in those at age 45 and over. The levelling-off of the invasive CMM incidence rate, mainly in native Israeli Jews under age 45, could be attributed to increasing awareness and early diagnosis.",
        "Doc_title":"Incidence of cutaneous malignant melanoma in Israel, 1960-1989.",
        "Journal":"Public health reviews",
        "Do_id":"7761605",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Age Distribution;Aged;Female;Humans;Incidence;Israel;Jews;Linear Models;Male;Melanoma;Middle Aged;Risk Factors;Sex Distribution;Skin Neoplasms",
        "Doc_meshqualifiers":"epidemiology;epidemiology;ethnology;epidemiology;ethnology",
        "_version_":1605764149578563584},
      {
        "Doc_abstract":"Early detection of colorectal cancer is a decisive step in the successful and complete cure of the disease. Epigenetic markers, in particular, those based on aberrant DNA methylation, can be used to diagnose cancer. B melanoma antigens (BAGE) are a family of genes and truncated genes located in the heterochromatic regions of several human chromosomes. Our previous work showed that BAGE loci (i.e., genes and truncated genes) were hypermethylated in normal tissues and hypomethylated in 98% of human cancers. In the present study, we analyzed DNA methylation of the BAGE loci in 54 colon cancers and in neighboring histopathologic normal tissue samples. Using a combined bisulfite restriction assay, we showed that BAGE loci were hypomethylated in 81% of carcinoma samples. Colon cancer could be diagnosed with 94% specificity, 83% sensitivity, and 89% accuracy. No correlation was found between DNA methylation of BAGE loci and age, gender of patients, nor with the tumor stage or site. Based on the hypothesis that during neoplastic transformation, hypomethylation occurs in juxtacentromeric CpG islands, we suggest that other genes located in the heterochromatic compartment should be tested. These new markers enrich the list of currently studied epigenetic alterations in colon cancer and could be associated with hypermethylation markers to develop reliable diagnostic tests.",
        "Doc_title":"BAGE hypomethylation, a new epigenetic biomarker for colon cancer detection.",
        "Journal":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
        "Do_id":"18541613",
        "Doc_ChemicalList":"Antigens, Neoplasm;BAGE protein, human;Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Biomarkers, Tumor;Colorectal Neoplasms;CpG Islands;DNA Methylation;Female;Humans;Male;Middle Aged;Sensitivity and Specificity;Statistics, Nonparametric",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605850682546454528},
      {
        "Doc_abstract":"alpha-Thrombomodulin (alpha-TM) with a truncated glycosaminoglycan-protein linkage tetrasaccharide, GlcAbeta1-3Galbeta1-3Galbeta1-4Xyl, was tested as an acceptor together with a sugar donor, UDP-N-[3H]acetylgalactosamine, using a cell-free enzyme system prepared from the serum-free culture medium of a human melanoma cell line. The truncated tetrasaccharide on alpha-TM served as an acceptor, whereas the linkage tetrasaccharide-serine did not. Our characterization of the radioactively labelled product by enzymic digestion revealed that the N-[3H]acetylgalactosamine residue was transferred to alpha-TM through a beta1,4-linkage. The substrate competition experiments with the chondro-hexasaccharide and alpha-TM reinforced our speculation that a common N-acetylgalactosaminyltransferase catalysed the transfer of N-acetylgalactosamine to both the linkage tetrasaccharide and the longer chondroitin oligosaccharides. Moreover, chondroitin polymerization was demonstrated on the tetrasaccharide of alpha-TM using both UDP-glucuronic acid and UDP-N-acetylgalactosamine as sugar donors. Much longer chains were synthesized on alpha-TM than on the linkage penta- and hexa-saccharide-serines. Together, these results indicated that the core protein is required for the transfer of the first N-acetylgalactosamine residue through a beta1,4-linkage and also for subsequent efficient chain polymerization reactions, and that the critical determining step for chondroitin sulphate biosynthesis is the transfer of the first N-acetylgalactosamine residue.",
        "Doc_title":"Involvement of the core protein in the first beta-N-acetylgalactosamine transfer to the glycosaminoglycan-protein linkage-region tetrasaccharide and in the subsequent polymerization: the critical determining step for chondroitin sulphate biosynthesis.",
        "Journal":"The Biochemical journal",
        "Do_id":"10333474",
        "Doc_ChemicalList":"Biopolymers;Glycosaminoglycans;Thrombomodulin;Chondroitin Sulfates;N-Acetylgalactosaminyltransferases;Acetylgalactosamine",
        "Doc_meshdescriptors":"Acetylgalactosamine;Biopolymers;Carbohydrate Sequence;Cell-Free System;Chondroitin Sulfates;Glycosaminoglycans;Humans;Molecular Sequence Data;N-Acetylgalactosaminyltransferases;Substrate Specificity;Thrombomodulin;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;biosynthesis;chemistry;metabolism;metabolism;chemistry;metabolism",
        "_version_":1605902299213856768},
      {
        "Doc_abstract":"In human melanoma cells, expression of the alpha v beta 3 integrin is correlated with the metastatic potential. The expression of osteopontin (OPN or OP), a protein ligand for the integrin alpha v beta 3, also correlates with metastatic potential of some tumors. Analysis of signal transduction, stimulated by OPN/alpha v beta 3 in human melanoma cells (M21), revealed activation of pp60c-src associated with the integrin. pp60c-src stimulation by OPN was dose dependent, and it was inhibited in vitro by a tyrosine kinase inhibitor, herbimycin-A. To determine the need for the cytoplasmic domain of the alpha v-subunit, in the association of pp60c-src with alpha v beta 3, a cell line expressing truncated alpha v was studied. M21-L cells lacked alpha v expression but stably transfected with complementary DNAs encoding alpha v full length protein alpha v 1018 or alpha v 995 (lacking 23 carboxyl-terminal amino acids), and a fibroblast cell line (FG) expressing alpha v beta 5 but not alpha v beta 3, were used. Western analysis and immune complex kinase assays of anti- alpha v immunoprecipitates demonstrated that M21-L/alpha v995 cells did not exhibit pp60c-src association with alpha v, whereas the alpha v1018 complementary DNA transfected cells and FG cells had pp60c-src associated with the alpha v integrins. Immunofluorescence analysis revealed pp60c-src, alpha v beta 3 integrin, and actin distribution along the plasma membrane of M21 cells. 35S-labeling of cells and analysis of complexes immunoprecipitated by a monoclonal antibody against alpha v beta 3 demonstrated association of actin with the immune complexes. We conclude that OPN stimulates pp60c-src kinase activity associated with the alpha v beta 3 integrin and that the association requires the cytoplasmic tail of the alpha v chain.",
        "Doc_title":"Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit.",
        "Journal":"Endocrinology",
        "Do_id":"8641196",
        "Doc_ChemicalList":"Actins;Antigens, CD;Integrin alpha5;Receptors, Vitronectin;Recombinant Fusion Proteins;SPP1 protein, human;Sialoglycoproteins;Osteopontin;Proto-Oncogene Proteins pp60(c-src)",
        "Doc_meshdescriptors":"Actins;Amino Acid Sequence;Antigens, CD;Cell Membrane;Enzyme Activation;Fluorescent Antibody Technique;Humans;Immunosorbent Techniques;Integrin alpha5;Melanoma;Molecular Sequence Data;Osteopontin;Phosphorylation;Proto-Oncogene Proteins pp60(c-src);Receptors, Vitronectin;Recombinant Fusion Proteins;Sialoglycoproteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;chemistry;physiology;chemistry;drug effects;metabolism;analysis;metabolism;analysis;metabolism;pharmacology;pharmacology",
        "_version_":1605910840924438528},
      {
        "Doc_abstract":"ABCB5, an ATP-binding cassette (ABC) transporter, is highly expressed in melanoma cells, and may contribute to the extreme resistance of melanomas to chemotherapy by efflux of anti-cancer drugs. Our goal was to determine whether we could functionally express human ABCB5 in the model yeast Saccharomyces cerevisiae, in order to demonstrate an efflux function for ABCB5 in the absence of background pump activity from other human transporters. Heterologous expression would also facilitate drug discovery for this important target. DNAs encoding ABCB5 sequences were cloned into the chromosomal PDR5 locus of a S. cerevisiae strain in which seven endogenous ABC transporters have been deleted. Protein expression in the yeast cells was monitored by immunodetection using both a specific anti-ABCB5 antibody and a cross-reactive anti-ABCB1 antibody. ABCB5 function in recombinant yeast cells was measured by determining whether the cells possessed increased resistance to known pump substrates, compared to the host yeast strain, in assays of yeast growth. Three ABCB5 constructs were made in yeast. One was derived from the ABCB5-Î² mRNA, which is highly expressed in human tissues but is a truncation of a canonical full-size ABC transporter. Two constructs contained full-length ABCB5 sequences: either a native sequence from cDNA or a synthetic sequence codon-harmonized for S. cerevisiae. Expression of all three constructs in yeast was confirmed by immunodetection. Expression of the codon-harmonized full-length ABCB5 DNA conferred increased resistance, relative to the host yeast strain, to the putative substrates rhodamine 123, daunorubicin, tetramethylrhodamine, FK506, or clorgyline. We conclude that full-length ABCB5 can be functionally expressed in S. cerevisiae and confers drug resistance. ",
        "Doc_title":"Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5.",
        "Journal":"Molecular pharmaceutics",
        "Do_id":"25115303",
        "Doc_ChemicalList":"ABCB5 protein, human;P-Glycoprotein;Rhodamines;Rhodamine 123;tetramethylrhodamine;Clorgyline;Tacrolimus;Daunorubicin",
        "Doc_meshdescriptors":"Clorgyline;Daunorubicin;Humans;Melanoma;P-Glycoprotein;Rhodamine 123;Rhodamines;Saccharomyces cerevisiae;Tacrolimus",
        "Doc_meshqualifiers":"pharmacology;pharmacology;metabolism;genetics;metabolism;pharmacology;pharmacology;drug effects;genetics;metabolism;pharmacology",
        "_version_":1605818632836743169},
      {
        "Doc_abstract":"The importance of mitogen-activated protein kinase signaling in melanoma is underscored by the prevalence of activating mutations in N-Ras and B-Raf, yet clinical development of inhibitors of this pathway has been largely ineffective, suggesting that alternative oncogenes may also promote melanoma. Notch is an interesting candidate that has only been correlated with melanoma development and progression; a thorough assessment of tumor-initiating effects of activated Notch on human melanocytes would clarify the mounting correlative evidence and perhaps identify a novel target for an otherwise untreatable disease. Analysis of a substantial panel of cell lines and patient lesions showed that Notch activity is significantly higher in melanomas than their nontransformed counterparts. The use of a constitutively active, truncated Notch transgene construct (N(IC)) was exploited to determine if Notch activation is a \"driving\" event in melanocytic transformation or instead a \"passenger\" event associated with melanoma progression. N(IC)-infected melanocytes displayed increased proliferative capacity and biological features more reminiscent of melanoma, such as dysregulated cell adhesion and migration. Gene expression analyses supported these observations and aided in the identification of MCAM, an adhesion molecule associated with acquisition of the malignant phenotype, as a direct target of Notch transactivation. N(IC)-positive melanocytes grew at clonal density, proliferated in limiting media conditions, and also exhibited anchorage-independent growth, suggesting that Notch alone is a transforming oncogene in human melanocytes, a phenomenon not previously described for any melanoma oncogene. This new information yields valuable insight into the basic epidemiology of melanoma and launches a realm of possibilities for drug intervention in this deadly disease.",
        "Doc_title":"Active Notch1 confers a transformed phenotype to primary human melanocytes.",
        "Journal":"Cancer research",
        "Do_id":"19549918",
        "Doc_ChemicalList":"Antigens, CD146;MCAM protein, human;NOTCH1 protein, human;Receptor, Notch1",
        "Doc_meshdescriptors":"Antigens, CD146;Cell Division;Disease Progression;Foreskin;Humans;Male;Melanocytes;Melanoma;Phenotype;Receptor, Notch1;Reverse Transcriptase Polymerase Chain Reaction;Skin Neoplasms;Up-Regulation",
        "Doc_meshqualifiers":"genetics;physiology;cytology;pathology;physiology;genetics;pathology;prevention & control;antagonists & inhibitors;genetics;physiology;genetics;pathology;prevention & control",
        "_version_":1605789901210517504},
      {
        "Doc_abstract":"Mutation screening of the breast and ovarian cancer predisposition genes BRCA1 and BRCA2 is becoming an increasingly important part of clinical practice. Classification of rare non-truncating sequence variants in the BRCA1 and BRCA2 genes is problematic because it is not known whether these subtle changes alter function sufficiently to predispose cells to cancer development. Several studies have reported the biochemical analysis of BRCA2 variants, which disrupted the 5' and 3'splicing consensus elements (the GU-AG rule). However, little has been done to look into the consequences of variants located outside the 5' and 3' consensus splice sites. cDNA analysis demonstrates that the BRCA2*IVS4-12del5 splice site variant results in the deletion of exon 5, and the gene putatively produces a truncated BRCA2 protein of 164 amino acids instead of 3418 with the incorporation of 22 out of frame amino acids. The pattern of breast, melanoma, and pancreatic cancers in the paternal kindred is consistent with autosomal dominant inheritance of a deleterious BRCA2 mutation. Analysis of a tumor specimen indicates loss of heterozygosity (LOH). Sequence alignment indicates the deleted region is well conserved across different species. These results support the conclusion that BRCA2 IVS4-12del5 is a deleterious mutation. This study will shed light on the reclassification of intronic variants that do not disrupt the 5' and 3' splice sites (the GU-AG rule).",
        "Doc_title":"cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.",
        "Journal":"Mutation research",
        "Do_id":"19070627",
        "Doc_ChemicalList":"BRCA2 Protein;DNA, Complementary;RNA, Messenger",
        "Doc_meshdescriptors":"Adult;Aged;Alleles;Alternative Splicing;BRCA2 Protein;Base Sequence;Chromosome Segregation;DNA Mutational Analysis;DNA, Complementary;Exons;Female;Humans;Introns;Loss of Heterozygosity;Male;Middle Aged;Molecular Sequence Data;Mutation;Pedigree;RNA, Messenger;Sequence Alignment",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;metabolism",
        "_version_":1605791531565842432},
      {
        "Doc_abstract":"Mouse tumor cells transfected with syngeneic MHC class II genes are highly immunogenic in the autologous host, and induce a potent tumor-specific immunity against wild type tumor. Previous studies with sarcoma tumor cells expressing transfected class II gene products with truncated cytoplasmic domains suggested that during the process of tumor rejection costimulatory molecules are induced on the tumor cells, contributing to the cells' ability to stimulate immunity. In the present study we directly demonstrate that tumor cells containing full-length class II heterodimers are induced to express B7-1 and B7-2 costimulatory molecules during the rejection process. In contrast, tumor cells expressing class II heterodimers truncated for their cytoplasmic tails are not induced to express B7-1 and/or B7-2. Blocking the interaction of the induced costimulatory molecules with their corresponding receptors on T cells prevents tumor rejection. These results support the hypothesis that the cytoplasmic domain of the MHC class II molecule is involved in induction of costimulatory molecule expression, perhaps via intracellular signalling pathways. Because class II, B7 transfected tumor cells are such effective immunogens against ascites and solid tumors, they have also been tested in metastatic disease. K1735 and B16BL6 mouse melanomas, when transfected with syngeneic MHC class II and B7-1 genes, are significantly less metastatic than parental cells, and immunization with the transfectants protects against subsequent challenge with wild type tumor.",
        "Doc_title":"Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.",
        "Journal":"Tissue antigens",
        "Do_id":"8795142",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD80;Antigens, CD86;Cd86 protein, mouse;Histocompatibility Antigens Class II;Membrane Glycoproteins",
        "Doc_meshdescriptors":"Animals;Antigens, CD;Antigens, CD80;Antigens, CD86;Gene Expression Regulation, Neoplastic;Graft Rejection;Histocompatibility Antigens Class II;Melanoma, Experimental;Membrane Glycoproteins;Mice;Mice, Inbred A;Mice, Inbred C3H;Mice, Inbred C57BL;Mice, Mutant Strains;Mice, Nude;Neoplasm Metastasis;Neoplasm Transplantation;Sarcoma, Experimental;T-Lymphocyte Subsets;Transfection",
        "Doc_meshqualifiers":"biosynthesis;genetics;immunology;biosynthesis;genetics;immunology;immunology;biosynthesis;genetics;immunology;genetics;immunology;pathology;biosynthesis;genetics;immunology;immunology;immunology;genetics;immunology;pathology;immunology",
        "_version_":1605875176820441088},
      {
        "Doc_abstract":"Additional sex combs-like (ASXL)1, ASXL2 and ASXL3 are human homologues of the Drosophila Asx gene that are involved in the regulation or recruitment of the Polycomb-group repressor complex (PRC) and trithorax-group (trxG) activator complex. ASXL proteins consist of ASXN, ASXH, ASXM1, ASXM2 and PHD domains. ASXL1 directly interacts with BAP1, KDM1A (LSD1), NCOA1 and nuclear hormone receptors (NHRs), such as retinoic acid receptors, oestrogen receptor and androgen receptor. ASXL family members are epigenetic scaffolding proteins that assemble epigenetic regulators and transcription factors to specific genomic loci with histone modifications. ASXL1 is involved in transcriptional repression through an interaction with PRC2 and also contributes to transcriptional regulation through interactions with BAP1 and/or NHR complexes. Germ-line mutations of human ASXL1 and ASXL3 occur in Bohring-Opitz and related syndromes. Amplification and overexpression of ASXL1 occur in cervical cancer. Truncation mutations of ASXL1 occur in colorectal cancers with microsatellite instability (MSI), malignant myeloid diseases, chronic lymphocytic leukaemia, head and neck squamous cell carcinoma, and liver, prostate and breast cancers; those of ASXL2 occur in prostate cancer, pancreatic cancer and breast cancer and those of ASXL3 are observed in melanoma. EPC1-ASXL2 gene fusion occurs in adult T-cell leukaemia/lymphoma. The prognosis of myeloid malignancies with misregulating truncation mutations of ASXL1 is poor. ASXL family members are assumed to be tumour suppressive or oncogenic in a context-dependent manner. ",
        "Doc_title":"Functional and cancer genomics of ASXL family members.",
        "Journal":"British journal of cancer",
        "Do_id":"23736028",
        "Doc_ChemicalList":"ASXL1 protein, human;ASXL2 protein, human;ASXL3 protein, human;Repressor Proteins;Transcription Factors",
        "Doc_meshdescriptors":"Adult;Amino Acid Sequence;Animals;Genomics;Humans;Molecular Sequence Data;Neoplasms;Phylogeny;Repressor Proteins;Sequence Homology;Transcription Factors",
        "Doc_meshqualifiers":"methods;genetics;classification;genetics;metabolism;classification;genetics;metabolism",
        "_version_":1605880298652827648},
      {
        "Doc_abstract":"Xeroderma pigmentosum (XP) is an autosomal recessive disorder of, in most cases, defective nucleotide excision repair (NER) of ultraviolet radiation (UV)- and chemical-induced DNA damage. The condition is characterized by an increased sensitivity of the skin to UV radiation, with early development of pigmentary changes and premalignant lesions in sun-exposed areas of the skin, signs of photoageing and a greatly increased incidence from a young age of skin tumours including melanoma. Approximately 20% of patients with XP show neurological abnormalities of varying severity due to primary neuronal degeneration. Genetic analysis by somatic cell hybridization has led to the identification in the NER-defective form of XP of seven complementation groups, designated XP-A to XP-G. These complementation groups correspond to different proteins involved in the NER process. XP-A classically includes some of the most severely affected patients.;We describe a 61-year-old Punjabi woman with XP. Remarkably she had only mild cutaneous abnormalities, minimal neurological features and unusual longevity, and developed a malignant spindle cell melanoma. There are few previous reports of spindle cell melanoma associated with XP. To gain insight into the aetiology of these unusual features, we sought to analyse the DNA repair properties of the patient and identify the complementation group and the causative mutation in the defective gene.;Unscheduled DNA synthesis and the inhibition of RNA synthesis were measured. The complementation group was assigned by fusing the cells of our patient with XP cells of known complementation groups and determining the ability to carry out unscheduled DNA repair. Molecular analysis of the cDNA was carried out by polymerase chain reaction and DNA sequencing.;Levels of DNA repair were extremely low and complementation analysis assigned the defect to the XP-A group. Sequencing of the XPA gene revealed a novel homozygous mutation of A-->G at the eighth nucleotide of intron 4 causing aberrant splicing and a nonfunctional truncated XP-A protein. However, a small amount of normally spliced mRNA was detected at <5% the level in normal cells.;The small amount of normally spliced mRNA detected may be sufficient to explain the relatively mild clinical features in our patient.",
        "Doc_title":"A novel mutation in the XPA gene associated with unusually mild clinical features in a patient who developed a spindle cell melanoma.",
        "Journal":"The British journal of dermatology",
        "Do_id":"16792756",
        "Doc_ChemicalList":"Xeroderma Pigmentosum Group A Protein",
        "Doc_meshdescriptors":"Afghanistan;DNA Repair;Female;Genetic Complementation Test;Homozygote;Humans;London;Melanoma;Middle Aged;Point Mutation;Reverse Transcriptase Polymerase Chain Reaction;Sequence Analysis, DNA;Skin Neoplasms;Xeroderma Pigmentosum;Xeroderma Pigmentosum Group A Protein",
        "Doc_meshqualifiers":"ethnology;complications;genetics;pathology;complications;genetics;pathology;complications;genetics;pathology;genetics",
        "_version_":1605903826476335104},
      {
        "Doc_abstract":"The development of malignant and benign tumors in patient with neurofibromatosis type 1 (NF1) was investigated in a long term follow-up study of 70 adult NF1 patients living in GÃ¶teborg, Sweden, on January 1, 1978. Their mean age at that time was 44 years (range, 20-81 years). The 70 NF1 patients had previously been investigated in a population-based study.;The first part of this study involved a cancer registry study. The authors compared the number of tumors in the 70 NF1 patients reported to the Swedish Cancer Registry during the period 1978-1989 with the number of tumors expected in the general population by matching the incidence rates of the two populations specific to age, time of follow-up, and gender. The 95% confidence interval for the risk quotient between the risk to the patients and the risk to the general population was estimated. The second part of the study was a clinical pathologic follow-up study. All living patients were offered a clinical reexamination in 1990. All hospital records for all the NF1 patients were reviewed, and death certificates were also reviewed when available.;Malignant tumors were reported to the Cancer Registry four times as often in the NF1 patient group as in the general population (95% confidence interval, 2.1-7.6) during the follow-up period 1978-1989. Before 1978, 5 of 70 patients (7%) had 6 malignant tumors; these patients were not included in the Cancer Registry study. Using all available clinical data on the 70 NF1 patients from their birth up to 1990, the authors found that 17 of 70 patients (24%) had developed a total of 19 malignant tumors, namely, 5 sarcomas (in 7% of patients), 13 carcinomas (in 16%), and 1 malignant melanoma (in 1%). Four pheochromocytomas (in 6% of patients), 2 adenomas, and 1 C-cell hyperplasia were diagnosed. Five gastrointestinal stromal tumors (in 7% of patients) were also diagnosed.;Malignant tumors were reported to the Swedish Cancer Registry significantly more often in the NF1 patients than was expected in the general population matched for age, gender, and time of follow-up. The development of tumors is part of the NF1 disease process, and this deserves attention both in the clinical setting and in family counseling dealing with complications of NF1 in adulthood.",
        "Doc_title":"Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population.",
        "Journal":"Cancer",
        "Do_id":"9179058",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Adult;Aged;Aged, 80 and over;Carcinoma;Female;Follow-Up Studies;Humans;Incidence;Male;Middle Aged;Neoplasms;Neurofibromatosis 1;Pheochromocytoma;Registries;Sarcoma;Sex Factors;Sweden",
        "Doc_meshqualifiers":"epidemiology;pathology;epidemiology;pathology;epidemiology;etiology;complications;epidemiology;pathology;epidemiology;pathology;epidemiology;pathology;epidemiology",
        "_version_":1605763183292710912},
      {
        "Doc_abstract":"NG2, the rat homologue of the human melanoma chondroitin sulfate proteoglycan (MCSP), is a ligand for collagen VI (COL6). We have examined skeletal muscles of patients affected by Ullrich scleroatonic muscular dystrophy (UCMD), an inherited syndrome caused by COL6 genes mutations. A significant decrease of NG2 immunolabeling was found in UCMD myofibers, as well as in skeletal muscle and cornea of COL6 null-mice. In UCMD muscles, truncated NG2 core protein isoforms were detected. However, real-time RT-PCR analysis revealed marked increase in NG2 mRNA content in UCMD muscle compared to controls. We hypothesize that NG2 immunohistochemical and biochemical behavior may be compromised owing to the absence of its physiological ligand. MCSP/NG2 proteoglycan may be considered an important receptor mediating COL6-sarcolemma interactions, a relationship that is disrupted by the pathogenesis of UCMD muscle.",
        "Doc_title":"Altered expression of the MCSP/NG2 chondroitin sulfate proteoglycan in collagen VI deficiency.",
        "Journal":"Molecular and cellular neurosciences",
        "Do_id":"16169245",
        "Doc_ChemicalList":"Antigens;Collagen Type VI;Protein Isoforms;Proteoglycans;RNA, Messenger;chondroitin sulfate proteoglycan 4",
        "Doc_meshdescriptors":"Animals;Antigens;Child;Child, Preschool;Collagen Type VI;Cornea;Female;Gene Expression;Humans;Immunohistochemistry;Male;Mice;Mice, Knockout;Muscle Fibers, Skeletal;Muscle, Skeletal;Muscular Dystrophies;Mutation;Protein Isoforms;Proteoglycans;RNA, Messenger;Sarcolemma;Skin",
        "Doc_meshqualifiers":"genetics;metabolism;deficiency;genetics;metabolism;physiopathology;genetics;metabolism;pathology;metabolism;pathology;physiopathology;genetics;metabolism;physiopathology;genetics;genetics;metabolism;genetics;metabolism;metabolism;metabolism;pathology;metabolism;physiopathology",
        "_version_":1605783778754560000},
      {
        "Doc_abstract":"The cell surface hyaluronan receptor CD44 promotes tumor growth and metastasis by mechanisms that remain poorly understood. We show here that CD44 associates with a proteolytic form of the matrix metalloproteinase-9 (MMP-9) on the surface of mouse mammary carcinoma and human melanoma cells. CD44-associated cell surface MMP-9 promotes cell-mediated collagen IV degradation in vitro and mediates tumor cell invasion of G8 myoblast monolayers. Several distinct CD44 isoforms coprecipitate with MMP-9 and CD44/MMP-9 coclustering is observed to be dependent on the ability of CD44 to form hyaluronan-induced aggregates. Disruption of CD44/MMP-9 cluster formation, by overexpression of soluble or truncated cell surface CD44, is shown to inhibit tumor invasiveness in vivo. Our observations indicate that CD44 serves to anchor MMP-9 on the cell surface and define a mechanism for CD44-mediated tumor invasion.",
        "Doc_title":"Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.",
        "Journal":"Genes & development",
        "Do_id":"9887098",
        "Doc_ChemicalList":"Antigens, CD44;RNA, Messenger;Hyaluronic Acid;Collagen;Collagenases;Matrix Metalloproteinase 9",
        "Doc_meshdescriptors":"Animals;Antigens, CD44;Collagen;Collagenases;Endocytosis;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Neoplastic;Humans;Hyaluronic Acid;Immunohistochemistry;Mammary Neoplasms, Experimental;Matrix Metalloproteinase 9;Melanoma;Mice;Neoplasm Invasiveness;Protein Binding;RNA, Messenger;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"immunology;metabolism;metabolism;physiology;genetics;genetics;metabolism;enzymology;pathology;enzymology;physiopathology;genetics;genetics",
        "_version_":1605818712925929472},
      {
        "Doc_abstract":"The preferentially expressed antigen of melanoma (PRAME) is expressed at high levels in large fractions of human malignancies, e.g., acute myeloid leukemia. Therefore, PRAME is an important marker for diagnosis of various malignant diseases and a relevant parameter for monitoring minimal residual disease. It is supposed to be involved in tumorigenic processes. Because of these important aspects we investigated its transcriptional regulation in detail. Most relevant was a detailed DNA methylation analysis of the PRAME 5' region by genomic sequencing in correlation with PRAME expression in various human patient samples and cell lines. In combination with DNA-truncation/transfection experiments with respect to DNA methylation, we show that changes in the methylation pattern in defined parts of the regulatory regions of PRAME are sufficient for its upregulation in cells usually not expressing the gene.",
        "Doc_title":"Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"17534929",
        "Doc_ChemicalList":"Antigens, Neoplasm;PRAME protein, human",
        "Doc_meshdescriptors":"5' Flanking Region;Antigens, Neoplasm;Bone Marrow;Cell Line, Tumor;DNA Methylation;Gene Expression Regulation, Neoplastic;Humans;Leukemia, Myeloid, Acute;Promoter Regions, Genetic;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605917410939895808},
      {
        "Doc_abstract":"Calcium-sensing receptors (CaR) regulate cell proliferation, differentiation, and apoptosis through the MAPK pathway. MAPK pathway activation requires the cytoskeletal scaffold protein filamin A. Here we examine the interactions of CaR with filamin A in HEK-293 and M2 or A7 melanoma cells to determine how interactions with filamin A facilitate signaling. Filamin A interacts with CaR through two predicted beta-strands from residues 962 to 981; interactions between filamin A and CaR are greatly enhanced by exposure to 5 mM Ca2+. Truncations or deletions (from 972 to 997 or 962 to 981) of the CaR carboxyl terminus eliminate high affinity interactions with filamin A, but CaR-mediated MAPK pathway activation still occurs. CaR-mediated ERK phosphorylation can be localized to a predicted alpha-helix proximal to the membrane, which has been shown to be important for G protein-mediated signaling (residues 868-879). In M2 cells (-filamin A), CaR expression levels are very low; cotransfection of CaR with filamin A increases total cellular CaR and increases plasma membrane localization of CaR, facilitating CaR signaling to the MAPK pathway; similar results were obtained in HEK-293 cells. Interaction with filamin A increases cellular CaR by preventing CaR degradation, thereby facilitating CaR signaling. In addition, filamin A facilitates signaling to the MAPK pathway even by CaR truncations or deletion mutants that cannot engage in high affinity interactions with filamin A, suggesting the targeting of critical signaling proteins to CaR.",
        "Doc_title":"High affinity interaction with filamin A protects against calcium-sensing receptor degradation.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"15657061",
        "Doc_ChemicalList":"Contractile Proteins;Filamins;Microfilament Proteins;Receptors, Calcium-Sensing;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Cell Line;Cell Membrane;Contractile Proteins;Filamins;Humans;MAP Kinase Signaling System;Microfilament Proteins;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Receptors, Calcium-Sensing",
        "Doc_meshqualifiers":"metabolism;chemistry;physiology;chemistry;physiology;metabolism;metabolism;metabolism",
        "_version_":1605795950323826688},
      {
        "Doc_abstract":"Differential mRNA splicing and alternative promoter usage of the TP73 gene results in the expression of multiple NH2-truncated isoforms that act as oncogenes. Abundant levels of these p73 variants in a variety of human cancers correlated with adverse clinical prognosis and response failure to conventional therapies, underscoring their relevance as marker for disease severity and target for cancer intervention. With respect to an equally important role for amino-truncated p73 splice forms (DeltaTAp73) and DeltaNp73 (summarized as DNp73) in the tumorigenic process, we designed locked nucleic acid (LNA) antisense oligonucleotide (ASO) gapmers against individual species that were complementary to DeltaEx2 and DeltaEx2/3 splice junctions and a region in exon 3B unique for DeltaN' and DeltaN.;Treatment of cancer cells with these ASOs resulted in a strong and specific reduction of tumorigenic p73 transcripts and proteins, importantly, without abolishing the wild-type p73 tumor suppressor form as observed with p73-shRNA. The specific antisense oligonucleotides rescued cells from apoptosis inhibition due to overexpression of their corresponding amino-truncated p73 isoform and decreased tumor cell proliferation. Furthermore, ASO-116 against DeltaEx2/3 coupled to magnetic nanobead polyethyleneimine (MNB/PEI) carriers significantly inhibited malignant melanoma growth, which correlated with a shift in the balance between endogenous TAp73 and DeltaEx2/3 towards apoptotic full-length p73.;Our study demonstrates the successful development of LNA-ASOs that selectively differentiate between the closely related p73 oncoproteins, and provide new tools to further delineate their biological properties in different human malignancies and for therapeutic cancer targeting.",
        "Doc_title":"Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.",
        "Journal":"Molecular cancer",
        "Do_id":"19671150",
        "Doc_ChemicalList":"DNA-Binding Proteins;Nuclear Proteins;Oligonucleotides, Antisense;Protein Isoforms;RNA, Messenger;RNA, Small Interfering;Trp73 protein, mouse;Tumor Protein p73;Tumor Suppressor Proteins;delta Np73 protein, human;p73 protein, human;Green Fluorescent Proteins",
        "Doc_meshdescriptors":"Alternative Splicing;Animals;Apoptosis;Base Sequence;Blotting, Western;Cell Line;Cell Line, Tumor;DNA-Binding Proteins;Female;Green Fluorescent Proteins;Humans;Melanoma, Experimental;Mice;Mice, Nude;Microscopy, Fluorescence;Molecular Sequence Data;Nuclear Proteins;Oligonucleotides, Antisense;Protein Isoforms;RNA, Messenger;RNA, Small Interfering;Reverse Transcriptase Polymerase Chain Reaction;Transfection;Tumor Burden;Tumor Protein p73;Tumor Suppressor Proteins;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605928163078045696},
      {
        "Doc_abstract":"Gelsolin, an actin-binding protein, is implicated as a critical regulator in cell motility. In addition, we have reported that cellular levels of gelsolin are decreased in various tumor cells, and overexpression of gelsolin by gene transfer suppresses tumorigenicity. We sought to assess the effects of gelsolin overexpression on metastasis and to determine the importance of a carboxyl-terminus that confers Ca(2+) dependency on gelsolin for effects of its overexpression. Expression vectors with cDNA encoding either full-length wild-type or His321 mutant form, isolated from a flat revertant of Ras-transformed cells and a carboxyl-terminal truncate, C-del of gelsolin, were transfected into a highly metastatic murine melanoma cell line, B16-BL6. Expression of introduced cDNA in transfectants was confirmed using Western blotting, 2-dimensional gel electrophoresis and reverse transcription-polymerase chain reaction (RT-PCR). We characterized phenotypes of transfectants, such as growth rate, colony formation in soft agar, cell motility and metastasis formation in vivo. Transfectants expressing the wild-type, His321 mutant and C-del gelsolin exhibited reduced growth ability in soft agar. Although expression of integrin beta1 or alpha4 on the cell surface of transfectants was not changed, wild-type and His321 mutant gelsolin, except for C-del gelsolin, exhibited retardation of cell spreading, reduced chemotatic migration to fibronectin and suppressed lung colonization in spontaneous metastasis assay. Gelsolin may function as a metastasis suppressor as well as a tumor suppressor gene. The carboxyl-terminus of gelsolin is important for retardation of cell spreading, reduced chemotasis and metastasis suppression.",
        "Doc_title":"Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect.",
        "Journal":"International journal of cancer",
        "Do_id":"11519036",
        "Doc_ChemicalList":"DNA, Complementary;Gelsolin;Histidine;Calcium",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Calcium;Cell Movement;DNA, Complementary;Electrophoresis, Gel, Two-Dimensional;Flow Cytometry;Gelsolin;Histidine;Male;Melanoma;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Mutation;Neoplasm Metastasis;Phenotype;Reverse Transcriptase Polymerase Chain Reaction;Time Factors;Transfection",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;pharmacology;chemistry;drug therapy;genetics;drug therapy;genetics",
        "_version_":1605784449778188288},
      {
        "Doc_abstract":"Drosha is a key enzyme in microRNA biogenesis, generating the precursor miRNA (pre-miRNA) by excising the stem-loop embedded in the primary transcripts (pri-miRNA). The specificity for the pri-miRNAs and determination of the cleavage site are provided by its binding partner DGCR8, which is necessary for efficient processing. The crucial Drosha domains for pri-miRNA cleavage are the middle part, the two enzymatic RNase III domains (RIIID), and the dsRNA binding domain (dsRBD) in the C-terminus. Here, we identify alternatively spliced transcripts in human melanoma and NT2 cell lines, encoding C-terminally truncated Drosha proteins lacking part of the RIIIDb and the entire dsRBD. Proteins generated from these alternative splice variants fail to bind to DGCR8 but still interact with Ewing sarcoma protein (EWS). In vitro as well as in vivo, the Drosha splice variants are deficient in pri-miRNA processing. However, the aberrant transcripts in melanoma cells do not consistently reduce mature miRNA levels compared with melanoma cell lines lacking those splice variants, possibly owing to their limited abundance. Our findings show that alternative processing-deficient Drosha splice variants exist in melanoma cells. In elevated amounts, these alternatively spliced transcripts could provide one potential mechanism accounting for the deregulation of miRNAs in cancer cells. On the basis of our results, the search for alternative inactive splice variants might be fruitful in different tumor entities to unravel the molecular basis of the previously observed decreased microRNA processing efficiency in cancer.",
        "Doc_title":"Rare Drosha splice variants are deficient in microRNA processing but do not affect general microRNA expression in cancer cells.",
        "Journal":"Neoplasia (New York, N.Y.)",
        "Do_id":"22496623",
        "Doc_ChemicalList":"DGCR8 protein, human;MicroRNAs;Proteins;RNA-Binding Proteins;DROSHA protein, human;Ribonuclease III",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Cell Line;Cytoplasm;Gene Order;Humans;MicroRNAs;Molecular Sequence Data;Neoplasms;Protein Binding;Proteins;RNA-Binding Proteins;Ribonuclease III;Sequence Alignment",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;metabolism;metabolism;chemistry;genetics;metabolism",
        "_version_":1605879735986946048},
      {
        "Doc_abstract":"Genomic instability has been accepted as providing a phenotypic variety of malignant cells within a developing tumour. Defects in genetic recombination can often lead to phenotypic differences; therefore, it is possible that metastatic variant cell lines exhibit their particular phenotype as a result of an altered ability to catalyse homologous recombination. We have investigated recombination efficiency in B16 melanoma metastatic variants, using a plasmid, pDR, as a recombination substrate. The plasmid contains two truncated, nontandem but overlapping segments of the neomycin resistance gene (neo 1 and neo 2), separated by the functional gpt gene unit. Only a successful recombination of the two neo segments will generate a functionally intact neomycin gene. Extrachromosomal recombination here was a transient measure of the cells to recombine the neo fragments in an intra- or intermolecular manner. Extrachromosomal recombination frequencies were higher in the high metastasis variants (BL6, ML8) compared with the low metastatic F1 cells. On the other hand, the frequency of chromosomal recombination (after plasmid integration) was higher for the low metastasis (F1) cell line compared with the highly metastatic variants, BL6 and ML8. Since the recombination assay measures only successful recombination events, we have interpreted the observed higher incidence of chromosomal recombination in the low metastatic variant line as indicative of a more stable genome. Similarly, a higher inherent instability in the genome of the high metastasis variants would render these less efficient at producing and maintaining successful recombination events, and this was found to be true by Southern analysis. The results presented show that frequency of recombination may be adduced as evidence for implicating genomic instability in the generation of variant cell populations during metastatic spread. Such an interpretation is also compatible with the Nowell hypothesis for tumour progression.",
        "Doc_title":"Homologous recombination in variants of the B16 murine melanoma with reference to their metastatic potential.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"8726349",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Animals;Blotting, Southern;Cloning, Molecular;Genetic Variation;Melanoma, Experimental;Mice;Neoplasm Metastasis;Recombination, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"methods;genetics;genetics",
        "_version_":1605792315793735680},
      {
        "Doc_abstract":"Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN) are tumor-suppressor syndromes. Each syndrome is an orphan disease; however, the tumors that arise within them represent the most common tumors of the nervous system worldwide. Systematic investigation of the pathways impacted by the loss of function of neurofibromin (encoded byNF1) and merlin (encoded byNF2) have led to therapeutic advances for patients with NF1 and NF2. In the syndrome of SWN, the genetic landscape is more complex, with 2 known causative genes (SMARCB1andLZTR1) accounting for up to 50% of familial SWN patients. The understanding of the molecular underpinnings of these syndromes is developing rapidly and offers more therapeutic options for the patients. In addition, common sporadic cancers harbor somatic alterations inNF1(ie, glioblastoma, breast cancer, melanoma),NF2(ie, meningioma, mesothelioma) andSMARCB1(ie, atypical teratoid/rhabdoid tumors) such that advances in management of syndromic tumors may benefit patients both with and without germline mutations. In this review, we discuss the clinical and genetic features of NF1, NF2 and SWN, the therapeutic advances for the tumors that arise within these syndromes and the interaction between these rare tumor syndromes and the common tumors that share these mutations. ",
        "Doc_title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.",
        "Journal":"Neuro-oncology",
        "Do_id":"26851632",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605802518211723264},
      {
        "Doc_abstract":"Î³-MSH (Î³-melanocyte-stimulating hormone, H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-OH), with its exquisite specificity and potency, has recently created much excitement as a drug lead. However, this peptide is like most peptides susceptible to proteolysis in vivo, which potentially decreases its beneficial activities. In our continued effort to design a proteolytically stable ligand with specific receptor binding, we have engineered peptides by cyclizing Î³-MSH using a thioether bridge. A number of novel cyclic truncated Î³-MSH analogues were designed and synthesized, in which a thioether bridge was incorporated between a cysteine side chain and an N-terminal bromoacyl group. One of these peptides, cyclo-[(CH(2))(3)CO-Gly(1)-His(2)-D-Phe(3)-Arg(4)-D-Trp(5)-Cys(S-)(6)]-Asp(7)-Arg(8)-Phe(9)-Gly(10)-NH(2), demonstrated potent antagonist activity and receptor selectivity for the human melanocortin 1 receptor (hMC1R) (IC(50) = 17 nM). This novel peptide is the most selective antagonist for the hMC1R to date. Further pharmacological studies have shown that this peptide can specifically target melanoma cells. The nuclear magnetic resonance analysis of this peptide in a membrane-like environment revealed a new turn structure, specific to the hMC1R antagonist, at the C-terminus, where the side chain and backbone conformation of D-Trp(5) and Phe(9) of the peptide contribute to hMC1R selectivity. Cyclization strategies represent an approach for stabilizing bioactive peptides while keeping their full potencies and should boost applications of peptide-based drugs in human medicine.",
        "Doc_title":"An unusual conformation of Î³-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.",
        "Journal":"Biochemistry",
        "Do_id":"23276279",
        "Doc_ChemicalList":"Antineoplastic Agents;Peptides, Cyclic;Receptor, Melanocortin, Type 1;cyclo((CH2)3-Gly-His-D-Phe-Arg-D-Trp-Cys(S-))-Asp-Arg-Phe-Gly-NH2;gamma-MSH;SHU 9119;Melanocyte-Stimulating Hormones",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antineoplastic Agents;Cell Line, Tumor;Humans;Hydrogen Bonding;Inhibitory Concentration 50;Melanocyte-Stimulating Hormones;Melanoma;Molecular Dynamics Simulation;Molecular Targeted Therapy;Peptides, Cyclic;Protein Binding;Protein Structure, Secondary;Receptor, Melanocortin, Type 1;Structure-Activity Relationship;gamma-MSH",
        "Doc_meshqualifiers":"pharmacology;drug effects;chemistry;pharmacology;drug therapy;pharmacology;antagonists & inhibitors;metabolism;pharmacology",
        "_version_":1605742043364065280},
      {
        "Doc_abstract":"Formin-homology-domain-containing proteins interact with Rho-family GTPases and regulate actin cytoskeleton organization and gene transcription. FHOD1 is a member of this family, interacts with Rac1 and induces transcription from the serum response element. In this study, we examined the effects of FHOD1 expression on cytoskeletal organization and function in mammalian cells. FHOD1 proteins were stably expressed in WM35 melanoma cells and NIH-3T3 fibroblasts. Cells expressing full-length FHOD1 demonstrated an elongated phenotype compared with vector-transfected cells and cells expressing a truncated FHOD1 (1-421) that lacks the conserved FH1 and FH2 domains. Full-length FHOD1 co-localized with filamentous actin at cell peripheries. Cells transiently expressing a C-terminal FHOD1 truncation mutant (DeltaC, residues 1-1010), which lacks an autoinhibitory protein-protein interaction domain, displayed prominent stress fibers. FHOD1 (1-421) did not induce stress fibers but localized to membrane ruffles in a manner similar to the full-length protein, indicating that the FH1 and FH2 domains are required for stress fiber appearance. FHOD1 DeltaC (1-1010)-dependent stress fibers were sensitive to dominant-negative RacN17 and the RhoA and ROCK inhibitors, C3 transferase and Y-27632. Stable overexpression of full-length FHOD1 enhanced the migration of WM35 and NIH-3T3 cells to type-I collagen and fibronectin, respectively. Cells expressing FHOD1 (1-421) migrated similar to control cells. Integrin expression and activation were not affected by FHOD1 expression. Moreover, FHOD1 overexpression did not alter integrin usage during adhesion or migration. These data demonstrate that FHOD1 interacts with and regulates the structure of the cytoskeleton and stimulates cell migration in an integrin-independent manner.",
        "Doc_title":"The formin-homology-domain-containing protein FHOD1 enhances cell migration.",
        "Journal":"Journal of cell science",
        "Do_id":"12665555",
        "Doc_ChemicalList":"Actins;FHOD1 protein, human;Fetal Proteins;Integrins;Intracellular Signaling Peptides and Proteins;Nuclear Proteins;Recombinant Proteins;Protein-Serine-Threonine Kinases;rho-Associated Kinases;rac1 GTP-Binding Protein;rhoA GTP-Binding Protein",
        "Doc_meshdescriptors":"Actins;Animals;Cell Adhesion;Cell Line;Cell Movement;Cytoskeleton;Fetal Proteins;Humans;Integrins;Intracellular Signaling Peptides and Proteins;Mice;NIH 3T3 Cells;Nuclear Proteins;Protein Structure, Tertiary;Protein-Serine-Threonine Kinases;Recombinant Proteins;Sequence Deletion;rac1 GTP-Binding Protein;rho-Associated Kinases;rhoA GTP-Binding Protein",
        "Doc_meshqualifiers":"metabolism;physiology;physiology;chemistry;genetics;physiology;metabolism;chemistry;genetics;physiology;metabolism;chemistry;genetics;metabolism;metabolism;metabolism",
        "_version_":1605758146494595072},
      {
        "Doc_abstract":"The human prothrombin kringle-2 protein inhibits angiogenesis and LLC (Lewis lung carcinoma) growth and metastasis in mice. Additionally, the NSA9 peptide (NSAVQLVEN) derived from human prothrombin kringle-2 has been reported to inhibit the proliferation of BCE (bovine capillary endothelial) cells and CAM (chorioallantoic membrane) angiogenesis. In the present study, we examined the structure-activity relationships of the NSA9 peptide in inhibiting the proliferation of endothelial cells lines e.g. BCE and HUVE (human umbilical vein endothelial). N- or C-terminal truncated derivatives and reverse sequence analogues of NSA9 were prepared and their anti-proliferative activities were assessed using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. This cell proliferation assay demonstrated that both the N-terminal region and sequence orientation of NSA9 are important for inhibiting the proliferation of endothelial cells. In particular 2 C-terminal truncation derivatives of NSA9 [NSA7 (NSAVQLV) and NSA8 (NSAVQLVE)] inhibited cellular proliferation to a greater extent than did NSA9. The heptapeptide NSA7, was found to be more potent than NSA9 in inhibiting CAM angiogenesis, and tubular formation and migration of HUVE cells. In addition NSA9, NSA8 and NSA7 peptides exhibited considerable inhibitory effects on the proliferation of tumour cells such as B16F10 (murine melanoma), LLC and L929 (murine fibroblast). Also, cellular internalization studies demonstrated that NSA7 was internalized into both endothelial and tumour cells more easily than was NSA9. In conclusion, these results suggest that NSA7, residing within the full sequence of NSA9, contains the required sequence for anti-proliferative activity and cellular internalization.",
        "Doc_title":"Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization.",
        "Journal":"The Biochemical journal",
        "Do_id":"16390327",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Peptides;Prothrombin",
        "Doc_meshdescriptors":"Amino Acid Sequence;Angiogenesis Inhibitors;Animals;Cattle;Cell Line, Tumor;Cell Movement;Cell Proliferation;Cells, Cultured;Chick Embryo;Chorioallantoic Membrane;Endocytosis;Endothelial Cells;Humans;Kringles;Mice;Molecular Sequence Data;Neoplasms;Peptides;Prothrombin;Structure-Activity Relationship",
        "Doc_meshqualifiers":"chemistry;pharmacology;drug effects;drug effects;drug effects;cytology;drug effects;metabolism;pathology;chemistry;metabolism;pharmacology;chemistry",
        "_version_":1605762846229004288},
      {
        "Doc_abstract":"We are studying the biological activity and regulation of mammalian Ras protein in tumours and in physiological signalling. We have shown that GAP (the GTPase-activating protein) is a potent negative regulator of normal Ras in cells. Reduction or loss of the NF1 gene product neurofibromin, in association with genetic abnormalities of the NF1 locus, has been identified in schwannoma cell lines from patients with neurofibromatosis and in melanoma and neuroblastoma lines from patients without neurofibromatosis. Although loss of neurofibromin in the schwannoma lines was associated with a high proportion of normal Ras protein in the active GTP-bound state, Ras-GTP appeared to be appropriately regulated in the melanoma and neuroblastoma lines, which contain normal levels of GAP. Therefore the GTPase-activating activity of neurofibromin is not essential for negative regulation of Ras in some cell types and the putative tumour suppressor function of neurofibromin in such cell types is independent of its GTPase-activating activity. Mitogen activation of Ras in fibroblasts is mediated primarily by exchange factors, which probably interact with a region on the Ras protein distinct from the region required for interaction with GAP. Multiple full-length cDNAs have identified a mouse gene whose products are related to yeast CDC25 guanine nucleotide exchange factor.",
        "Doc_title":"Cell transformation by ras and regulation of its protein product.",
        "Journal":"Ciba Foundation symposium",
        "Do_id":"8299427",
        "Doc_ChemicalList":"Guanine Nucleotides;Proto-Oncogene Proteins;GTP Phosphohydrolases;GTP-Binding Proteins",
        "Doc_meshdescriptors":"Animals;Cell Transformation, Neoplastic;GTP Phosphohydrolases;GTP-Binding Proteins;Gene Expression Regulation;Genes, Neurofibromatosis 1;Genes, ras;Guanine Nucleotides;Humans;Proto-Oncogene Proteins;Signal Transduction",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;physiology;physiology;metabolism;physiology;genetics",
        "_version_":1605822125218725888},
      {
        "Doc_abstract":"Malignant blue nevus is a rare melanocytic tumor that is described by some authors as a variant of malignant melanoma, whereas others regard it as a distinct entity. To our knowledge no molecular studies of this tumor have been performed, although the molecular pathogenesis of conventional melanomas has been extensively described. We present a case of malignant blue nevus that developed in a 15-cm congenital blue nevus on the back of a 41-year-old man. Subsequent regional lymph node and lung metastases developed within 1 and 29 months, respectively. We performed a molecular analysis for loss of heterozygosity on microdissected samples from the spectrum of benign to malignant blue nevus, using a panel of eight genes (MTS1, MXI1, CMM1, p53, NF1, L-myc hOGG1, and MCC), many of which are commonly associated with conventional melanomas. No loss of heterozygosity was detected, despite informativeness in seven genes. We suggest that malignant blue nevus may represent a distinct entity with a different molecular pathway to tumorigenesis than that of conventional melanomas.",
        "Doc_title":"Malignant blue nevus: a case report and molecular analysis.",
        "Journal":"The American Journal of dermatopathology",
        "Do_id":"12544095",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA Primers;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Combined Modality Therapy;DNA Mutational Analysis;DNA Primers;DNA, Neoplasm;Humans;Loss of Heterozygosity;Lung Neoplasms;Lymph Nodes;Male;Nevus, Blue;Polymerase Chain Reaction;Skin Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;analysis;secondary;pathology;genetics;secondary;therapy;genetics;pathology;therapy",
        "_version_":1605893352494989312},
      {
        "Doc_abstract":"High activity of GLI family zinc finger protein 2 (GLI2) promotes tumor progression. Removal of the repressor domain at the N terminus (GLI2âN) by recombinant methods converts GLI2 into a powerful transcriptional activator. However, molecular mechanisms leading to the formation of GLI2âN activator proteins have not been established. Herein we report for the first time that the functional activities of GLI2 are parted into different protein isoforms by alternative promoter usage, selection of alternative splicing, transcription initiation and termination sites. Functional studies using melanoma cells revealed that transcriptional regulation of GLI2 is TGFbeta-dependent and supports the predominant production of GLI2âN and C-terminally truncated GLI2 (GLI2âC) isoforms in cells with high migratory and invasive phenotype. Taken together, these results highlight the role of transcription and RNA processing as major processes in the regulation of GLI2 activity with severe impacts in cancer development. ",
        "Doc_title":"GLI2 cell-specific activity is controlled at the level of transcription and RNA processing: Consequences to cancer metastasis.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"26459048",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605750184350842880},
      {
        "Doc_abstract":"We examined the histologic features of the posterior scleral foramen in 27 enucleated eyes (16 during autopsy and 11 with choroidal malignant melanoma). The histologic findings of the posterior scleral foramen were similar to those in previous reports. The shape of the scleral foramen was either cylindrical or truncated, the latter occurring when the inner margin of the sclera projected with a crest-like edge pressing into the optic nerve. This configuration was encountered more frequently in the upper and lower temporal aspects of the scleral foramen in 10 eyes, while the nasal rim was free of such projection in all the eyes. We hypothesize that the effect of prolonged high intraocular pressure exerted on the axonal tissue against these crest-like edges of the non-distensible scleral foramen might be the major factor in the etiology of early arcuate nerve fiber bundle defects in primary open-angle glaucoma.",
        "Doc_title":"Histology of posterior scleral foramen in normal eyes: its possible role in optic nerve damage in chronic open angle glaucoma.",
        "Journal":"Israel journal of medical sciences",
        "Do_id":"8865829",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Chronic Disease;Dissection;Glaucoma, Open-Angle;Humans;Intraocular Pressure;Optic Nerve;Optic Nerve Injuries;Sclera",
        "Doc_meshqualifiers":"etiology;pathology;physiopathology;anatomy & histology;anatomy & histology",
        "_version_":1605928687802253312},
      {
        "Doc_abstract":"Cancer registries collect cancer incidence data that can be used to calculate incidence rates in a population and track changes over time. For incidence rates to be accurate, it is critical that diagnosed cases be reported in a timely manner. Registries typically allow a fixed amount of time (e.g. two years) for diagnosed cases to be reported before releasing the initial case counts for a particular diagnosis year. Inevitably, however, additional cases are reported after the initial counts are released; these extra cases are included in subsequent releases that become more complete over time, while incidence rates based on earlier releases will underestimate the true rates. Statistical methods have been developed to estimate the distribution of reporting delay (the amount of time until a diagnosed case is reported) and to correct incidence rates for underestimation due to reporting delay. Since the observed reporting delays must be less than the length of time the registry has been collecting data, most methods estimate a truncated delay distribution. These methods can be applied to a group of registries that began collecting data in the same diagnosis year. In this paper, we extend the methods to two groups of registries that began collecting data in two different diagnosis years (so that the delay distributions are truncated at different times). We apply the proposed method to data from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program, a consortium of U.S. cancer registries that includes nine registries with data collection beginning in 1981 and four registries with data collection beginning in 1992. We use the method to obtain delay-adjusted incidence rates for melanoma, liver cancer, and Hodgkin lymphoma. ",
        "Doc_title":"Adjusting for reporting delay in cancer incidence when combining different sets of cancer registries.",
        "Journal":"Biometrical journal. Biometrische Zeitschrift",
        "Do_id":"23873707",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Aged;Female;Humans;Incidence;Male;Middle Aged;National Cancer Institute (U.S.);Neoplasms;Registries;Research Design;Statistics as Topic;Time Factors;United States",
        "Doc_meshqualifiers":"epidemiology;methods;epidemiology",
        "_version_":1605845221833179136},
      {
        "Doc_abstract":"We have characterized the ligand-enhanced phosphorylation of the CXC chemokine receptor-2 (CXCR2) in a series of clonal 3ASubE cell lines expressing receptors truncated or mutated in the carboxyl-terminal domain. Truncation of CXCR2 by substitution of a stop codon for Ser-342 (342T) or Ser-331 (331T) results in total loss of melanoma growth stimulatory activity/growth-related protein (MGSA/GRO)-enhanced receptor phosphorylation, which cannot be explained based upon altered ligand binding affinity or receptor number. 3ASubE cells expressing 342T or CXCR2 with mutation of Ser-342, -346, -347, and -348 to alanine (4A) exhibit strong mobilization of Ca2+ in response to ligand (interleukin-8 or MGSA/GRO), with a recovery phase significantly slower than that of cells expressing wild type (WT) CXCR2. In contrast to the WT CXCR2, which is 93% desensitized by 20 nM ligand, the 331T, 342T, and 4A CXCR2 mutants do not undergo significant ligand-induced desensitization, and respond to a second ligand challenge by mobilizing Ca2+. The 3ASubE cells expressing CXCR2 with mutation of Ser-346, -347, and -348 to alanine, or with mutation of only one serine in this domain, continue to be phosphorylated in response to ligand and are 60-70% desensitized following the initial ligand challenge. WT CXCR2 phosphorylation and desensitization occur in <1 min, while receptor sequestration is a much later event (30-60 min). However, mutant receptors that are neither phosphorylated nor desensitized in response to ligand are <10% sequestered 60 min following ligand challenge. These data demonstrate for the first time that ligand binding to CXCR2 results in receptor phosphorylation, desensitization, and sequestration and that serine residues 342 and 346-348 participate in the desensitization and sequestration processes.",
        "Doc_title":"Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"9079638",
        "Doc_ChemicalList":"CXCL1 protein, human;Chemokine CXCL1;Chemokines, CXC;Chemotactic Factors;Growth Substances;Intercellular Signaling Peptides and Proteins;Receptors, Interleukin;Receptors, Interleukin-8B;Serine;Tetradecanoylphorbol Acetate;Calcium",
        "Doc_meshdescriptors":"Amino Acid Sequence;Calcium;Chemokine CXCL1;Chemokines, CXC;Chemotactic Factors;Growth Substances;Humans;Intercellular Signaling Peptides and Proteins;Molecular Sequence Data;Peptide Mapping;Phosphorylation;Polymerase Chain Reaction;Receptors, Interleukin;Receptors, Interleukin-8B;Serine;Structure-Activity Relationship;Tetradecanoylphorbol Acetate",
        "Doc_meshqualifiers":"metabolism;pharmacology;pharmacology;chemistry;genetics;genetics;metabolism;pharmacology",
        "_version_":1605831326965956608},
      {
        "Doc_abstract":"Hot spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in tumors of neuroectodermal origin such as melanoma and glioma. Many of these tumors are of neuroectodermal or ectomesenchymal origin which is suggestive of TERT promoter mutations playing a role in the development of malignant peripheral nerve sheath tumors (MPNSTs). In melanoma a correlation has been suggested between the occurrence of TERT promoter mutations and v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutations. We investigated TERT promoter and BRAF mutation frequency in respectively 94 and 86 consecutive MPNST cases from our institute. TERT promoter mutation analysis on DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis. Sequence analysis of BRAF was performed by bidirectional DNA sequencing. We identified TERT C228T or C250T promoter mutations in 10 % (9/94) and BRAF V600E mutations in 3 % (3/86) of MPNSTs. All TERT promoter- and BRAF mutations occurred in NF1 unrelated tumors. One co-occurrence of a TERT promoter- and a BRAF mutation was observed. In comparison with other neuroectodermal derived malignant neoplasms, TERT promoter mutations occur at relatively low frequency in MPNSTs. The observation of TERT promotor and BRAF mutations in sporadic MPNSTs and the absence of TERT promotor and rarity of BRAF mutations in NF1 related tumors may imply an alternative genetic route of tumor progression in both patient groups.",
        "Doc_title":"TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.",
        "Journal":"Journal of neuro-oncology",
        "Do_id":"25035100",
        "Doc_ChemicalList":"BRAF protein, human;Proto-Oncogene Proteins B-raf;TERT protein, human;Telomerase",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;DNA Mutational Analysis;Female;Follow-Up Studies;Humans;Infant;Male;Middle Aged;Mutation;Neurilemmoma;Neurofibromatosis 1;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Proto-Oncogene Proteins B-raf;Telomerase;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605746440970174465},
      {
        "Doc_abstract":"Adenovirus (Ad)-mediated E2F-1 gene transfer induces apoptosis in cancer cells in vitro and in vivo, but clinical application of E2F-1 in cancer gene therapy remains controversial because of the oncogenic potential of E2F-1. This barrier can be circumvented by using the truncated form of the E2F-1 gene (E2Ftr) (amino acids 1 through 375), which lacks the E2F-1 transactivation domain and cell cycle-promoting effects.;The authors constructed 3 adenoviral vectors that expressed E2Ftr under regulation of the tetracycline (Tet)-off system (AdTet-E2Ftr1, AdTet-E2Ftr2, and AdTet-E2Ftr3). These vectors were compared for E2Ftr expression and apoptosis induction in cancer cells and normal cells. E2Ftr antitumor activity in vivo also was assessed in a melanoma xenograft model.;One of the 3 vectors, AdTet-E2Ftr3, had the highest E2Ftr protein expression levels, which were correlated with the greatest induction of apoptosis and inhibition of cancer cell growth. E2Ftr induced apoptosis in a variety of cancer cell lines independent of p53 status with little cytotoxicity in normal cell lines. In a mouse melanoma xenograft model, AdTet-E2Ftr3 exhibited an approximately 80% decrease in tumor size compared with controls in vivo.;The current results indicated that AdTet-E2Ftr3 is a novel anticancer agent that has significant therapeutic activity in vitro and in vivo.",
        "Doc_title":"Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo.",
        "Journal":"Cancer",
        "Do_id":"20549818",
        "Doc_ChemicalList":"E2F1 Transcription Factor;E2F1 protein, human",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Apoptosis;Cell Line, Tumor;E2F1 Transcription Factor;Genes, p53;Genetic Therapy;Genetic Vectors;Mice;Mice, Inbred BALB C;Neoplasms;Sequence Deletion;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"genetics;chemistry;genetics;methods;therapy",
        "_version_":1605756350394007552},
      {
        "Doc_abstract":"Nitric oxide (NO) plays important physiological roles in the vasculature to regulate angiogenesis, blood flow, and hemostasis. In solid tumors, NO is generally acknowledged to mediate angiogenic responses to several growth factors. This contrasts with conflicting evidence that NO can acutely increase tumor perfusion through local vasodilation or diminish perfusion by preferential relaxation of peripheral vascular beds outside the tumor. Because thrombospondin 1 (TSP1) is an important physiological antagonist of NO in vascular cells, we examined whether, in addition to inhibiting tumor angiogenesis, TSP1 can acutely regulate tumor blood flow. We assessed this activity of TSP1 in the context of perfusion responses to NO as a vasodilator and epinephrine as a vasoconstrictor. Nitric oxide treatment of wild type and TSP1 null mice decreased perfusion of a syngeneic melanoma, whereas epinephrine transiently increased tumor perfusion. Acute vasoactive responses were also independent of the level of tumor-expressed TSP1 in a melanoma xenograft, but recovery of basal perfusion was modulated by TSP1 expression. In contrast, overexpression of truncated TSP1 lacking part of its CD47 binding domain lacked this modulating activity. These data indicate that TSP1 primarily regulates long-term vascular responses in tumors, in part, because the tumor vasculature has a limited capacity to acutely respond to vasoactive agents.",
        "Doc_title":"Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.",
        "Journal":"Neoplasia (New York, N.Y.)",
        "Do_id":"18670646",
        "Doc_ChemicalList":"Thrombospondin 1;Vasoconstrictor Agents;Vasodilator Agents;Nitric Oxide;Epinephrine",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Epinephrine;Female;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Mice, Knockout;Nitric Oxide;Regional Blood Flow;Thrombospondin 1;Time Factors;Vasoconstrictor Agents;Vasodilator Agents;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;blood supply;drug therapy;pathology;pharmacology;drug effects;deficiency;genetics;pharmacology;pharmacology;pharmacology",
        "_version_":1605841659724038144},
      {
        "Doc_abstract":"The Melan-A/MART-1(26-35) antigenic peptide is one of the best studied human tumor-associated antigens. It is expressed in healthy melanocytes and malignant melanoma and is recognized by CD8(+) T cells in the context of the MHC class I molecule HLA-A*0201. While an unusually large repertoire of CD8(+) T cells specific for this antigen has been documented, the reasons for its generation have remained elusive. In this issue of the European Journal of Immunology, Pinto et al. [Eur. J. Immunol. 2014. 44: 2811-2821] uncover one important mechanism by comparing the thymic expression of the Melan-A gene to that in the melanocyte lineage. This study shows that medullary thymic epithelial cells (mTECs) dominantly express a truncated Melan-A transcript, the product of misinitiation of transcription. Consequently, the protein product in mTECs lacks the immunodominant epitope spanning residues 26-35, thus precluding central tolerance to this antigen. In contrast, melanocytes and melanoma tumor cells express almost exclusively the full-length Melan-A transcript, thus providing the target antigen for efficient recognition by HLA-A2-restricted CD8(+) T cells. The frequency of these alternative gene transcription modes may be more common than previously appreciated and may represent an important factor modulating the efficiency of central tolerance induction in the thymus.",
        "Doc_title":"Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans.",
        "Journal":"European journal of immunology",
        "Do_id":"25154881",
        "Doc_ChemicalList":"Epitopes, T-Lymphocyte;MART-1 Antigen;MLANA protein, human",
        "Doc_meshdescriptors":"CD8-Positive T-Lymphocytes;Epithelial Cells;Epitopes, T-Lymphocyte;Female;Humans;MART-1 Antigen;Male;Thymus Gland;Transcription Initiation, Genetic",
        "Doc_meshqualifiers":"immunology;immunology;immunology;immunology;immunology;immunology",
        "_version_":1605818777000214529},
      {
        "Doc_abstract":"Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent relapse. Here we examined whether combining a GSI (Î³-Secretase Inhibitor) with ABT-737 (a small molecule BCL-2/BCL-XL/BCL-W inhibitor) can kill both the non-MICs (bulk of melanoma) and MICs. To address the limitations of melanoma therapies, we included multiple tumor samples of patients relapsed from current treatments, with a diverse genetic background (with or without the common BRAF, NRAS or NF1 mutations) in these studies. Excitingly, the combination treatment reduced cell viability and induced apoptosis of the non-MICs; disrupted primary spheres, decreased the ALDH+ cells, and inhibited the self-renewability of the MICs in multiple melanoma cell lines and relapsed patient samples. Using a low-cell-number mouse xenograft model, we demonstrated that the combination significantly reduced the tumor initiating ability of MIC-enriched cultures from relapsed patient samples. Mechanistic studies also indicate that cell death is NOXA-dependent. In summary, this combination may be a promising strategy to address treatment relapse and for triple wild-type patients who do not respond to immunotherapy.",
        "Doc_title":"Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.",
        "Journal":"Oncotarget",
        "Do_id":"27829238",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605824157523640320},
      {
        "Doc_abstract":"Neuraminic acid is the core structure of most known sialic acids. In natural systems, the amino group at the 5 position of neuraminic acid residues is usually assumed to be acylated. Previously, synthetic de-N-acetyl-gangliosides (with free amino groups at the 5 position of neuraminic acids) have been shown to modulate cellular proliferation and tyrosine phosphokinase reactions. While indirect evidence has suggested that traces of these molecules exist naturally in certain tumor cells, further exploration has been hampered by the lack of a system showing consistent expression at an easily detectable level. Using synthetic compounds as antigens, we have developed highly specific monoclonal antibodies against de-N-acetyl-GM3 and de-N-acetyl-GD3 that require both the free amino group and the exocyclic side chain of sialic acids for recognition. Cultured human melanoma cells showed low but variably detectable levels of reactivity with these antibodies. The ability of various biologically active molecules to stimulate this reactivity was explored. Of many compounds tested, only the tyrosine kinase inhibitor genistein induced reactivity in a dose-dependent manner. Antibody reactivity with ganglioside extracts from genistein-treated cells was abolished by chemical re-N-acetylation and/or truncation of sialic acid side chains by mild periodate oxidation. High performance thin layer chromatography immuno-overlay analysis confirmed the presence of the novel compound de-N-acetyl-GD3 in these extracts. Several other tyrosine kinase inhibitors tested did not give the same increase in de-N-acetyl-ganglioside expression. However, the microtubule inhibitor nocodazole caused a similar accumulation of these molecules, particularly in non-adherent cells expected to be arrested at metaphase. Thus, genistein may induce de-N-acetyl-ganglioside expression by virtue of its known ability to arrest cells in the G2M phase, rather than as a general consequence of tyrosine kinase inhibition. These studies also provide a system in which to analyze the enzymatic basis of de-N-acetyl-ganglioside expression and their potential roles as growth regulating molecules.",
        "Doc_title":"Expression of de-N-acetyl-gangliosides in human melanoma cells is induced by genistein or nocodazole.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"7852370",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Benzoquinones;G(M3) Ganglioside;Isoflavones;Lactams, Macrocyclic;Quinones;Rifabutin;herbimycin;Genistein;Protein-Tyrosine Kinases;Nocodazole",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Benzoquinones;Cell Line;Chromatography, High Pressure Liquid;Chromatography, Thin Layer;Enzyme-Linked Immunosorbent Assay;Flow Cytometry;G(M3) Ganglioside;Genistein;Humans;Isoflavones;Lactams, Macrocyclic;Melanoma;Nocodazole;Protein-Tyrosine Kinases;Quinones;Rifabutin;Spectrometry, Mass, Fast Atom Bombardment;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analogs & derivatives;analysis;biosynthesis;isolation & purification;pharmacology;metabolism;pharmacology;antagonists & inhibitors;pharmacology;analogs & derivatives",
        "_version_":1605801790607982592},
      {
        "Doc_abstract":"We have identified two different mutations in the tyrosinase genes of Japanese patients with tyrosinase-negative oculocutaneous albinism (OCA). One is a single base insertion in the exon 2 of the tyrosinase gene that shifts the reading frame and introduces a premature termination codon (TGA) after the amino acid residue 298 (codon 316). The other is a G to A transition at residue 312, leading to a single amino acid substitution, arginine at position 59 (codon 77) to glutamine. The promoter activity of the patients' tyrosinase genes was evaluated in the cell-free transcription system prepared from pigmented melanoma cells, indicating that the patients' genes were accurately transcribed in vitro. It is therefore conceivable that the tyrosinase gene is expressed in their melanocytes. Furthermore, transient expression of the mutated genes indicates that the truncated tyrosinase or the tyrosinase containing glutamine 59 is unable to form melanin in melanocytes. We therefore propose that these mutations in the tyrosinase genes lead to a phenotype of tyrosinase-negative OCA.",
        "Doc_title":"Molecular bases of tyrosinase-negative oculocutaneous albinism: a single base insertion or a missense point mutation in the tyrosinase gene.",
        "Journal":"Pigment cell research",
        "Do_id":"1409445",
        "Doc_ChemicalList":"Recombinant Fusion Proteins;Monophenol Monooxygenase",
        "Doc_meshdescriptors":"Albinism, Oculocutaneous;Amino Acid Sequence;Animals;Base Sequence;DNA Mutational Analysis;Genes;Humans;Melanoma, Experimental;Mice;Molecular Sequence Data;Monophenol Monooxygenase;Mutation;Polymerase Chain Reaction;Promoter Regions, Genetic;Recombinant Fusion Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;biosynthesis;deficiency;genetics;biosynthesis;metabolism",
        "_version_":1605832459273895936},
      {
        "Doc_abstract":"The tumor suppressor gene, CDKN2A (p16), encodes a cyclin-dependent kinase inhibitor and functions as a negative regulator in the retinoblastoma pathway that blocks cell cycle progression from the G1 phase. The gene has been found to be deleted, truncated, mutated, or silenced by promoter methylation in a wide range of tumor types. Where melanoma CDKN2A mutations have been characterized, C --> T and CC --> TT transitions were found, indicating a direct role for ultraviolet radiation (UVR)-induced pyrimidine dimers in the formation of some tumors. The South American opossum, Monodelphis domestica, has been shown by our group and others to be susceptible to the induction of melanoma on chronic exposure to UVR alone. The CDKN2A gene and its exon 1beta alternate transcript p19ARF were cloned and sequenced from M. domestica to investigate the role of these genes in the development of UVR-induced melanoma and non-melanoma tumors. Both genes were first amplified by polymerase chain reaction (PCR) using cDNA from an opossum corneal-tumor cell-line library and degenerate primers based on human, mouse, and rat CDKN2A gene sequences. To verify these as normal sequences, both genes were then RT-PCR amplified from cultured normal opossum melanocyte mRNA. When comparing the tumor and melanocyte sequences, we found a UVR signature point mutation, a C --> T transition, within exon 2 in the corneal tumor cell line. The same mutation at this site in other tumors has been shown to alter the CDKN2A protein's ability to bind CDK4 kinase, which may lead to uncontrolled cell cycling. A comparison of the amino acid sequence of opossum CDKN2A showed identities relative to human, mouse, and rat between 57% and 63%, and when conserved amino acid substitutions are considered (similarity), the range is 63% to 67%. The amino acid identity and similarity for p19ARF ranged from 39% to 49%.",
        "Doc_title":"Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.",
        "Journal":"DNA and cell biology",
        "Do_id":"9839807",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Complementary;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Cloning, Molecular;Cyclin-Dependent Kinase Inhibitor p16;DNA, Complementary;Humans;Melanoma;Mice;Molecular Sequence Data;Mutation;Neoplasms, Radiation-Induced;Opossums;Phylogeny;Proteins;Rats;Sequence Alignment;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Ultraviolet Rays",
        "Doc_meshqualifiers":"genetics;etiology;genetics;genetics;classification;genetics;genetics",
        "_version_":1605754462273536000},
      {
        "Doc_abstract":"Over 125 pigmentation-related genes have been identified to date. Of those, PMEL17/GP100 has been widely studied as a melanoma-specific antigen as well as a protein required for the formation of fibrils in melanosomes. PMEL17 is synthesized, glycosylated, processed, and delivered to melanosomes, allowing them to mature from amorphous round vesicles to elongated fibrillar structures. In contrast to other melanosomal proteins such as TYR and TYRP1, the processing and sorting of PMEL17 is highly complex. Monoclonal antibody HMB45 is commonly used for melanoma detection, but has the added advantage that it specifically reacts with sialylated PMEL17 in the fibrillar matrix in melanosomes. In this study, we generated mutant forms of PMEL17 to clarify the subdomain of PMEL17 required for formation of the fibrillar matrix, a process critical to pigmentation. The internal proline/serine/threonine-rich repeat domain (called the RPT domain) of PMEL17 undergoes variable proteolytic cleavage. Deletion of the RPT domain abolished its recognition by HMB45 and its capacity to form fibrils. Truncation of the C-terminal domain did not significantly affect the processing or trafficking of PMEL17, but, in contrast, deletion of the N-terminal domain abrogated both. We conclude that the RPT domain is essential for its function in generating the fibrillar matrix of melanosomes and that the luminal domain is necessary for its correct processing and trafficking to those organelles.",
        "Doc_title":"The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"16682408",
        "Doc_ChemicalList":"Antigens, Neoplasm;Melanoma-Specific Antigens;Membrane Glycoproteins;Neoplasm Proteins;PMEL protein, human;gp100 Melanoma Antigen",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antigens, Neoplasm;Cell Line, Tumor;Gene Deletion;Golgi Apparatus;HeLa Cells;Humans;Melanoma-Specific Antigens;Melanosomes;Membrane Glycoproteins;Models, Genetic;Molecular Sequence Data;Mutation;Neoplasm Proteins;Protein Structure, Tertiary;Transfection;gp100 Melanoma Antigen",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;physiology;chemistry",
        "_version_":1605774820825366528},
      {
        "Doc_abstract":"Crotalid venoms are rich sources of components that affect the hemostatic system. Snake venom metalloproteinases are zinc-dependent enzymes responsible for hemorrhage that also interfere with hemostasis. The disintegrin domain is a part of snake venom metalloproteinases, which involves the binding of integrin receptors. Integrins play an essential role in cancer survival and invasion, and they have been major targets for drug development and design. Both native and recombinant disintegrins have been widely investigated for their anti-cancer activities in biological systems as well as inÂ vitro and inÂ vivo systems. Here, three new cDNAs encoding ECD disintegrin-like domains of metalloproteinase precursor sequences obtained from a Venezuelan mapanare (Bothrops colombiensis) venom gland cDNA library have been cloned. Three different N- and C-terminal truncated ECD disintegrin-like domains of metalloproteinases named colombistatins 2, 3, and 4 were amplified by PCR, cloned into a pGEX-4T-1 vector, expressed in Escherichia coli BL21, and tested for inhibition of platelet aggregation and inhibition of adhesion of human skin melanoma (SK-Mel-28) cancer cell lines on collagen I. Purified recombinant colombistatins 2, 3, and 4 were able to inhibit ristocetin- and collagen-induced platelet aggregation. r-Colombistatins 2 showed the most potent inhibiting SK-Mel-28 cancer cells adhesion to collagen. These results suggest that colombistatins may have utility in the development of therapeutic tools in the treatment of melanoma cancers and also thrombotic diseases.",
        "Doc_title":"Expression, purification, and analysis of three recombinant ECD disintegrins (r-colombistatins) from P-III class snake venom metalloproteinases affecting platelet aggregation and SK-MEL-28 cell adhesion.",
        "Journal":"Toxicon : official journal of the International Society on Toxinology",
        "Do_id":"27641750",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605903484584984576},
      {
        "Doc_abstract":"GPR56 is an adhesion-class G-protein-coupled receptor responsible for bilateral frontoparietal polymicrogyria (BFPP), a severe disorder of cortical formation. Additionally, GPR56 is involved in biological processes as diverse as hematopoietic stem cell generation and maintenance, myoblast fusion, muscle hypertrophy, immunoregulation and tumorigenesis. Collagen III and tissue transglutaminase 2 (TG2) have been revealed as the matricellular ligands of GPR56 involved in BFPP and melanoma development, respectively. In this study, we identify heparin as a glycosaminoglycan interacting partner of GPR56. Analyses of truncated and mutant GPR56 proteins reveal two basic-residue-rich clusters, R(26)GHREDFRFC(35) and L(190)KHPQKASRRP(200), as the major heparin-interacting motifs that overlap partially with the collagen III- and TG2-binding sites. Interestingly, the GPR56-heparin interaction is modulated by collagen III but not TG2, even though both ligands are also heparin-binding proteins. Finally, we show that the interaction with heparin reduces GPR56 receptor shedding, and enhances cell adhesion and motility. These results provide novel insights into the interaction of GPR56 with its multiple endogenous ligands and have functional implications in diseases such as BFPP and cancer. ",
        "Doc_title":"Heparin interacts with the adhesion GPCR GPR56, reduces receptor shedding, and promotes cell adhesion and motility.",
        "Journal":"Journal of cell science",
        "Do_id":"27068534",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605766460537307136},
      {
        "Doc_abstract":"Cancer is one of the most important health problems in developed countries. The aim of this paper is to analyze mortality trends due to cancer in Catalonia from 1975 to 1990.;Cancer mortality trends have been studied for each sex separately. Rates were standardized by direct method, using world population as standard; also, truncated (35-65 years old) and cumulative rates (0-74) were calculated. Annual percentage of change was estimated from a Poisson's regression model.;An increase of cancer mortality was observed between 1975 and 1990 among men but not in women. Lung cancer is the main cause of death from cancer in men and breast cancer in women. Both these cancers showed a significative increase in their mortality during the period of study. Among men, there is a significative increase in the following cancers: oral cavity, colon, pancreas, melanoma, non-Hodgkin's lymphoma and myeloma; and there is a decrease in the following cancers: stomach, testicle and brain. Among women, there is a significative increase in cancer mortality due to the following: ovarian, colon, pancreas, melanoma and non-Hodgkin's lymphoma; while decrease in the following: stomach, liver and uterus. Also, lung cancer mortality among women is decreasing.;The increasing trend observed in lung cancer mortality rates among men and in breast cancer among women are the main causes of concern. Therefore, priorities in cancer control underlined by this analysis should include emphasis on smoking control and developing breast cancer screening.",
        "Doc_title":"[Cancer mortality trends in Catalonia: 1975-1990].",
        "Journal":"Medicina clinica",
        "Do_id":"8208035",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Child;Child, Preschool;Female;Humans;Infant;Infant, Newborn;Male;Middle Aged;Neoplasms;Sex Factors;Spain",
        "Doc_meshqualifiers":"mortality",
        "_version_":1605746979570188288},
      {
        "Doc_abstract":"Tumor progression depends on the support of cells in the microenvironment, and is driven in part by the generation of reactive oxygen species (ROS). ROS can damage DNA, and the repair of damaged DNA is a well-known process involved in tumor initiation and promotion, but the role of DNA repair in tumor progression is not fully understood. In this regard the X-ray cross complementing 1 (XRCC1) protein is known to orchestrate the assembly of repair complexes at sites of DNA single strand breaks either directly or indirectly through repair of damaged bases, largely as the result of ROS-induced damage. XRCC1 polymorphisms have been shown to be associated with increased cancer. It was therefore of interest to investigate the effect of XRCC1 gene mutations on cancer progression. In an attempt to make XRCC1 point mutant mice, we generated a truncated protein (XRCC1tp) by the insertion of a neomycin cassette in intron12 of the XRCC1 gene. This unique finding allowed us to investigate cellular and tumor progression phenotypes in mice associated with expression and function of an altered XRCC1 protein on one allele. XRCC1tp cells showed increased toxicity to MMS, enhanced MMS-induced depletion of NADH suggesting increased PARP activity, and normal functional repair of MMS-induced DNA damage. Six months following treatment with the alkylating carcinogen azoxymethane (AOM) at 10 mg/kg once a week for 6 weeks, XRCC1tp mice had a decrease in average colon tumor volume of 14Â±3 mm(3) compared to 34Â±4 mm(3) in WT littermates (p â¤ 0.03, N= 20/genotype). XRCC1tp mice had a 72 per cent decrease in B16 melanoma tumor burden compared to wt littermates. Average tumor volume in transgenic PyMT metastatic breast cancer mice expressing XRCC1tp was 359 cubic mm in PyMT mice expressing XRCC1tp compared to 730 cubic mm in PyMT mice expressing XRCC1wt (p â¤ 0.001, N= 20/genotype). These data suggest that the presence of an XRCC1 truncated protein alters XRCC1 function independent of DNA repair, and is associated with anti-tumor activity.",
        "Doc_title":"Tumor growth is suppressed in mice expressing a truncated XRCC1 protein.",
        "Journal":"American journal of cancer research",
        "Do_id":"22432057",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605903804677488640},
      {
        "Doc_abstract":"Cutaneous tumor metastasis may be the first manifestation of cancer, but more often is a harbinger of advanced disease that portends an ominous prognosis. All skin accessions over the past 10 years from a large Veterans Administration (VA) hospital were reviewed.;Archived histories, glass slides, and the immunohistochemical battery (IHC), were assessed to determine diagnostic accuracy.;Of the 100,453 cases reviewed, there were a total of 77 cases (75 males and 2 females) of cutaneous metastasis from the lungs (28.6%), metastatic melanoma (18.2%), gastrointestinal tract (14.2%), genitourinary tract (10.4%), head and neck (9.1%), hematologic (5.2%), breast (5.2%), and miscellaneous (<2%). Metastasis represented the first indication of an internal malignancy in 7.8% of cases. The cutaneous sites of involvement included the head and neck (28%), the trunk (40%), the extremities (18%), and multiple sites (14%). The age range was 38-83 years, with a mean of 62 years. The average time interval between diagnosis of internal malignancy and cutaneous presentation was 33 months (range: <1 month-22 years), and the average survival following diagnosis was 7.5 months (range: <1 month-8 years). In a cohort of subjects, a truncated immunohistochemical battery consisting of CK-7, CK-20, and S-100 was consistent with the expected staining pattern of the primary source of cutaneous metastasis in 83.33% of the patients.;Excluding the potential for age and gender bias in this study conducted in a VA setting, cutaneous metastases represent an uncommon, deadly, and late-developing occurrence in many patients. Compared with previous studies, lung carcinoma remains the most common of the cutaneous metastases, with a relative rise in the incidence of metastatic melanoma. The immunohistochemical battery of CK-7, CK-20, and S-100 is a helpful adjunct in narrowing the differential diagnosis of the primary site of a large proportion of cutaneous metastases, particularly tumors with an epithelioid appearance such as carcinomas and melanomas.",
        "Doc_title":"Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal.",
        "Journal":"Journal of cutaneous pathology",
        "Do_id":"15186430",
        "Doc_ChemicalList":"Biomarkers, Tumor;S100 Proteins;Keratins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Diagnosis, Differential;Female;Humans;Immunohistochemistry;Keratins;Male;Middle Aged;Retrospective Studies;S100 Proteins;Skin Neoplasms",
        "Doc_meshqualifiers":"analysis;metabolism;metabolism;diagnosis;metabolism;secondary",
        "_version_":1605898595613016064},
      {
        "Doc_abstract":"Most malignant peripheral nerve sheath tumors (MPNSTs) exhibit combined inactivation of NF1, CDKN2A, and polycomb repressive complex 2 component genes (Embryonic Ectoderm Development [EED] and Suppressor of Zeste 12 [SUZ12]). Mutations in EED and SUZ12 induce loss of trimethylation at lysine 27 of histone 3 (H3K27me3), with subsequent aberrant transcriptional activation of polycomb repressive complex 2-repressed homeobox master regulators. These findings prompted us to investigate the performance of an anti-H3K27me3 monoclonal antibody clone C36B11 as an immunohistochemical marker for MPNSTs. We assessed the C36B11 reactivity pattern in a pathologically and genetically well-characterized cohort of 68 MPNSTs, spanning various clinical presentations, such as type 1 neurofibromatosis (NF1), radiotherapy, and sporadic MPNSTs. We found that 69% (n=47) of all MPNSTs demonstrated loss of H3K27me3 expression, with 42 (61%) showing complete loss and 5 (7%) showing partial loss, whereas 31% (n=21) retained H3K27me3 expression. Among the NF1-related high-grade MPNSTs, 60% demonstrated loss of expression. In contrast, the majority of both sporadic (95%) and radiotherapy-related (91%) MPNSTs showed loss of H3K27me3 expression. Two of the 3 low-grade MPNSTs and all neurofibromas showed retained expression. Furthermore, all 5 epithelioid MPNSTs retained H3K27me3 labeling. The specificity of H3K27me3 loss as a marker for MPNSTs was studied by testing a large spectrum of lesions included in MPNST differential diagnosis, such as spindle/desmoplastic melanomas, synovial sarcomas, myoepithelial tumors, and other mesenchymal neoplasms, all of which retained expression of H3K27me3. We conclude that immunohistochemical analysis of H3K27me3 has good sensitivity and robust specificity for the diagnosis of MPNST, particularly outside of NF1 clinical history, which represents the most challenging diagnostic setting. ",
        "Doc_title":"Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"26645727",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Biomarkers, Tumor;Histones;Jumonji Domain-Containing Histone Demethylases;KDM6B protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antibodies, Monoclonal;Biomarkers, Tumor;Child;Child, Preschool;DNA Methylation;Female;Histones;Humans;Jumonji Domain-Containing Histone Demethylases;Male;Middle Aged;Neurilemmoma;Sensitivity and Specificity;Tissue Array Analysis;Young Adult",
        "Doc_meshqualifiers":"analysis;analysis;diagnosis",
        "_version_":1605798340514021376},
      {
        "Doc_abstract":"Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN (which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT-PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.",
        "Doc_title":"UTRN on chromosome 6q24 is mutated in multiple tumors.",
        "Journal":"Oncogene",
        "Do_id":"17384672",
        "Doc_ChemicalList":"Tumor Suppressor Proteins;UTRN protein, human;Utrophin",
        "Doc_meshdescriptors":"Animals;Base Sequence;Breast Neoplasms;Chromosomes, Human, Pair 6;Female;Humans;Male;Mammary Neoplasms, Experimental;Melanoma;Melanoma, Experimental;Mice;Mice, Nude;NIH 3T3 Cells;Neoplasms, Experimental;Neuroblastoma;Point Mutation;Sequence Deletion;Tumor Suppressor Proteins;Utrophin",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605746480088350722},
      {
        "Doc_abstract":"We induced thrombosis of blood vessels in solid tumors in mice by a fusion protein consisting of the extracellular domain of tissue factor (truncated tissue factor, tTF) and the peptide GNGRAHA, targeting aminopeptidase N (CD13) and the integrin alpha(v)beta(3) (CD51/CD61) on tumor vascular endothelium. The designed fusion protein tTF-NGR retained its thrombogenic activity as demonstrated by coagulation assays. In vivo studies in mice bearing established human adenocarcinoma (A549), melanoma (M21), and fibrosarcoma (HT1080) revealed that systemic administration of tTF-NGR induced partial or complete thrombotic occlusion of tumor vessels as shown by histologic analysis. tTF-NGR, but not untargeted tTF, induced significant tumor growth retardation or regression in all 3 types of solid tumors. Thrombosis induction in tumor vessels by tTF-NGR was also shown by contrast enhanced magnetic resonance imaging (MRI). In the human fibrosarcoma xenograft model, MRI revealed a significant reduction of tumor perfusion by administration of tTF-NGR. Clinical first-in-man application of low dosages of this targeted coagulation factor revealed good tolerability and decreased tumor perfusion as measured by MRI. Targeted thrombosis in the tumor vasculature induced by tTF-NGR may be a promising strategy for the treatment of cancer.",
        "Doc_title":"Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.",
        "Journal":"Blood",
        "Do_id":"19179306",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;NGR peptide;Oligopeptides;Thromboplastin",
        "Doc_meshdescriptors":"Adult;Angiogenesis Inhibitors;Animals;Cells, Cultured;Drug Delivery Systems;Embolism;Female;Humans;Male;Mice;Mice, Inbred BALB C;Mice, Nude;Middle Aged;Neoplasms;Neovascularization, Pathologic;Oligopeptides;Salvage Therapy;Thromboplastin;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"therapeutic use;methods;chemically induced;blood supply;drug therapy;drug therapy;metabolism;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605742793844588544},
      {
        "Doc_abstract":"CCN3, a founding member of the CCN family of growth regulators, was linked with hematology in 2003(1) when it was detected in human serum. CCN3 is expressed and secreted by hematopoietic progenitor cells in normal bone marrow. CCN3 acts through the core stem cell signalling pathways including Notch and Bone Morphogenic Protein, connecting CCN3 with the modulation of self-renewal and maturation of a number of cell lineages including hematopoietic, osteogenic and chondrogenic. CCN3 expression is disrupted in Chronic Myeloid Leukemia as a consequence of the BCR-ABL oncogene and allows the leukemic clone to evade growth regulation. In contrast, naÃ¯ve cord blood progenitors undergo enhanced clonal expansion in response to CCN3. Altered CCN3 expression is associated with numerous solid tumors including glioblastoma, melanoma, adrenocortical tumours, prostate cancer and bone malignancies including osteosarcoma. Mature CCN3 protein has five distinct modules and truncated protein variants with altered function are found in many cancers. Regulation by CCN3 is therefore cell type and isoform specific. CCN3 has emerged as a key player in stem cell regulation, hematopoiesis and a crucial component within the bone marrow microenvironment.",
        "Doc_title":"CCN3--a key regulator of the hematopoietic compartment.",
        "Journal":"Blood reviews",
        "Do_id":"18752874",
        "Doc_ChemicalList":"NOV protein, human;Nephroblastoma Overexpressed Protein",
        "Doc_meshdescriptors":"Amino Acid Sequence;Hematopoietic Stem Cells;Humans;Molecular Sequence Data;Nephroblastoma Overexpressed Protein",
        "Doc_meshqualifiers":"physiology;blood;chemistry;physiology",
        "_version_":1605742666055680000},
      {
        "Doc_abstract":"Previously, we showed that prostate and prostate cancer cells express a truncated T-cell receptor gamma chain mRNA that uses an alternative reading frame to produce a novel nuclear T-cell receptor gamma chain alternate reading frame protein (TARP). TARP is expressed in the androgen-sensitive LNCaP prostate cancer cell line but not in the androgen-independent PC3 prostate cancer cell line, indicating that TARP may play a role in prostate cancer progression. To elucidate the function of TARP, we generated a stable PC3 cell line that expresses TARP in a constitutive manner. Expression of TARP in PC3 cells resulted in a more rapid growth rate with a 5-h decrease in doubling time. cDNA microarray analysis of 6538 genes revealed that caveolin 1, caveolin 2, amphiregulin, and melanoma growth stimulatory activity alpha were significantly up-regulated, whereas IL-1beta was significantly down-regulated in PC3 cells expressing TARP. We also demonstrated that TARP expression is up-regulated by testosterone in LNCaP cells that express a functional androgen receptor. These results suggest that TARP has a role in regulating growth and gene expression in prostate cancer cells.",
        "Doc_title":"T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.",
        "Journal":"Cancer research",
        "Do_id":"11719440",
        "Doc_ChemicalList":"AREG protein, human;Amphiregulin;Androgens;Caveolins;EGF Family of Proteins;Glycoproteins;Growth Substances;Intercellular Signaling Peptides and Proteins;Nuclear Proteins;TARP",
        "Doc_meshdescriptors":"Amphiregulin;Androgens;Caveolins;Cell Division;EGF Family of Proteins;Gene Expression Regulation, Neoplastic;Glycoproteins;Growth Substances;Humans;Intercellular Signaling Peptides and Proteins;Male;Neoplasms, Hormone-Dependent;Nuclear Proteins;Prostatic Neoplasms;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"physiology;biosynthesis;genetics;genetics;physiology;biosynthesis;genetics;biosynthesis;genetics;genetics;metabolism;pathology;biosynthesis;genetics;physiology;genetics;metabolism;pathology",
        "_version_":1605794720691257344},
      {
        "Doc_abstract":"Family studies are a useful alternative to twin studies for disentangling genetic and environmental effects on human diseases. However, although age-at-onset traits are often of interest, family-based quantitative genetic analysis of such data is still not commonly used. One reason is that we need multiple random components to capture the genetic and environmental contributions, so it becomes hard to use the existing frailty models for correlated survival data. In this paper we consider the alternative accelerated failure-time models with random effects. The method allows both left truncation and right censoring, and it can deal with an arbitrary family structure and multiple random components. For estimation we use the h-likelihood procedure, which avoids the integration of the random effects in the marginal likelihood approach. To deal with large cohort data, we propose a case-control scheme, where we ascertain all families with at least two events and a subsample of control families. A pseudo-h-likelihood approach is used to analyse the ascertained data. We study the performance of the method using simulated data, and provide an illustration with analysis of melanoma in the Swedish population.",
        "Doc_title":"Genetic analysis of age-at-onset traits based on case-control family data.",
        "Journal":"Statistics in medicine",
        "Do_id":"21170919",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Age of Onset;Computer Simulation;Family;Humans;Melanoma;Models, Genetic;Models, Statistical;Quantitative Trait, Heritable;Sweden",
        "Doc_meshqualifiers":"epidemiology;genetics",
        "_version_":1605792271663366144},
      {
        "Doc_abstract":"Tegument proteins of herpes simplex virus type 1 (HSV-1) are hypothesized to contain the functional information required for the budding or envelopment process proposed to occur at cytoplasmic compartments of the host cell. One of the most abundant tegument proteins of HSV-1 is the U(L)49 gene product, VP22, a 38-kDa protein of unknown function. To study its subcellular localization, a VP22-green fluorescent protein chimera was expressed in transfected human melanoma (A7) cells. In the absence of other HSV-1 proteins, VP22 localizes to acidic compartments of the cell that may include the trans-Golgi network (TGN), suggesting that this protein is membrane associated. Membrane pelleting and membrane flotation assays confirmed that VP22 partitions with the cellular membrane fraction. Through truncation mutagenesis, we determined that the membrane association of VP22 is a property attributed to amino acids 120 to 225 of this 301-amino-acid protein. The above results demonstrate that VP22 contains specific information required for targeting to membranes of acidic compartments of the cell which may be derived from the TGN, suggesting a potential role for VP22 during tegumentation and/or final envelopment.",
        "Doc_title":"Membrane association of VP22, a herpes simplex virus type 1 tegument protein.",
        "Journal":"Journal of virology",
        "Do_id":"12663795",
        "Doc_ChemicalList":"Luminescent Proteins;Recombinant Fusion Proteins;Viral Structural Proteins;Green Fluorescent Proteins",
        "Doc_meshdescriptors":"Cell Membrane;Green Fluorescent Proteins;Herpesvirus 1, Human;Humans;Luminescent Proteins;Melanoma;Microscopy, Confocal;Recombinant Fusion Proteins;Transfection;Tumor Cells, Cultured;Viral Structural Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;pathogenicity;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605747564883214338},
      {
        "Doc_abstract":"Chemokines mediate the inflammatory response by attracting various leukocyte types. MCP-2/CC chemokine ligand 8 (CCL8) was induced at only suboptimal levels in fibroblasts and endothelial cells by IL-1beta or IFN-gamma, unless these cytokines were combined. IFN-gamma also synergized with the TLR ligands peptidoglycan (TLR2), dsRNA (TLR3) or LPS (TLR4). Under these conditions, intact MCP-2/CCL8(1-76) produced by fibroblasts was found to be processed into MCP-2/CCL8(6-75), which lacked chemotactic activity for monocytic cells. Furthermore, the capacity of MCP-2/CCL8(6-75) to increase intracellular calcium levels through CCR1, CCR2, CCR3 and CCR5 was severely reduced. However, the truncated isoform still blocked these receptors for other ligands. MCP-2/CCL8(6-75) induced internalization of CCR2, inhibited MCP-1/CCL2 and MCP-2/CCL8 ERK signaling and antagonized the chemotactic activity of several CCR2 ligands (MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7). In contrast to MCP-3/CCL7, parvoviral delivery of MCP-2/CCL8 into B78/H1 melanoma failed to inhibit tumor growth, partially due to proteolytic cleavage into inactive MCP-2/CCL8 missing five NH(2)-terminal residues. However, in an alternative tumor model, using HeLa cells, MCP-2/CCL8 retarded tumor development. These data indicate that optimal induction and delivery of MCP-2/CCL8 is counteracted by converting this chemokine into a receptor antagonist, thereby losing its anti-tumoral potential.",
        "Doc_title":"Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects.",
        "Journal":"European journal of immunology",
        "Do_id":"19224633",
        "Doc_ChemicalList":"CCL2 protein, human;CCL8 protein, human;Chemokine CCL2;Chemokine CCL8;Culture Media, Conditioned;Interleukin-1beta;Lipopolysaccharides;Peptidoglycan;Receptors, Chemokine;Toll-Like Receptors;Interferon-gamma;Calcium",
        "Doc_meshdescriptors":"Animals;Calcium;Cell Line;Cell Line, Tumor;Chemokine CCL2;Chemokine CCL8;Culture Media, Conditioned;Fibroblasts;Humans;Interferon-gamma;Interleukin-1beta;Lipopolysaccharides;Mice;Neoplasms;Peptidoglycan;Receptors, Chemokine;Toll-Like Receptors;Up-Regulation",
        "Doc_meshqualifiers":"analysis;immunology;metabolism;immunology;metabolism;immunology;metabolism;analysis;immunology;metabolism;pharmacology;pharmacology;pharmacology;immunology;pharmacology;immunology;metabolism;agonists;immunology;metabolism;drug effects;immunology",
        "_version_":1605845963840159744},
      {
        "Doc_abstract":"Cytolytic T lymphocytes (CTL) cause cytolysis of foreign or virus-infected syngeneic cells when recognition of the target plus major histocompatibility complex (MHC) occurs via the T-cell receptor (TCR). The recognition event leads to intimate contact between the two cells and activation of the cytolytic effector. Activation and target cell lysis can also occur in the presence of antibodies to the TCR. This is accomplished by bridging the effector cell TCR to the target cell FcR by an anti-TCR monoclonal antibody (MoAb). Recent findings have placed the role of the FcR in this event in a questionable light. We confirm the importance of Fc gamma R by demonstrating that: (a) melanoma cells are killed by CTL clones in the presence of anti-TCR-CD3 antibodies only when the melanoma cells express the Fc gamma R on their surface; (b) native Ig, heat-aggregated Ig, or an Fc fragment from an antibody expressing the same isotype as the anti-TCR antibody can block the killing of high avidity Fc gamma RI-bearing cells mediated by anti-TCR antibody (F23.1); and (c) anti-Fc gamma R MoAb (2.4G2) and a truncated soluble Fc gamma RII molecule inhibit the killing of low-avidity Fc gamma RII-bearing cells mediated by anti-CD3 MoAb (145-2C11). Thus, we show that both high-avidity Fc gamma RI and low-avidity Fc gamma RII can mediate sideways killing depending upon the isotype of the anti-TCR antibody and the type of FcR present on the target cell surface.",
        "Doc_title":"Sideways killing: the cytolysis of Fc receptor-bearing cells through bridging to cytolytic T lymphocytes by antibodies specific for the T-cell receptor-T3 complex.",
        "Journal":"Scandinavian journal of immunology",
        "Do_id":"2525807",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antigens, CD3;Antigens, Differentiation, T-Lymphocyte;Antigens, Surface;Cell Adhesion Molecules;Receptors, Antigen, T-Cell;Receptors, Fc",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antigens, CD3;Antigens, Differentiation, T-Lymphocyte;Antigens, Surface;Cell Adhesion Molecules;Cytotoxicity, Immunologic;Mice;Mice, Inbred BALB C;Receptors, Antigen, T-Cell;Receptors, Fc;T-Lymphocytes, Cytotoxic",
        "Doc_meshqualifiers":"immunology;immunology;physiology;immunology;analysis;immunology",
        "_version_":1605840876883410944},
      {
        "Doc_abstract":"The noncoding genome affects gene regulation and disease, yet we lack tools for rapid identification and manipulation of noncoding elements. We developed a CRISPR screen using ~18,000 single guide RNAs targeting >700 kilobases surrounding the genes NF1, NF2, and CUL3, which are involved in BRAF inhibitor resistance in melanoma. We find that noncoding locations that modulate drug resistance also harbor predictive hallmarks of noncoding function. With a subset of regions at the CUL3 locus, we demonstrate that engineered mutations alter transcription factor occupancy and long-range and local epigenetic environments, implicating these sites in gene regulation and chemotherapeutic resistance. Through our expansion of the potential of pooled CRISPR screens, we provide tools for genomic discovery and for elucidating biologically relevant mechanisms of gene regulation.",
        "Doc_title":"High-resolution interrogation of functional elements in the noncoding genome.",
        "Journal":"Science (New York, N.Y.)",
        "Do_id":"27708104",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605757412134879232},
      {
        "Doc_abstract":"The expression of gamma/delta T cell antigen receptors (TcR) in T cell lines or clones derived from tumor-infiltrating lymphocytes (TIL) from patients with solid tumors was investigated. gamma/delta TcR T cell lines were derived from TIL from patients with Wilms tumor, sarcoma or metastatic melanoma by stimulation with autologous tumor cells alone and recombinant interleukin 2 and they exhibited nonspecific cytotoxicity against autologous and allogeneic tumor cells, or cells of the K562 or the MEL21 tumor cell lines. Two T cell lines were derived from a patient with Wilms tumor. One of them expressed a non-disulfide-linked gamma/delta TcR using the 60-kDa gamma chain, whereas, the other expressed a disulfide-linked gamma/delta TcR. A T cell line was derived from a patient with sarcoma and expressed a disulfide-linked gamma/delta TcR, whereas, a T cell line derived from a patient with melanoma expressed a non-disulfide-linked gamma chain of 62 kDa. Several T cell clones were developed from patients with metastatic melanoma or Wilms tumor and expressed either disulfide- or non-disulfide-linked gamma/delta TcR. Northern analysis of RNA from certain of these clones revealed a full-length gamma chain transcript, whereas, the alpha or beta chain transcripts were either absent or truncated. These T cell clones exhibited nonspecific cytotoxicity. Both disulfide- and non-disulfide-linked TIL T cell lines and clones expressed the delta TCS1 determinant. gamma/delta TcR+ cells in freshly prepared TIL from these patients were present in low proportions (less than 5%) and their delta TCS1/delta 1 ratios were within the range observed in the peripheral blood of normal donors. These results demonstrate that both disulfide- and non-disulfide-linked gamma/delta TcR are expressed on T cell lines and clones derived from TIL from solid tumors. Non-disulfide-linked gamma/delta TcR using the 56-66-kDa gamma chain are frequently found on TIL-derived T cell lines and clones. These 56-66-kDa gamma chains are rarely expressed on T cell lines or clones derived from peripheral blood lymphocytes of normal donors.",
        "Doc_title":"Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors.",
        "Journal":"European journal of immunology",
        "Do_id":"1312472",
        "Doc_ChemicalList":"Receptors, Antigen, T-Cell, gamma-delta",
        "Doc_meshdescriptors":"Cell Line;Clone Cells;Cytotoxicity, Immunologic;Humans;Kidney Neoplasms;Lymphocytes, Tumor-Infiltrating;Melanoma;Neoplasms;Receptors, Antigen, T-Cell, gamma-delta;Sarcoma;Wilms Tumor",
        "Doc_meshqualifiers":"immunology;immunology;immunology;immunology;analysis;immunology;immunology",
        "_version_":1605766920198422528},
      {
        "Doc_abstract":"We have identified a new gene, gbp-5, with high homology to the guanylate binding proteins (GBP) belonging to the GTPase superfamily including the ras gene. gbp-5 is transcribed at least into three splicing variants (gbp-5a, -5b, and -5ta) leading to two different proteins (GBP-5a/b, GBP-5ta). GBP-5ta is C-terminally truncated by 97aa and has therefore lost its isoprenylation site. Although RT-PCR results indicated expression of GBP-5 members in selected normal tissues, western blotting using two newly generated antibodies revealed that expression of both proteins is restricted to peripheral blood monocytes with GBP-5ta at lower levels. In contrast, cutaneous T-cell lymphoma (CTCL) tumor tissues (seven of seven) were positive solely for GBP-5ta, and four of four CTCL cell lines expressed both proteins. Eight of nine melanoma cell lines expressed GBP-5a/b and four of nine additionally low levels of GBP-5ta. SEREX retesting using CTCL sera indicated a higher immunogenicity for GBP-5ta (nine of 16) than for GBP-5a/b (two of 11). Treatment of CTCL cell lines with interferon-gamma did not alter protein expression of GBP-5ta or GBP-5a/b. The restricted expression pattern of both GBP-5ta and GBP-5a/b and the pivotal role of many known members of the GTP-binding proteins in proliferation and differentiation suggest possible cancer-related functions of gbp-5.",
        "Doc_title":"GBP-5 splicing variants: New guanylate-binding proteins with tumor-associated expression and antigenicity.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"15175044",
        "Doc_ChemicalList":"Antineoplastic Agents;Interferon-gamma;GTP-Binding Proteins;Gbp5 protein, mouse",
        "Doc_meshdescriptors":"Alternative Splicing;Antineoplastic Agents;Biopsy;GTP-Binding Proteins;Gene Expression Regulation, Neoplastic;Humans;Interferon-gamma;Melanoma;Skin Neoplasms",
        "Doc_meshqualifiers":"pharmacology;genetics;pharmacology;pathology;physiopathology;pathology;physiopathology",
        "_version_":1605757323186274304},
      {
        "Doc_abstract":"Zfra is a 31-amino-acid zinc finger-like protein, which participates in the tumor necrosis factor signaling. Here, we determined that when nude mice and BALB/c mice were pre-injected with nanogram levels of a synthetic Zfra1-31 or truncated Zfra4-10 peptide via tail veins, these mice became resistant to the growth, metastasis and stemness of melanoma cells, and many malignant cancer cells. The synthetic peptides underwent self-polymerization in phosphate-buffered saline. Alteration of the Ser8 phosphorylation site to Gly8 abolished Zfra aggregation and its-mediated cancer suppression in vivo. Injected Zfra peptide autofluoresced due to polymerization and was trapped mainly in the spleen. Transfer of Zfra-stimulated spleen cells to naÃ¯ve mice conferred resistance to cancer growth. Zfra-binding cells, designated Hyal-2+ CD3- CD19- Z cells, are approximately 25-30% in the normal spleen, but are significantly downregulated (near 0-3%) in tumor-growing mice. Zfra prevented the loss of Z cells caused by tumors. In vitro stimulation or education of naÃ¯ve spleen cells with Zfra allowed generation of activated Z cells to confer a memory anticancer response in naÃ¯ve or cancer-growing mice. In particular, Z cells are abundant in nude and NOD-SCID mice, and can be readily activated by Zfra to mount against cancer growth. ",
        "Doc_title":"Zfra activates memory Hyal-2+ CD3- CD19- spleen cells to block cancer growth, stemness, and metastasis in vivo.",
        "Journal":"Oncotarget",
        "Do_id":"25686832",
        "Doc_ChemicalList":"APBB2 protein, human;Adaptor Proteins, Signal Transducing;Antigens, CD19;Antigens, CD3;Cell Adhesion Molecules;GPI-Linked Proteins;Peptide Fragments;Hyal2 protein, human;Hyal2 protein, mouse;Hyaluronoglucosaminidase",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Amino Acid Sequence;Animals;Antigens, CD19;Antigens, CD3;Cell Adhesion Molecules;GPI-Linked Proteins;Humans;Hyaluronoglucosaminidase;Male;Mice;Mice, Inbred BALB C;Mice, Inbred NOD;Mice, Nude;Mice, SCID;Molecular Sequence Data;Neoplasm Metastasis;Neoplasms;Peptide Fragments;Spleen",
        "Doc_meshqualifiers":"pharmacology;immunology;immunology;genetics;immunology;genetics;immunology;genetics;immunology;drug therapy;immunology;pathology;pharmacology;drug effects;immunology;pathology",
        "_version_":1605763136471695360},
      {
        "Doc_abstract":"Metastasis is a major cause of mortality in cancer patients. However, the mechanisms governing the metastatic process remain elusive, and few accurate biomarkers exist for predicting whether metastasis will occur, something that would be invaluable for guiding therapy. We report here that the carboxypeptidase E gene (CPE) is alternatively spliced in human tumors to yield an N-terminal truncated protein (CPE-ÎN) that drives metastasis. mRNA encoding CPE-ÎN was found to be elevated in human metastatic colon, breast, and hepatocellular carcinoma (HCC) cell lines. In HCC cells, cytosolic CPE-ÎN was translocated to the nucleus and interacted with histone deacetylase 1/2 to upregulate expression of the gene encoding neural precursor cell expressed, developmentally downregulated gene 9 (Nedd9)--which has been shown to promote melanoma metastasis. Nedd9 upregulation resulted in enhanced in vitro proliferation and invasion. Quantification of mRNA encoding CPE-ÎN in HCC patient samples predicted intrahepatic metastasis with high sensitivity and specificity, independent of cancer stage. Similarly, high CPE-ÎN mRNA copy numbers in resected pheochromocytomas/paragangliomas (PHEOs/PGLs), rare neuroendocrine tumors, accurately predicted future metastasis or recurrence. Thus, CPE-ÎN induces tumor metastasis and should be investigated as a potentially powerful biomarker for predicting future metastasis and recurrence in HCC and PHEO/PGL patients.",
        "Doc_title":"An N-terminal truncated carboxypeptidase E  splice isoform induces tumor growth  and is a biomarker for predicting  future metastasis in human cancers.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"21285511",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Biomarkers, Tumor;NEDD9 protein, human;Phosphoproteins;Protein Isoforms;Carboxypeptidase H",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Alternative Splicing;Biomarkers, Tumor;Carboxypeptidase H;Cell Line, Tumor;Cytosol;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Neoplasm Invasiveness;Neoplasm Metastasis;Paraganglioma;Pheochromocytoma;Phosphoproteins;Protein Isoforms;Protein Structure, Tertiary;Recurrence",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605774609060200449},
      {
        "Doc_abstract":"Selective activation of blood coagulation in tumor vessels with subsequent tumor infarction is a promising anticancer strategy. To this end, a fusion protein consisting of the extracellular domain of tissue factor [truncated tissue factor (tTF)] was fused to the peptide GRGDSP selectively targeting alpha(v)-integrins on tumor endothelial cells. tTF-RGD retained its thrombogenic and integrin-binding activity in vitro. In vivo studies in mice bearing human adenocarcinomas (CCL185), melanoma (M21), and fibrosarcoma (HT1080) revealed that i.v. administration of tTF-RGD induced thrombotic occlusion of tumor vessels resulting in tumor growth retardation or regression in all three types of solid tumors. No apparent side effects, such as thrombosis, in other organs or other treatment-related toxicities were observed. Reduced tumor blood flow in tTF-RGD-treated animals as determined by contrast-enhanced magnetic resonance imaging underlines the proposed mechanism. In conclusion, we consider RGD peptide-directed delivery of tTF as alternative to previously used antibody fusion proteins. Small peptide-directed delivery of coaguligands does not cause immunologic side effects and those caused by accumulation in the reticuloendothelial system. This is the first report to describe the induction of selective thrombosis in tumor vessels by RGD peptide-directed delivery of tTF, which may be a promising strategy for the treatment of cancer.",
        "Doc_title":"Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"16144936",
        "Doc_ChemicalList":"Integrin alphaVbeta3;Oligopeptides;Recombinant Fusion Proteins;tTF-RGD peptide;Thromboplastin;glycyl-arginyl-glycyl-aspartyl-seryl-proline",
        "Doc_meshdescriptors":"Animals;Blood Flow Velocity;Endothelium, Vascular;Humans;Immunoenzyme Techniques;Integrin alphaVbeta3;Magnetic Resonance Imaging;Male;Mice;Mice, Inbred BALB C;Neoplasms, Experimental;Neovascularization, Pathologic;Oligopeptides;Recombinant Fusion Proteins;Thromboplastin",
        "Doc_meshqualifiers":"metabolism;metabolism;blood supply;drug therapy;pathology;drug therapy;metabolism;therapeutic use;metabolism;therapeutic use;genetics;metabolism;therapeutic use",
        "_version_":1605832074416095232},
      {
        "Doc_abstract":"Recent evidence has resurrected the concept of specialized populations of T lymphocytes that are able to suppress an antigen-specific immune response. T-regulatory cells (T-reg) have been characterized as CD4+ CD25+ T cells. Previous reports describing differential gene expression analysis have shown that the glucocorticoid-induced tumor necrosis family receptor family-related gene (GITR) is upregulated in these cells. Furthermore, antibodies specific for GITR have been shown to inhibit the T-suppressor function of CD4+ CD25+ T-reg. The ligands for both mouse and human GITR have been cloned recently. We have inserted the sequences for natural, membrane-bound GITR-ligand (GITR-L) and a truncated secreted form of GITR-L (GITR-Lsol) into the adenovirus-5 genome. Coculture experiments show that cells infected with Ad-GITR-L and supernatants from cells infected with Ad-GITR-Lsol can increase the proliferation of both CD4+ CD25- and CD8+ T cells in response to anti-CD3 stimulation, in the presence, as well as in the absence, of CD4+ CD25+ T cells. The virus constructs were injected into growing B16 melanoma tumors. Ad-GITR-L was shown to attract infiltration with both CD4+ and CD8+ T cells. Both constructs were shown to inhibit tumor growth.",
        "Doc_title":"Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L.",
        "Journal":"Cancer gene therapy",
        "Do_id":"15472713",
        "Doc_ChemicalList":"Antigens, CD28;Antigens, CD4;Carrier Proteins;Ligands;Tnfsf18 protein, mouse;Tumor Necrosis Factors",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Antigens, CD28;Antigens, CD4;CD4-Positive T-Lymphocytes;Carrier Proteins;Cell Membrane;Cell Proliferation;Coculture Techniques;Female;Immunosuppression;Ligands;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Plasmids;T-Lymphocytes, Regulatory;Tumor Necrosis Factors",
        "Doc_meshqualifiers":"genetics;physiology;analysis;immunology;metabolism;genetics;metabolism;therapeutic use;metabolism;genetics;immunology;therapy;physiology",
        "_version_":1605909391777726464},
      {
        "Doc_abstract":"Interleukin 8 (IL-8) is a potent neutrophil chemoattractant and activator. Two IL-8 receptor subtypes, A and B, are expressed in neutrophils. In this work, we analyzed the role of the C terminus domain of the IL-8 receptor on the signal transduction and receptor internalization mechanisms. The IL-8 receptor A was tagged with an epitope corresponding to the monoclonal antibody 1D4 to monitor the localization of the IL-8 receptor. We demonstrated IL-8-dependent receptor internalization by monitoring the density of surface 125I-labeled IL-8 binding sites and by immunofluorescence microscopy. Truncation of the last 27 amino acids of the IL-8 receptor A severely impaired the IL-8-induced internalization of the receptor. Of importance was the observation that binding of IL-8 to receptors A and B triggered a dramatically faster rate of internalization of receptor B than receptor A, suggesting that the heterologous C termini among receptor subtypes modulate the rate of internalization of IL-8 receptors. However, substitution of the C terminus of the receptor subtype A for the C terminus of receptor B reduced the internalization rate of receptor A. Furthermore, we found that the rate of internalization of IL-8 receptor B triggered by IL-8 was faster than the one induced by the IL-8-related peptide, melanoma growth stimulatory activity. Studies with human neutrophils pretreated with 100 nM IL-8 for 5 min revealed a positive and a negative calcium response mediated by receptors A and B, respectively. In contrast, neutrophils pretreated with melanoma growth stimulatory activity showed positive calcium responses to both receptors A and B. These data suggest that the neutrophil responses mediated by IL-8 are modulated by the rate of internalization of receptors.",
        "Doc_title":"Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"8702597",
        "Doc_ChemicalList":"Antigens, CD;CXCL1 protein, human;Chemokine CXCL1;Chemokines, CXC;Chemotactic Factors;DNA, Complementary;Epitopes;Growth Substances;Intercellular Signaling Peptides and Proteins;Interleukin-8;Receptors, Interleukin;Receptors, Interleukin-8A;Calcium",
        "Doc_meshdescriptors":"Animals;Antigens, CD;Base Sequence;CHO Cells;Calcium;Chemokine CXCL1;Chemokines, CXC;Chemotactic Factors;Cloning, Molecular;Cricetinae;DNA, Complementary;Epitopes;Growth Substances;Humans;Intercellular Signaling Peptides and Proteins;Interleukin-8;Molecular Sequence Data;Neutrophils;Radioligand Assay;Receptors, Interleukin;Receptors, Interleukin-8A;Signal Transduction",
        "Doc_meshqualifiers":"genetics;immunology;metabolism;metabolism;pharmacology;immunology;pharmacology;metabolism;pharmacology;drug effects;metabolism;genetics;immunology;metabolism",
        "_version_":1605741940027949058},
      {
        "Doc_abstract":"In many cases, the biologic responses of cells to extracellular signals and the specificity of the responses cannot be explained solely on the basis of the interactions of known signaling proteins. Recently, scaffolding and adaptor proteins have been identified that organize signaling proteins in cells and that contribute to the nature and specificity of signaling pathways. In an effort to identify proteins that might organize the signaling system(s) activated by the extracellular Ca(2+) receptor (CaR), we used a bait construct representing the intracellular C terminus of the human CaR and the yeast two hybrid system to screen a human kidney cDNA library. We identified a clone representing the C-terminal 1042 amino acids (aa) of the cytoskeletal protein filamin (ABP-280). Analysis of truncation and deletion constructs of the CaR C terminus and the filamin cDNA clone demonstrated that the CaR and filamin interact via regions containing aa 907-997 of the CaR C terminus and aa 1566-1875 of filamin. Interaction of the two proteins in mammalian HEK-293 cells was demonstrated by co-immunoprecipitation and colocalization of them using immunofluorescence microscopy. The functional importance of their interaction was documented by transiently expressing the CaR in M2 melanoma cells that lack filamin, or in A7 melanoma cells that stably express filamin, and demonstrating that the CaR activated ERK only in the presence of filamin. Co-expression of the CaR with a peptide derived from the region of the CaR C terminus that interacts with filamin reduced the ability of the CaR to activate p42ERK in a dose-dependent manner, but did not inhibit the ability of the ET(A) receptor to activate ERK. The fact that filamin interacts with the CaR and other cell signaling proteins including mitogen-activated protein kinases and small GTPases, indicates that it may act as a scaffolding protein to organize cell signaling systems involving the CaR.",
        "Doc_title":"Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"11390379",
        "Doc_ChemicalList":"Contractile Proteins;Filamins;Microfilament Proteins;Receptors, Calcium-Sensing;Receptors, Cell Surface;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Contractile Proteins;Filamins;Humans;Immunohistochemistry;Microfilament Proteins;Mitogen-Activated Protein Kinases;Molecular Sequence Data;Receptors, Calcium-Sensing;Receptors, Cell Surface",
        "Doc_meshqualifiers":"analysis;chemistry;physiology;analysis;chemistry;physiology;metabolism;analysis;chemistry;physiology",
        "_version_":1605783239459340288},
      {
        "Doc_abstract":"None",
        "Doc_title":"Oncogene Status of an Interdigitating Dendritic Cell Sarcoma: Recurrent Mutations in NF1, TP53, and ARID2 Shared With Melanoma.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"27680605",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605757175020388352},
      {
        "Doc_abstract":"Necdin, a pleiotropic protein that promotes differentiation and survival of mammalian neurons, is a member of MAGE (melanoma antigen) family proteins that share a highly conserved MAGE homology domain. Several MAGE proteins interact with ubiquitin E3 ligases and modulate their activities. However, it remains unknown whether MAGE family proteins interact with SUMO (small ubiquitin-like modifier) E3 ligases such as PIAS (protein inhibitor of activated STAT) family, Nsmce2/Mms21 and Cbx4/Pc2. In the present study, we examined whether necdin interacts with these SUMO E3 ligases. Co-immunoprecipitation analysis revealed that necdin, MAGED1, MAGEF1 and MAGEL2 bound to PIAS1 but not to Nsmce2 or Cbx4. These SUMO E3 ligases bound to MAGEA1 but failed to interact with necdin-like 2/MAGEG1. Necdin bound to PIAS1 central domains that are highly conserved among PIAS family proteins and suppressed PIAS1-dependent sumoylation of the substrates STAT1 and PML (promyelocytic leukemia protein). Remarkably, necdin promoted degradation of PIAS1 via the ubiquitin-proteasome pathway. In transfected HEK293A cells, amino- and carboxyl-terminally truncated mutants of PIAS1 bound to necdin but failed to undergo necdin-dependent ubiquitination. Both PIAS1 and necdin were associated with the nuclear matrix, where the PIAS1 terminal deletion mutants failed to localize, implying that the nuclear matrix is indispensable for necdin-dependent ubiquitination of PIAS1. Our data suggest that necdin suppresses PIAS1 both by inhibiting SUMO E3 ligase activity and by promoting ubiquitin-dependent degradation. ",
        "Doc_title":"Necdin promotes ubiquitin-dependent degradation of PIAS1 SUMO E3 ligase.",
        "Journal":"PloS one",
        "Do_id":"24911587",
        "Doc_ChemicalList":"Melanoma-Specific Antigens;Nerve Tissue Proteins;Nuclear Proteins;Protein Inhibitors of Activated STAT;Ubiquitin;necdin;Ubiquitin-Protein Ligases;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Animals;Cell Line;Humans;Melanoma-Specific Antigens;Mice;Nerve Tissue Proteins;Nuclear Proteins;Proteasome Endopeptidase Complex;Protein Binding;Protein Inhibitors of Activated STAT;Protein Interaction Domains and Motifs;Proteolysis;Substrate Specificity;Sumoylation;Ubiquitin;Ubiquitin-Protein Ligases;Ubiquitination",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;metabolism;chemistry;metabolism;metabolism;metabolism",
        "_version_":1605747062842851329},
      {
        "Doc_abstract":"The BL6 subline was derived from the F10 line, which was derived from the B16 mouse melanoma cell line. BL6 cells are more invasive than F10 cells and differ genetically from F10 cells by an alteration of the gene encoding the B56gamma regulatory subunit of protein phosphatase 2A (PP2A). This alteration results in the transcription of mRNA encoding a truncated variant of the B56gamma1 isoform (Deltagamma1). When F10 cells were stained with a polyclonal antibody that recognizes three B56gamma isoforms, B56gamma1, B56gamma2, and B56gamma3, the immunofluorescent signals co-localized well with the cis-Golgi marker proteins. When BL6 cells were fractionated in a sucrose gradient, B56gamma1 and B56gamma2, but not B56gamma3, were present in the Golgi-enriched fraction. This fraction also contained the catalytic subunit of PP2A. FLAG-tagged Deltagamma1 preferentially localized to the trans-Golgi area rather than the cis-Golgi. This localization was the same as that of FLAG-tagged B56gamma1. NIH3T3 cells stably expressing Deltagamma1 transported a mutant viral protein from the endoplasmic reticulum to the plasma membrane much faster than wild-type cells. Their directional migration, as assessed by the advance of cells into a cell-free area, was also elevated. As Deltagamma1 reduces the activity of the B56gamma-containing PP2A holoenzymes, these results suggest that the normal holoenzymes suppress vesicle transport and that Deltagamma1 might increase the invasive ability of BL6 cells by activating Golgi function.",
        "Doc_title":"Localization of the PP2A B56gamma regulatory subunit at the Golgi complex: possible role in vesicle transport and migration.",
        "Journal":"The American journal of pathology",
        "Do_id":"12547706",
        "Doc_ChemicalList":"DNA Primers;Protein Subunits;Recombinant Proteins;Phosphoprotein Phosphatases;Protein Phosphatase 2",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cell Cycle;Cell Fractionation;DNA Primers;Golgi Apparatus;Melanoma, Experimental;Mice;Mutagenesis, Site-Directed;Phosphoprotein Phosphatases;Plasmids;Protein Phosphatase 2;Protein Subunits;Recombinant Proteins;Transfection",
        "Doc_meshqualifiers":"methods;enzymology;enzymology;pathology;isolation & purification;metabolism;isolation & purification;metabolism;isolation & purification;metabolism",
        "_version_":1605845219550429184},
      {
        "Doc_abstract":"Human dermal fibroblasts in culture secrete three protein-like neutrophil chemotactic factors, when stimulated either with human rIL-1 alpha or IL-1 beta; not, however, after incubation with LPS. These three fibroblast-derived neutrophil-activating proteins (FINAP) could be purified by subsequently performed reversed phase and size exclusion HPLC. By high resolution SDS-PAGE, all the proteins were shown to migrate with an Mr of 6,700 (alpha-FINAP), 3,600 (beta-FINAP), and 5,300 (gamma-FINAP). All purified cytokine preparations were found to be chemotactic for human neutrophils. In addition, all FINAP induced release of lysosomal enzymes in neutrophils. Deactivation of chemotaxin-elicitable enzyme release showed cross-desensitization of all FINAP with NAP-1/IL-8. Western blot analysis of alpha-FINAP by using mAb against neutrophil-activating protein (NAP)-1/IL-8 reveals immunologic cross-reactivity with NAP-1/IL-8. By amino-terminal amino acid sequence analysis alpha-FINAP could be identified as the 77-residue extended form of NAP-1/IL-8 containing the 79-residue form as a minor contaminant. Whereas beta-FINAP has been found to be a truncation product of alpha-FINAP, gamma-FINAP shows identity with authentic melanoma growth stimulatory activity with respect to retention time upon reversed phase HPLC, high resolution SDS-PAGE, and biologic properties, as well as amino-terminal amino acid sequence. These data show that human dermal fibroblasts may actively participate in inflammatory reactions by secretion of proinflammatory cytokines.",
        "Doc_title":"IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"2179408",
        "Doc_ChemicalList":"Chemotactic Factors;Interleukin-1;Interleukin-8;Interleukins;Tumor Necrosis Factor-alpha",
        "Doc_meshdescriptors":"Amino Acid Sequence;Cells, Cultured;Chemotactic Factors;Chemotaxis, Leukocyte;Chromatography, High Pressure Liquid;Fibroblasts;Humans;In Vitro Techniques;Interleukin-1;Interleukin-8;Interleukins;Molecular Sequence Data;Molecular Weight;Neutrophils;Secretory Rate;Skin;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"genetics;isolation & purification;secretion;metabolism;pharmacology;genetics;isolation & purification;secretion;physiology;drug effects;cytology;metabolism;pharmacology",
        "_version_":1605844719611412480},
      {
        "Doc_abstract":"Sonic hedgehog (SHH), Indian hedgehog (IHH) and Desert hedgehog (DHH) are Hedgehog family ligands, which play key roles in embryogenesis and carcinogenesis, especially in pancreatic cancer and gastric cancer. Drosophila Costal-2 (Cos2) is a Hedgehog signaling regulator, interacting with Smoothened (Smo), Cubitus interruptus (Ci), Fused (Fu) and microtubule. KIF27 is one of the mammalian orthologs for Drosophila Cos2. KIF7 gene is the paralog of KIF27 gene; however, complete coding sequence (CDS) of KIF7 remains elusive. Here we characterized human KIF7 gene by using bioinformatics. Human LOC374654 cDNA (NM_198525.1) was a 5'-truncated partial KIF7 cDNA, corresponding to the nucleotide position 1418-4538 of KIF7 complete CDS. KIF7 gene, consisting of 19 exons, was found to encode a 1343-amino-acid KIF7 protein. Human KIF7 showed 43.6% total-amino-acid identity with human KIF27. Kinesin motor catalytic (KISc) domain (codon 15-347 of KIF7) and novel KIF7-KIF27 homologous (KIF727H) domain (codon 699-1196 of KIF7) were well conserved between KIF7 and KIF27. Three coiled-coil regions were located within the KIF727H domain. KIF7 and KIF27 were N-type Kinesins with the KIF727H domain. KIF7 mRNA was expressed in embryonic stem (ES) cells, melanotic melanoma and Jurkat T cells, while KIF27 mRNA was expressed in testis, pancreatic islet, germ cell tumors and Jurkat T cells. This is the first report on the characterization of the KIF7 gene as well as on the identification of KIF727H domain.",
        "Doc_title":"Characterization of KIF7 gene in silico.",
        "Journal":"International journal of oncology",
        "Do_id":"15547730",
        "Doc_ChemicalList":"DNA-Binding Proteins;KIF27 protein, human;KIF7 protein, human;Kinesin",
        "Doc_meshdescriptors":"Amino Acid Sequence;Cell Transformation, Neoplastic;Computational Biology;DNA-Binding Proteins;Expressed Sequence Tags;Humans;Kinesin;Molecular Sequence Data;Neoplasms;Proteomics;Sequence Analysis, DNA;Sequence Homology",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605813162158850048},
      {
        "Doc_abstract":"A recombinant immunotoxin was constructed from the hybridoma antibody TH-69 directed against human CD7, a surface antigen of leukemic T cells. The antibody was subcloned as a single chain Fv (scFv) fragment and genetically linked to a truncated Pseudomonas exotoxin A fragment containing the catalytic domains II and III but lacking the receptor binding domain I. Domain I was replaced by the scFv, thus conferring restricted specificity for CD7-positive cells. The bacterially expressed and purified toxin retained binding specificity for CD7-positive cells. It promoted apoptosis in two CD7-positive cell lines derived from T-lineage acute lymphoblastic leukemias, CEM and Jurkat, but not in the CD7-negative B-lymphoid lines REH, Nalm-6, and SEM. Maximum killing in excess of 95% was reached after 96 h in CEM and Jurkat cells with a single dose of 100 ng/ml. Cells treated with a similarly constructed scFv-exotoxin A immunotoxin against melanoma-associated chondroitin sulfate proteoglycan, an antigen absent from leukemic T cells, remained unaffected. Lysis of target cells occurred via apoptosis as evidenced by staining with Annexin V and specific cleavage of poly(ADP-ribose) polymerase. Approximately 20% of leukemic cells from a patient with CD7-positive acute T-cell leukemia kept in long-term primary culture for 30 cell generations were killed within 96 h after treatment with the toxin. These findings justify further evaluation of the agent in view of potential therapeutic applications.",
        "Doc_title":"A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.",
        "Journal":"Cancer research",
        "Do_id":"12019163",
        "Doc_ChemicalList":"Antigens, CD7;Bacterial Toxins;Epitopes;Exotoxins;Immunoglobulin Fragments;Immunotoxins;Recombinant Proteins;Virulence Factors;ADP Ribose Transferases;Poly(ADP-ribose) Polymerases;toxA protein, Pseudomonas aeruginosa",
        "Doc_meshdescriptors":"ADP Ribose Transferases;Animals;Antibody Specificity;Antigens, CD7;Apoptosis;Bacterial Toxins;COS Cells;Child;Epitopes;Exotoxins;Female;Humans;Immunoglobulin Fragments;Immunotoxins;Infant;Jurkat Cells;Leukemia, T-Cell;Poly(ADP-ribose) Polymerases;Protein Structure, Tertiary;Recombinant Proteins;Tumor Cells, Cultured;Virulence Factors",
        "Doc_meshqualifiers":"pharmacology;immunology;drug effects;immunology;immunology;pharmacology;genetics;immunology;pharmacology;genetics;immunology;pharmacology;cytology;drug effects;drug therapy;immunology;pathology;genetics;immunology;pharmacology",
        "_version_":1605896207798894592},
      {
        "Doc_abstract":"It has been shown that the small DNA fragment thymidine dinucleotide, (pTpT) induces photoprotective responses in cultured cells and intact skin. These responses include increased melanogenesis, enhanced DNA repair, and induction of TNF-alpha, and are accomplished, at least in part, through the induction and activation of the p53 tumor suppressor and transcription factor. Here it is reported that other, but not all, larger oligonucleotides induce the pigmentation response even more efficiently than pTpT. A 9 base oligonucleotide (p9mer) stimulated pigmentation in Cloudman S91 murine melanoma cells to 6-times the level of control cells while a 5 base oligonucleotide (p5mer#1) was inactive. In addition, the p9mer increased p21 mRNA levels and inhibited cell proliferation to a greater degree than did pTpT, consistent with the presumptive mechanism of action involving p53. Smaller, truncated versions of the p9mer also stimulated pigmentation, although to a lesser extent than did the p9mer. The ability of these oligonucleotides to stimulate pigmentation was highly dependent on the presence of a 5' phosphate group on the molecule, which was shown by confocal microscopy and fluorescent activated cell sorter (FACS) analysis to greatly facilitate the uptake of these oligonucleotides into the cells. Although the melanogenic activity of the oligonucleotides was directly related to increased length and 5' phosphorylation, nucleotide sequence is also critical because a p20mer was efficiently internalized yet was a poor inducer of pigmentation.",
        "Doc_title":"Stimulation of melanogenesis by DNA oligonucleotides: effect of size, sequence and 5' phosphorylation.",
        "Journal":"Journal of dermatological science",
        "Do_id":"11164709",
        "Doc_ChemicalList":"Melanins;Oligonucleotides;Thymine Nucleotides;Tumor Suppressor Protein p53;DNA",
        "Doc_meshdescriptors":"Animals;Base Sequence;DNA;Melanins;Mice;Oligonucleotides;Phosphorylation;Thymine Nucleotides;Tumor Cells, Cultured;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;biosynthesis;chemistry;metabolism;pharmacokinetics;pharmacology;chemistry;metabolism;pharmacology;physiology",
        "_version_":1605881234715574272},
      {
        "Doc_abstract":"Fibronectin contains at least two distinct oligopeptide sequences serving as signals for the interaction with cell surface adhesion receptors termed integrins. One of these sequences, Arg-Gly-Asp-Ser (RGDS) tetrapeptide, was shown to be transferred to a truncated form of Staphylococcal IgG-binding protein (hereafter referred to as tSPA) with retention of its cell-adhesive activity [Maeda, T. et al. (1989) J. Biol. Chem. 264, 15165-15168]. We have extended the observation to another cell-adhesive sequence, Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr (referred to as \"CS1\" sequence), to demonstrate that: i) the tSPA grafted with the sequence mediated adhesion of human lymphoma and rhabdomyosarcoma cells, mouse melanoma cells, but not of hamster fibroblasts; ii) antibodies against integrin alpha 4 and beta 1 subunits specifically inhibited cell adhesion mediated by the CS1-grafted tSPA; iii) a heterodivalent tSPA grafted with both RGDS and CS1 sequences at different sites was more potent in promoting cell adhesion than the monovalent tSPAs grafted with either sequence alone. These results indicate that not only the RGDS but also the CS1 sequence can be transferred to tSPA with retention of its cell-adhesive activity as well as its cell-type specificity, and that the grafted CS1 sequence is recognized by the same integrin isotype as the authentic sequence within intact fibronectin.",
        "Doc_title":"Engineering of artificial cell-adhesive proteins by grafting EILDVPST sequence derived from fibronectin.",
        "Journal":"Journal of biochemistry",
        "Do_id":"8454570",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Cell Adhesion Molecules;Fibronectins;Integrins;Peptides;CS1 peptide",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Antibodies, Monoclonal;Base Sequence;Cell Adhesion;Cell Adhesion Molecules;Cell Line;Cricetinae;Electrophoresis, Polyacrylamide Gel;Fibronectins;Humans;Integrins;Mice;Microscopy, Fluorescence;Molecular Sequence Data;Peptides;Protein Engineering;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;immunology;metabolism;chemistry;metabolism",
        "_version_":1605905524892631040},
      {
        "Doc_abstract":"The simplicity of programming the CRISPR (clustered regularly interspaced short palindromic repeats)-associated nuclease Cas9 to modify specific genomic loci suggests a new way to interrogate gene function on a genome-wide scale. We show that lentiviral delivery of a genome-scale CRISPR-Cas9 knockout (GeCKO) library targeting 18,080 genes with 64,751 unique guide sequences enables both negative and positive selection screening in human cells. First, we used the GeCKO library to identify genes essential for cell viability in cancer and pluripotent stem cells. Next, in a melanoma model, we screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic RAF inhibitor. Our highest-ranking candidates include previously validated genes NF1 and MED12, as well as novel hits NF2, CUL3, TADA2B, and TADA1. We observe a high level of consistency between independent guide RNAs targeting the same gene and a high rate of hit confirmation, demonstrating the promise of genome-scale screening with Cas9. ",
        "Doc_title":"Genome-scale CRISPR-Cas9 knockout screening in human cells.",
        "Journal":"Science (New York, N.Y.)",
        "Do_id":"24336571",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CUL3 protein, human;Cullin Proteins;Indoles;MED12 protein, human;Mediator Complex;Protein Kinase Inhibitors;Sulfonamides;TADA2B protein, human;Transcription Factors;vemurafenib;raf Kinases",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Cell Survival;Clustered Regularly Interspaced Short Palindromic Repeats;Cullin Proteins;Drug Resistance, Neoplasm;Gene Knockout Techniques;Gene Library;Genes, Neurofibromatosis 1;Genes, Neurofibromatosis 2;Genetic Loci;Genetic Testing;Genome-Wide Association Study;Humans;Indoles;Lentivirus;Mediator Complex;Melanoma;Pluripotent Stem Cells;Protein Kinase Inhibitors;Selection, Genetic;Sulfonamides;Transcription Factors;raf Kinases",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;methods;therapeutic use;genetics;drug therapy;genetics;metabolism;therapeutic use;therapeutic use;genetics;antagonists & inhibitors",
        "_version_":1605839849550512128},
      {
        "Doc_abstract":"The tumor suppressor protein kinase LKB1 exerts its effects by phosphorylating and activating AMP-activated protein kinase (AMPK) and members of the AMPK-related kinase family, such as the brain-specific kinases BRSK1/BRSK2 (SAD-B/SAD-A). LKB1 contains a conserved serine residue near the C terminus (Ser-431 in mouse LKB1) that is phosphorylated by cyclic AMP-dependent protein kinase and p90-RSK. Although some studies suggest that LKB1 is constitutively active and is not rate-limiting for activation of AMPK, others have suggested that phosphorylation of Ser-431 is necessary to allow LKB1 to phosphorylate and activate AMPK and other downstream kinases. Prompted by our discovery of an LKB1 splice variant (LKB1S) that lacks Ser-431, we have reinvestigated this question. In HeLa cells (which lack endogenous LKB1), co-expression with STRADalpha and MO25alpha of wild type LKB1, the S431A or S431E mutants of LKB1, or LKB1(S) gave equal levels of activation of endogenous AMPK. Similarly, recombinant STRADalpha.MO25alpha complexes containing these LKB1 variants were equally effective at phosphorylating and activating AMPK, BRSK1, and BRSK2 in cell-free assays. Finally, all four LKB1 variants and a truncated LKB1 lacking the C-terminal region altogether were equally effective at causing cell cycle arrest when co-expressed with STRADalpha and MO25alpha in the G361 melanoma cell line. Our results do not support the idea that phosphorylation of Ser-431 increases the ability of LKB1 to phosphorylate downstream targets.",
        "Doc_title":"C-terminal phosphorylation of LKB1 is not required for regulation of AMP-activated protein kinase, BRSK1, BRSK2, or cell cycle arrest.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"18854318",
        "Doc_ChemicalList":"Adaptor Proteins, Vesicular Transport;Intracellular Signaling Peptides and Proteins;STRAD protein, human;Tumor Suppressor Proteins;STK11 protein, human;AMP-Activated Protein Kinases;BRSK1 protein, human;Brsk2 protein, human;Protein-Serine-Threonine Kinases;Ribosomal Protein S6 Kinases, 90-kDa",
        "Doc_meshdescriptors":"AMP-Activated Protein Kinases;Adaptor Proteins, Vesicular Transport;Alternative Splicing;Amino Acid Substitution;Cell Cycle;Cell-Free System;Enzyme Activation;HeLa Cells;Humans;Intracellular Signaling Peptides and Proteins;Mutation, Missense;Phosphorylation;Protein Structure, Tertiary;Protein-Serine-Threonine Kinases;Ribosomal Protein S6 Kinases, 90-kDa;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;physiology;physiology;physiology;genetics;metabolism;physiology;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605747089179934722},
      {
        "Doc_abstract":"Several tumor suppressor genes are located within human chromosome 11q23 region. We have cloned and characterized MFRP and RNF26 genes at 11q23.3. We also identified and characterized KIAA1735/MTHDIX gene at 11q23.1 and CLDN24 gene at 11q23.2 by using bioinformatics. Here, a novel human gene corresponding to a 5'-truncated FLJ20535 cDNA was identified. FLJ20535 corresponded to nucleotide position 55-2255 of FLJ13859, and nucleotide position 52-2169 of FLJ13859 was the coding region. Because of tetratricopeptide repeat (TPR) and armadillo repeat (ARM) domains within its gene product, the novel human gene was designated TPARM. Mouse E330017O07Rik cDNA was derived from mouse Tparm gene. Human TPARM (705 aa) and mouse Tparm (704 aa), showing 75.4% total-amino-acid identity, consist of TPR domain and three ARM domains. TPR domain of TPARM was most homologous to that of SMAP1, while ARM1-ARM3 domains of TPARM were most homologous to ARM7-ARM9 domains of CTNNB1 (also known as beta-catenin). TPARM might be implicated in the WNT-beta-catenin signaling pathway. TPARM mRNA was expressed in testis, prostate, lung, germinal center B-cells, and also in neuroblastoma, teratocarcinoma, colon cancer, and gastric cancer. Human TPARM gene was found to consist of 22 exons. TPARM gene, located between NCAM1 and DRD2 genes, was mapped to human chromosome 11q23.2. TPARM as well as NCAM1 and DRD2 were predicted to be candidate tumor suppressor genes within the commonly deleted region of malignant melanoma on 11q23.1-q23.2 (between microsatellite markers D11S1347 and D11S4122).",
        "Doc_title":"Identification and characterization of TPARM gene in silico.",
        "Journal":"International journal of oncology",
        "Do_id":"12964006",
        "Doc_ChemicalList":"CTNNB1 protein, human;CTNNB1 protein, mouse;Cytoskeletal Proteins;DNA, Complementary;Proteins;TTC12 protein, human;Trans-Activators;beta Catenin",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Chromosome Mapping;Chromosomes, Human, Pair 11;Computational Biology;Cytoskeletal Proteins;DNA, Complementary;Exons;Humans;Melanoma;Mice;Microsatellite Repeats;Models, Genetic;Molecular Sequence Data;Protein Biosynthesis;Protein Structure, Tertiary;Proteins;Sequence Homology, Amino Acid;Tissue Distribution;Trans-Activators;beta Catenin",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;chemistry;genetics;metabolism",
        "_version_":1605757248855867392},
      {
        "Doc_abstract":"Genomic instability is a major hallmark of cancer. To maintain genomic integrity, cells are equipped with dedicated sensors to monitor DNA repair or to force damaged cells into death programs. The tumor suppressor p53 is central in this process. Here, we report that the ubiquitous transcription factor Upstream Stimulatory factor 1 (USF1) coordinates p53 function in making proper cell fate decisions. USF1 stabilizes the p53 protein and promotes a transient cell cycle arrest, in the presence of DNA damage. Thus, cell proliferation is maintained inappropriately in Usf1 KO mice and in USF1-deficient melanoma cells challenged by genotoxic stress. We further demonstrate that the loss of USF1 compromises p53 stability by enhancing p53-MDM2 complex formation and MDM2-mediated degradation of p53. In USF1-deficient cells, the level of p53 can be restored by the re-expression of full-length USF1 protein similarly to what is observed using Nutlin-3, a specific inhibitor that prevents p53-MDM2 interaction. Consistent with a new function for USF1, a USF1 truncated protein lacking its DNA-binding and transactivation domains can also restore the induction and activity of p53. These findings establish that p53 function requires the ubiquitous stress sensor USF1 for appropriate cell fate decisions in response to DNA-damage. They underscore the new role of USF1 and give new clues of how p53 loss of function can occur in any cell type. Finally, these findings are of clinical relevance because they provide new therapeutic prospects in stabilizing and reactivating the p53 pathway.",
        "Doc_title":"p53 requires the stress sensor USF1 to direct appropriate cell fate decision.",
        "Journal":"PLoS genetics",
        "Do_id":"24831529",
        "Doc_ChemicalList":"TP53 protein, human;Tumor Suppressor Protein p53;USF1 protein, human;Upstream Stimulatory Factors;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Differentiation;Cell Line, Tumor;Cell Lineage;Cell Proliferation;DNA Damage;Genomic Instability;Humans;Mice;Neoplasms;Protein Interaction Maps;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p53;Upstream Stimulatory Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605763035242168320},
      {
        "Doc_abstract":"WNT signals play key roles in carcinogenesis and embryogenesis through the specification of cell fate and polarity. Dishevelled proteins are implicated in the WNT - beta-catenin pathway and the WNT-PCP pathway. DAAM1/KIAA0666 is a Dishevelled-binding protein transducing WNT signals to the PCP pathway. Here, we identified and characterized DAAM2 gene by using bioinformatics. Uncharacterized FLJ34430 and KIAA0381 cDNAs were homologous to DAAM1. FLJ34430 was recombined with URB (XM_087331) in the 3'-region, and KIAA0381 was truncated in the 5'-region. Nucleotide sequence of DAAM2 cDNA was determined in silico by adding nucleotide position 1-793 of FLJ34430 onto the 5'-end of KIAA0381. DAAM2 gene consists of 27 exons, and gives rise to four splicing variants due to alternative splicing of alternative promoter type as well as of cassette exon type. DAAM2 gene was linked to the MOCS1 gene on human chromosome 6p21.3 with an interval less than 1 kb. DAAM2 mRNA was expressed in fetal heart, adult hypothalamus, eye, spinal cord, lung, prostate, kidney, and also in glioblastoma, oligodendroglioma, melanoma, mammary adenocarcinoma and chondrosarcoma. DAAM2 was a 1077-amino-acid protein with Formin-homology FH1 and FH2 domains, which showed 68.9% total-amino-acid identity with DAAM1. Among Formin-homology proteins, FDD (Formin-like, Diaphanous, Daam) domain was conserved in FMNL1/FMNL/KW-13, FMNL2/KIAA1902/FHOD2, DIAPH1, DIAPH2, DAAM1 and DAAM2, but not in Fmn1, Fmn2, FHOD1 and Grid2ip. Therefore, it was concluded that FMNL1, FMNL2, DIAPH1, DIAPH2, DAAM1 and DAAM2 proteins constitute the Formin-homology FDD subfamily.",
        "Doc_title":"Identification and characterization of human DAAM2 gene in silico.",
        "Journal":"International journal of oncology",
        "Do_id":"12632087",
        "Doc_ChemicalList":"Carrier Proteins;DAAM2 protein, human;DNA, Complementary;Intracellular Signaling Peptides and Proteins;RNA, Messenger",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Carrier Proteins;Cell Line, Tumor;Chromosome Mapping;Chromosomes, Human, Pair 6;DNA, Complementary;Exons;Expressed Sequence Tags;Humans;Intracellular Signaling Peptides and Proteins;Introns;Models, Genetic;Molecular Sequence Data;Promoter Regions, Genetic;Protein Structure, Tertiary;RNA, Messenger;Sequence Homology, Amino Acid;Signal Transduction",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;metabolism",
        "_version_":1605783998845419520},
      {
        "Doc_abstract":"Raf kinase is a key component in regulating the MAPK pathway. B-Raf has been reported as an oncogene and is mutated in 60% of human melanomas. The main focus of Raf regulation studies has been on phosphorylation, dephosphorylation, and scaffolding proteins; however, Raf also has its own auto-regulatory domain. Removal of the N-terminal regulatory domain, initially discovered in the viral Raf oncogene (v-Raf), results in a kinase domain with high basal activity independent of Ras activation. In this report, we show that activating phosphorylations are still required for activity of the truncated C-terminal kinase domain (called 22W). The interaction between the N-terminal regulatory domain and the C-terminal kinase domain is disrupted by activated Ras. Mutations in the Ras binding domain, cysteine-rich domain, or S259A do not affect the inhibition of 22W by the N-terminal domain. When phosphomimetic residues are substituted at the activating sites (DDED) in 22W, this results in a higher basal activity that is no longer inhibited by expression of the N-terminal domain, although binding to the N-terminal domain still occurs. Although the interaction between 22W/DDED and the N-terminal domain may be in a different conformation, the interaction is still disrupted by activated Ras. These data demonstrate that N-terminal domain binding to the kinase domain inhibits the activity of the kinase domain. However, this inhibition is relieved when the C-terminal kinase domain is activated by phosphorylation.",
        "Doc_title":"Regulation of Raf through phosphorylation and N terminus-C terminus interaction.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"12865432",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-raf;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Binding Sites;Blotting, Western;Cell Line;Gene Expression Regulation, Enzymologic;Humans;Mitogen-Activated Protein Kinases;Mutation;Phosphorylation;Plasmids;Precipitin Tests;Protein Binding;Protein Structure, Tertiary;Proto-Oncogene Proteins c-raf;Transfection",
        "Doc_meshqualifiers":"metabolism;metabolism;biosynthesis;chemistry;genetics",
        "_version_":1605853586149867520},
      {
        "Doc_abstract":"Natural killer (NK)-cell malignancies are among the most aggressive lymphoid neoplasms with very poor prognosis. We performed array comparative genomic hybridization analysis on a number of NK cell lines and primary tumors to gain better understanding of the pathogenesis and tumor biology of these malignancies. We also obtained transcriptional profiles of genes residing in these regions and compared them with normal and activated NK cells. Only 30-50% of the genes residing in the gained or deleted regions showed corresponding increased or decreased expression. However, many of the upregulated genes in regions of gain are functionally important for the proliferation and growth of the neoplastic population. Genes downregulated in regions of loss included many transcription factors or repressors, tumor suppressors or negative regulators of the cell cycle. The minimal common region of deletion in 6q21 included three known genes (PRDM1, ATG5 and AIM1) showing generally low expression. Mutations resulting in truncated PRDM1 and changes in conserved amino-acid sequences of AIM1 were detected. Highly methylated CpG islands 5' of PRDM1 and AIM1 correlated with low expression of the transcripts. Reversal of methylation by Decitabine induced expression of PRDM1 and cell death. In conclusion, we have shown a general tumor-promoting effect of genetic alterations and have identified PRDM1 as the most likely target gene in del6q21. ATG5, an essential gene for autophagy and AIM1, a gene implicated in melanoma, may also participate in the functional abnormalities.",
        "Doc_title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.",
        "Journal":"Leukemia",
        "Do_id":"19194464",
        "Doc_ChemicalList":"AIM1 protein, human;ATG5 protein, human;Autophagy-Related Protein 5;Crystallins;Membrane Proteins;Microtubule-Associated Proteins;Repressor Proteins;PRDM1 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Autophagy-Related Protein 5;Cell Proliferation;Chromosomes, Human, Pair 6;Comparative Genomic Hybridization;Crystallins;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Humans;Killer Cells, Natural;Lymphoma;Membrane Proteins;Microtubule-Associated Proteins;Middle Aged;Repressor Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605822866536792064},
      {
        "Doc_abstract":"The contributions of the glycoproteins gI (ORF67) and gE (ORF68) to varicella-zoster virus (VZV) replication were investigated in deletion mutants made by using cosmids with VZV DNA derived from the Oka strain. Deletion of both gI and gE prevented virus replication. Complete deletion of gI or deletions of 60% of the N terminus or 40% of the C terminus of gI resulted in a small plaque phenotype as well as reduced yields of infectious virus. Melanoma cells infected with gI deletion mutants formed abnormal polykaryocytes with a disrupted organization of nuclei. In the absence of intact gI, gE became localized in patches on the cell membrane, as demonstrated by confocal microscopy. A truncated N-terminal form of gI was transported to the cell surface, but its expression did not restore plaque morphology or infectivity. The fusogenic function of gH did not compensate for gI deletion or the associated disruption of the gE-gI complex. These experiments demonstrated that gI was dispensable for VZV replication in vitro, whereas gE appeared to be required. Although VZV gI was dispensable, its deletion or mutation resulted in a significant decrease in infectious virus yields, disrupted syncytium formation, and altered the conformation and distribution of gE in infected cells. Normal cell-to-cell spread and replication kinetics were restored when gI was expressed from a nonnative locus in the VZV genome. The expression of intact gI, the ORF67 gene product, is required for efficient membrane fusion during VZV replication.",
        "Doc_title":"Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.",
        "Journal":"Journal of virology",
        "Do_id":"9343180",
        "Doc_ChemicalList":"Viral Envelope Proteins;glycoprotein IV, varicella-zoster virus;glycoprotein gp1, varicella-zoster virus",
        "Doc_meshdescriptors":"Biological Transport;Blotting, Western;Cell Fusion;Cell Membrane;Fluorescent Antibody Technique, Indirect;Herpesvirus 3, Human;Mutagenesis, Insertional;Protein Conformation;Protein Processing, Post-Translational;Sequence Deletion;Structure-Activity Relationship;Tumor Cells, Cultured;Viral Envelope Proteins;Virus Replication",
        "Doc_meshqualifiers":"metabolism;growth & development;physiology;ultrastructure",
        "_version_":1605818585836421120},
      {
        "Doc_abstract":"Truncating and missense mutations in the ATM gene, which cause insufficient DNA damage surveillance, allow damaged cells to proceed into mitosis, which eventually results in increased cancer susceptibility. We tested the hypotheses that ATM Ser49Cys and ATM Ser707Pro heterozygosity increase the risk of cancer overall, of breast cancer, and of 26 other cancer subtypes in the general population.;We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years, during which 2,056 developed cancer.;Multifactorially adjusted hazard ratios for ATM Ser49Cys heterozygotes versus noncarriers were 1.2 (95% CI, 0.9 to 1.5) for cancer overall, 0.8 (95% CI, 0.3 to 2.0) for breast cancer, 4.8 (95% CI, 2.2 to 11) for melanoma, 2.3 (95% CI, 1.1 to 5.0) for prostate cancer, and 3.4 (95% CI, 1.1 to 11) for cancer of the oral cavity/pharynx. Multifactorially adjusted hazard ratios for ATM Ser707Pro heterozygotes versus noncarriers were 0.8 (95% CI, 0.6 to 1.2) for cancer overall, 0.6 (95% CI, 0.2 to 1.6) for breast cancer, 10 (95% CI, 1.1 to 93) for thyroid/other endocrine tumors, and 2.7 (95% CI, 1.0 to 7.6) for cancer of corpus uteri.;ATM missense mutations do not increase the risk of cancer overall or of breast cancer in the general population; however, we observed in exploratory analyses that ATM missense mutations may be associated with an increased risk of other cancer subtypes. As we did multiple comparisons, some of these findings could represent chance findings rather than real phenomena.",
        "Doc_title":"Risk of cancer by ATM missense mutations in the general population.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"18565893",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;Tumor Suppressor Proteins;ATM protein, human;Ataxia Telangiectasia Mutated Proteins;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Adult;Ataxia Telangiectasia Mutated Proteins;Breast Neoplasms;Cell Cycle Proteins;DNA-Binding Proteins;Denmark;Female;Genetic Predisposition to Disease;Heterozygote;Humans;Male;Middle Aged;Mutation, Missense;Neoplasms;Prospective Studies;Protein-Serine-Threonine Kinases;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"epidemiology;genetics;genetics;genetics;epidemiology;epidemiology;genetics;genetics;genetics",
        "_version_":1605747093156134912},
      {
        "Doc_abstract":"Azurin is a periplasmic 128 amino acid protein in Pseudomonas aeruginosa, termed Paz, which has been shown to enter preferentially and induce apoptosis in cancer cells such as human melanoma or breast cancer. Its effectiveness against brain tumors such as glioblastomas has not been studied. The meningitis-causing bacterium Neisseria meningitidis also harbors an azurin-like protein. Unlike all other known azurins, Neisserial azurin, termed Laz, is surface-exposed and has in its N-terminal region a 39 amino acid epitope called H.8. Upstream of this H.8 moiety is a lipobox that results in the truncation of the protein at the N-terminal cysteine residue with modification by a lipid group. No function of Laz is known. We demonstrate that while Paz is deficient in entering glioblastoma cells and exhibits low cytotoxicity, Laz is much more proficient in entering glioblastoma cells and shows a higher level of cytotoxicity. When the Neisserial H.8 moiety containing the lipobox is fused in frame with Paz either in its N-terminal (H.8-Paz) or in its C-terminal (Paz-H.8), both had high cytotoxicity for glioblastoma cells and a higher level of internalization. When expressed in E. coli, H.8-Paz was much more exposed on the surface than Paz-H.8. The replacement of the Laz N-terminal cysteine residue involved in acylation with an alanine residue abolished the surface display, but had no effect on cytotoxicity or entry in glioblastoma cells, suggesting a role of the H.8 moiety, but not its lipidation, in disrupting the entry barrier in brain tumor cells.",
        "Doc_title":"Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"16861907",
        "Doc_ChemicalList":"Bacterial Outer Membrane Proteins;Epitopes;H.8 protein (Neisseria);Lipids;Membrane Proteins;Mutant Proteins;Peptides;Periplasmic Proteins;Recombinant Fusion Proteins;Azurin",
        "Doc_meshdescriptors":"Azurin;Bacterial Outer Membrane Proteins;Brain Neoplasms;Cell Death;Cloning, Molecular;Epitopes;Escherichia coli;Gene Expression;Glioblastoma;Humans;Lipids;Membrane Proteins;Mutant Proteins;Neisseria meningitidis;Peptides;Periplasmic Proteins;Protein Transport;Recombinant Fusion Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;immunology;pathology;chemistry;metabolism;metabolism;chemistry;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605846409384296448},
      {
        "Doc_abstract":"F10, a subline of the B16 mouse melanoma cell line, is itself the parent of the more metastatic BL6 line. BL6 cells differ from F10 cells by an alteration of the gene encoding the B56gamma regulatory subunit of protein phosphatase 2A (PP2A), which results in the expression of a truncated variant of the subunit (Deltagamma1). PP2A is involved in regulating the cell-cycle checkpoint and we found that the checkpoint in BL6 cells is aberrant when the Deltagamma1 protein is expressed. That is, although Deltagamma1 protein levels in cultured BL6 cells are low and these cells do not show an altered checkpoint on gamma-irradiation, irradiated footpad BL6 tumor cells show both a marked increase in Deltagamma1 levels and more extensive polyploidy and less apoptosis than F10 cells. These observations were reproduced with Deltagamma1 gene-transfected F10 cells (F10(Deltagamma1)). Deltagamma1 expression and an aberrant checkpoint are also associated with a higher metastatic ability because irradiated F10(Deltagamma1) tumors metastasized much more frequently than F10 tumors, which rarely metastasized whether irradiated or not. Nonirradiated F10(Deltagamma1) tumors, which do not express Deltagamma1 protein, had similarly low rates of metastasis. The greater metastatic ability of irradiated F10(Deltagamma1) tumors also correlated with the acquisition of many more genomic alterations. Thus, it seems that Deltagamma1 expression may damage the checkpoint, which may then allow the acquisition of genetic alterations that promote metastasis. These observations support the notion that mechanisms promoting the genetic instability of tumors could also aid tumor progression from the nonmetastatic to the metastatic state.",
        "Doc_title":"A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression.",
        "Journal":"The American journal of pathology",
        "Do_id":"12507892",
        "Doc_ChemicalList":"Isoenzymes;Protein Subunits;Phosphoprotein Phosphatases;Protein Phosphatase 2",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cell Cycle;Cell Division;Cell Survival;Cell Transformation, Neoplastic;DNA Mutational Analysis;Disease Progression;Gamma Rays;Genes, cdc;Isoenzymes;Lung Neoplasms;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Neoplasm Metastasis;Neoplasm Transplantation;Phosphoprotein Phosphatases;Protein Phosphatase 2;Protein Subunits;Sequence Deletion;Tumor Cells, Cultured;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"radiation effects;genetics;radiation effects;radiation effects;genetics;radiation effects;genetics;metabolism;secondary;genetics;metabolism;pathology;genetics;physiopathology;genetics;metabolism;genetics;metabolism;radiation effects",
        "_version_":1605873605666668544},
      {
        "Doc_abstract":"Substantial effort has been invested into optimization of vector structure, DNA formulation, or delivery methods to increase the effectiveness of DNA vaccines. In contrast, it has been only insufficiently explored how the higher order structure of an antigenic protein influences immunogenicity of embedded epitopes in vivo. Potent CD8+ T cell responses specific for a single immunogenic epitope are induced upon electrovaccination with plasmid DNA encoding the full-length heavy chain of the human HLA-Cw3 molecule. Contrary to expectations, a minimal construct, which provoked a substantial release of IFN-gamma from specific CTLs in vitro, did not induce a significant response in vivo. Systematically altered variants of the Cw3 molecule were thus tested both in vivo and in vitro to determine which structural parts are responsible for this discrepancy. In complementation experiments the participation of trans-acting helper epitopes was ruled out. Successive C-terminal truncations, human/mouse domain swap variants, and subdomain modifications defined the alpha3 region of the HLA heavy chain and membrane anchoring as critical elements. Based on these data, refined minimal constructs were engineered that triggered very high in vivo responses. The most advanced variant consisted only of an adenoviral leader, antigenic epitope, alpha3 domain, and 16 aa of the transmembrane domain. When a tumor Ag epitope was incorporated into one of these high performer minimal constructs, protection against melanoma metastases was attained upon vaccination. Thus, structural elements of the Ag can dominantly influence immunogenicity in vivo. These elements can also markedly improve the immunogenicity of unrelated Ags and may form the basis of a new generation of DNA vaccines.",
        "Doc_title":"Structural elements of a protein antigen determine immunogenicity of the embedded MHC class I-restricted T cell epitope.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"12218107",
        "Doc_ChemicalList":"Antigens, Neoplasm;Cancer Vaccines;Epitopes, T-Lymphocyte;H-2 Antigens;H-2K(K) antigen;HLA-C Antigens;HLA-C*03 antigen;Peptide Fragments",
        "Doc_meshdescriptors":"Animals;Antigens, Neoplasm;CD8-Positive T-Lymphocytes;Cancer Vaccines;Cell Membrane;Cytotoxicity, Immunologic;Epitopes, T-Lymphocyte;Female;Genetic Complementation Test;H-2 Antigens;HLA-C Antigens;Lymphocyte Activation;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Mice, Inbred DBA;Peptide Fragments;Plasmids;Protein Engineering;Protein Structure, Tertiary;Sequence Deletion;Structure-Activity Relationship;T-Lymphocytes, Cytotoxic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"administration & dosage;chemistry;immunology;immunology;administration & dosage;chemical synthesis;immunology;chemistry;genetics;immunology;genetics;biosynthesis;genetics;administration & dosage;chemistry;immunology;administration & dosage;chemistry;genetics;immunology;genetics;chemistry;immunology;prevention & control;administration & dosage;genetics;immunology;administration & dosage;chemical synthesis;immunology;methods;genetics;immunology",
        "_version_":1605837362818973696},
      {
        "Doc_abstract":"Necdin, a member of the MAGE (melanoma antigen) protein family, is expressed predominantly in terminally differentiated neurons. The necdin gene NDN is maternally imprinted and expressed only from the paternal allele, the deficiency of which is implicated in the pathogenesis of the neurodevelopmental disorder Prader-Willi syndrome. Necdin binds to its homologous MAGE protein MAGE-D1 (also known as NRAGE or Dlxin-1), which interacts with Msx (msh homeobox) and Dlx (distal-less homeobox) family homeodomain transcription factors. Members of the Dlx homeobox gene family are involved in the differentiation and specification of forebrain GABAergic neurons. Here we demonstrate that necdin associates with Dlx homeodomain proteins via MAGE-D1 to promote the differentiation of GABAergic neurons in mouse embryonic forebrain. Immunohistochemical analysis revealed that necdin was coexpressed with Dlx2, Dlx5, or MAGE-D1 in a subpopulation of embryonic forebrain cells. Necdin bound to Dlx2 and Dlx5 via MAGE-D1 and enhanced Dlx2-dependent activation of the Wnt1 (wingless-type MMTV integration site family) promoter. Necdin significantly increased the populations of cells expressing the GABAergic neuron markers calbindin D-28k and glutamic acid decarboxylase when overexpressed by electroporation in cultured forebrain slices. In this assay, Dlx5N, a truncated Dlx5 mutant that competes with Dlx2 to bind MAGE-D1, diminished the effect of necdin on GABAergic neuron differentiation. Furthermore, mutant mice lacking the paternal necdin allele showed a significant reduction in the differentiation of forebrain GABAergic neurons in vivo and in vitro. These results suggest that paternally expressed necdin facilitates the differentiation and specification of GABAergic neurons in cooperation with Dlx homeodomain proteins.",
        "Doc_title":"Necdin promotes GABAergic neuron differentiation in cooperation with Dlx homeodomain proteins.",
        "Journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience",
        "Do_id":"16707790",
        "Doc_ChemicalList":"Calbindins;Calcium-Binding Proteins;Distal-less homeobox proteins;Dlx5 protein, mouse;Homeodomain Proteins;Maged1 protein, mouse;Neoplasm Proteins;Nerve Tissue Proteins;Nuclear Proteins;S100 Calcium Binding Protein G;Transcription Factors;Wnt1 Protein;Wnt1 protein, mouse;necdin;gamma-Aminobutyric Acid;Glutamate Decarboxylase",
        "Doc_meshdescriptors":"Animals;Calbindins;Calcium-Binding Proteins;Cell Differentiation;Cell Line;Cells, Cultured;Glutamate Decarboxylase;Homeodomain Proteins;Humans;Mice;Mice, Inbred ICR;Mice, Knockout;Mutation;Neoplasm Proteins;Nerve Tissue Proteins;Neurons;Nuclear Proteins;Organ Culture Techniques;Promoter Regions, Genetic;Prosencephalon;Protein Binding;S100 Calcium Binding Protein G;Transcription Factors;Wnt1 Protein;gamma-Aminobutyric Acid",
        "Doc_meshqualifiers":"metabolism;physiology;metabolism;genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;genetics;embryology;metabolism;physiology;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605818783383945216},
      {
        "Doc_abstract":"Most current methods for identifying peptides that are bound to a distinct MHC-I product in a given cell sample utilize detergent solubilization of membrane proteins followed by immunoaffinity purification. Since detergent traces and cell debris hamper subsequent peptide analysis, exceedingly large cell samples are often required. To avoid the use of detergents, truncated MHC-I heavy chains have recently been expressed by stable DNA transfection or retroviral transduction, resulting in the secretion of soluble MHC-I complexes to the growth medium. The electroporation of in vitro-transcribed mRNA achieves remarkable efficacy and uniformity of gene expression in numerous cell types, exhibiting exceedingly fast kinetics. We reasoned that mRNA transfection offers a simple, fast and widely applicable alternative to current gene delivery protocols for expressing secreted MHC-I products in cells of interest. To test this assumption we used mRNA to express soluble derivatives of HLA-A2 in the human AF10 B cell myeloma and 624mel melanoma and H-2K(d) in the mouse SP2/0 B cell myeloma. The level of MHC-I complexes secreted by these cells peaked within less than 24h post-transfection and they could be affinity-purified directly from the culture medium in considerably greater yields when compared to nonionic detergent lysates on a cell-to-cell basis. Mass-spectrometry analysis of eluted peptides revealed larger pools in the secreted material than in lysates with substantial overlap in composition. Our results introduce mRNA transfection as a powerful tool for determining the cell's MHC-I peptidome, which can be potentially applied to a broad range of cell types. ",
        "Doc_title":"Efficient peptide recovery from secreted recombinant MHC-I molecules expressed via mRNA transfection.",
        "Journal":"Immunology letters",
        "Do_id":"25839126",
        "Doc_ChemicalList":"Histocompatibility Antigens Class I;Peptides;RNA, Messenger;Recombinant Proteins",
        "Doc_meshdescriptors":"Animals;Cell Line;Flow Cytometry;Gene Expression;Histocompatibility Antigens Class I;Humans;Mice;Peptides;RNA, Messenger;Recombinant Proteins;Transfection",
        "Doc_meshqualifiers":"chemistry;genetics;immunology;isolation & purification;immunology;genetics",
        "_version_":1605800084265500672},
      {
        "Doc_abstract":"Histopathological evaluation of melanocytic tumours usually allows reliable distinction of benign melanocytic naevi from melanoma. More difficult is the histopathological classification of Spitz tumours, a heterogeneous group of tumours composed of large epithelioid or spindle-shaped melanocytes. Spitz tumours are biologically distinct from conventional melanocytic naevi and melanoma, as exemplified by their distinct patterns of genetic aberrations. Whereas common acquired naevi and melanoma often harbour BRAF mutations, NRAS mutations, or inactivation of NF1, Spitz tumours show HRAS mutations, inactivation of BAP1 (often combined with BRAF mutations), or genomic rearrangements involving the kinases ALK, ROS1, NTRK1, BRAF, RET, and MET. In Spitz naevi, which lack significant histological atypia, all of these mitogenic driver aberrations trigger rapid cell proliferation, but after an initial growth phase, various tumour suppressive mechanisms stably block further growth. In some tumours, additional genomic aberrations may abrogate various tumour suppressive mechanisms, such as cell-cycle arrest, telomere shortening, or DNA damage response. The melanocytes then start to grow in a less organised fashion and may spread to regional lymph nodes, and are termed atypical Spitz tumours. Upon acquisition of even more aberrations, which often activate additional oncogenic pathways or alter cell differentiation, the neoplastic cells become entirely malignant and may colonise and take over distant organs (spitzoid melanoma). The sequential acquisition of genomic aberrations suggests that Spitz tumours represent a continuous biological spectrum, rather than a dichotomy of benign versus malignant, and that tumours with ambiguous histological features (atypical Spitz tumours) might be best classified as low-grade melanocytic tumours. The number of genetic aberrations usually correlates with the degree of histological atypia and explains why existing ancillary genetic techniques, such as array comparative genomic hybridisation (CGH) or fluorescence in situ hybridisation (FISH), are usually capable of accurately classifying histologically benign and malignant Spitz tumours, but are not very helpful in the diagnosis of ambiguous melanocytic lesions. Nevertheless, we expect that progress in our understanding of tumour progression will refine the classification of spitzoid melanocytic tumours in the near future. By integrating clinical, pathological, and genetic criteria, distinct tumour subsets will be defined within the heterogeneous group of Spitz tumours, which will eventually lead to improvements in diagnosis, prognosis and therapy. ",
        "Doc_title":"Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.",
        "Journal":"Pathology",
        "Do_id":"27020384",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605755560789016576},
      {
        "Doc_abstract":"The activation of an enzyme, inducible nitric oxide synthase (iNOS), catalyzes the production of endogenous nitric oxide (NO). NO, in turn, is associated with cell death, suppression of tumor development, and inhibition of metastasis of murine melanoma cells. Moreover, the in vivo induction of iNOS is associated with regression of established hepatic metastases. Whether this regression required the activation of the iNOS gene in every tumor cell or whether NO-producing tumor cells can also kill bystander (neighboring) cells has been previously unknown.;The goal of this study was to determine whether cells producing NO and then undergoing autolysis can also kill bystander cells in vitro and in vivo.;Murine K-1735 C4.parental (C4.P) melanoma cells were transfected with the functional iNOS gene (transfectant denoted as C4.L8) or with a control truncated-nonfunctional iNOS gene (transfectant denoted as C4.S2). NO-mediated cytolysis and bystander cell killing were determined in vitro and in vivo.;Only the functional iNOS-transfected C4.L8 cells produced NO and underwent autolysis. C4.L8 cells also produced statistically significant lysis of iNOS-negative C4.P cells. This lysis was suppressed by the specific iNOS inhibitor N(G)-methyl-L-arginine. NO-producing C4.L8 cells and control C4.P or C4.S2 cells were injected subcutaneously into syngeneic C3H/HeN mice. Control C4.P and C4.S2 cells produced rapidly growing subcutaneous tumors, whereas C4.L8 cells did not. The mixture of C4.P and C4.S2 cells (1:5 ratio) produced rapidly growing subcutaneous tumors, whereas the mixture of C4.P and C4.L8.5 cells (1:5 ratio) produced slow-growing tumors. The subcutaneous growth of C4.P cells was not affected by C4.L8.5 cells injected subcutaneously at a distant site. Mixtures of C4.P cells labeled with [(125)I]iododeoxyuridine and C4.L8 cells (NO producing) or C4.S2 cells (control) were injected subcutaneously. The survival rate of the radiolabeled cells indicated that the NO-producing C4.L8.5 cells lysed the bystander C4.P cells.;The production of high-level endogenous NO causes autolysis in tumor cells and lysis of bystander cells under in vitro and in vivo conditions.;NO-mediated cell killing does not require transfection of genes into every cell in a neoplasm.",
        "Doc_title":"Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"9091643",
        "Doc_ChemicalList":"Nitric Oxide;Nitric Oxide Synthase",
        "Doc_meshdescriptors":"Animals;Cell Death;Enzyme Induction;Melanoma, Experimental;Mice;Mice, Inbred C3H;Nitric Oxide;Nitric Oxide Synthase;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;physiopathology;biosynthesis;genetics;metabolism;physiology",
        "_version_":1605741907440304129},
      {
        "Doc_abstract":"Recently, the clonal integration of a new human polyomavirus (Merkel cell polyomavirus or MCPyV) has been reported in Merkel cell carcinoma (MCC). In order to investigate the presence of MCPyV in small cell carcinomas (SCCs) and small round cell tumors (SRCTs), we collected formalin-fixed paraffin-embedded tissue specimens including 14 MCCs, 24 SCCs, 7 Ewing sarcoma/primitive neuroectodermal tumors (ES/PNETs) and 5 neuroblastomas. We also collected specimens of other cancers including 12 malignant melanomas, 10 breast, 10 ovarian and 20 gastric cancers. We used 3 primer sets for which the sequences were previously published (LT1, LT3, and VP1) and 3 newly designed primer sets (LT1-1, LT1-1a, and LT3a). Quantitative real-time PCR was also performed with the LTq primer set. Nested PCR using the LT3a primer set detected more cases of MCPyV infection in MCC. In total, 12 of 14 (85.7%) MCC cases were positive for MCPyV by PCR, which was consistent with published data. Some SCC specimens were also positive for MCPyV (37.5%) by PCR. PCR products from MCC and SCC cases showed premature truncation and frameshift mutation. Furthermore, one case of ES/PNET and one gastric carcinoma showed MCPyV DNA. However, MCPyV DNA and transcript were only detected in MCCs with quantitative real-time PCR analysis. In addition, 11 of 13 (84.6%) MCC cases and 6 of 23 (26.1%) SCC cases showed immunoreactivity with monoclonal antibodies against MCPyV large T-antigen. Considering both PCR and IHC results, MCPyV was detected in all MCCs tested. The presence of MCPyV in all MCC cases tested and in some SCC cases suggests that MCPyV may be involved in the malignant transformation.",
        "Doc_title":"Detection of Merkel cell polyomavirus in Merkel cell carcinomas and small cell carcinomas by PCR and immunohistochemistry.",
        "Journal":"Histology and histopathology",
        "Do_id":"21870327",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Merkel Cell;Carcinoma, Small Cell;Female;Humans;Immunohistochemistry;Male;Merkel cell polyomavirus;Middle Aged;Polyomavirus Infections;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Tumor Virus Infections",
        "Doc_meshqualifiers":"pathology;virology;pathology;virology;isolation & purification;complications;pathology;virology;complications;pathology;virology",
        "_version_":1605766783225036800},
      {
        "Doc_abstract":"Capsase-3 plays an important role in chemotherapy-induced apoptosis in many cancers. Herein, we applied a multimodality reporter vector to monitor caspase-3 activation indirectly in live cells and tumors of living animals undergoing apoptosis.;A fusion protein (MTF) was constructed by combining three different reporter proteins, red fluorescent protein (mRFP1), firefly luciferase (FL), and HSV1-sr39 truncated thymidine kinase (TK), linked through a caspase-3 recognizable polypeptide linker. After cleavage by caspase-3, a significant gain in mRFP1, FL, and TK activity are observed by fluorescence-activated cell sorting and enzyme-based assays. A melanoma cell line (B16F10-mtf-hrl) stably expressing mtf (to measure caspase-3 activation) and hrl-IRES-gfp (to determine the decrease in a number of viable cells) vectors was generated to measure two independent molecular events upon treatment.;Upon induction with 8 mumol/L staurosporine, the fusion protein showed a 2.8-fold increase in FL (P = 0.03), a 1.5-fold increase in TK (P = not significant), and a 2-fold increase in mRFP1 (P = 0.05) activity in 293T cells. Bioluminescence and micropositron emission tomography imaging of the apoptotic B16F10-mtf-hrl tumors showed a 2-fold higher FL activity (897 versus 416) and a 2-fold higher TK activity (10.3 versus 3.87) than control tumors when normalized with RL activity. Using a similar normalization approach, the time kinetics of caspase-3 activation by two protein kinase-C inhibitors was noninvasively monitored in living mice.;This multimodality caspase sensor vector could effectively and noninvasively monitor caspase-3 activation from single live cells to a multicellular tumor environment and, thus, would be a valuable tool for drug screening in preclinical models and future patient cell based therapy.",
        "Doc_title":"Monitoring caspase-3 activation with a multimodality imaging sensor in living subjects.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"18794090",
        "Doc_ChemicalList":"Luminescent Proteins;Recombinant Fusion Proteins;Green Fluorescent Proteins;Luciferases, Firefly;Thymidine Kinase;Caspase 3",
        "Doc_meshdescriptors":"Animals;Apoptosis;Caspase 3;Cell Line;Cell Line, Tumor;Diagnostic Imaging;Enzyme Activation;Genetic Vectors;Green Fluorescent Proteins;Humans;Luciferases, Firefly;Luminescent Proteins;Mice;Models, Biological;Recombinant Fusion Proteins;Thymidine Kinase",
        "Doc_meshqualifiers":"genetics;methods;analysis;metabolism",
        "_version_":1605907212929073152},
      {
        "Doc_abstract":"Ovarian cancer has the highest mortality among the gynecologic malignancies. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated, leading to increased cell survival. This study aimed to identify secreted proteins regulated by the PI3K pathway in ovarian cancer cell lines. Surface-enhanced laser desorption-ionization time-of-flight mass spectrometry with cation-exchange protein-chips was used to analyze secreted proteins from five ovarian cancer cell lines (SKOV-3, PE01, OVCAR-3, OV167, and OV207). To activate the PI3K pathway, cells were treated with 50 ng/mL epidermal growth factor (EGF) with or without 10 micromol/L LY294002, a PI3K inhibitor. Proteins induced by EGF and inhibited by LY294002, in the m/z range 7,500 to 9,500, were purified chromatographically, identified by peptide mass fingerprinting and NH(2)-terminal sequencing, and confirmed by immunodepletion. Two immunologically related proteins, m/z approximately 8,385 and 8,922, were identified as truncated and intact forms, respectively, of interleukin 8, a chemokine previously shown to be elevated in serum of ovarian cancer patients. Another protein, m/z 7,866, was identified as CXC chemokine ligand 1 (CXCL1) or GRO-alpha, a chemokine associated with melanoma formation and some epithelial cancers. EGF-stimulated CXCL1 levels were variably decreased by mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase and p38 MAPK inhibition in the five cell lines, but only LY294002 fully reversed the EGF effect in all cell lines. Immunoreactive CXCL1 levels in 160 conditioned media were highly correlated with corresponding peak intensities at m/z 7,866 by mass spectrometry, indicating the quantitative nature of these analyses. We conclude that proteomic analysis of cell models of human disease may facilitate the discovery of pathway-dependent proteins.",
        "Doc_title":"Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines.",
        "Journal":"Cancer research",
        "Do_id":"16452192",
        "Doc_ChemicalList":"CXCL1 protein, human;Chemokine CXCL1;Chemokines, CXC;Intercellular Signaling Peptides and Proteins;Interleukin-8;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Blotting, Western;Cell Line, Tumor;Chemokine CXCL1;Chemokines, CXC;Female;Humans;Intercellular Signaling Peptides and Proteins;Interleukin-8;Ovarian Neoplasms;Phosphatidylinositol 3-Kinases;Phosphorylation;Protein Array Analysis;Proto-Oncogene Proteins c-akt;Radioimmunoassay;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Up-Regulation",
        "Doc_meshqualifiers":"biosynthesis;genetics;secretion;biosynthesis;genetics;secretion;biosynthesis;genetics;secretion;enzymology;genetics;metabolism;secretion;metabolism;metabolism",
        "_version_":1605929005437943808},
      {
        "Doc_abstract":"Evidence is accumulating that calcium homeostasis and calcium-regulated events may be selectively important in generation and maintenance of the malignant phenotype. CAI, a carboxyamido-triazole with a halogenated benzophenone tail, is a novel inhibitor of receptor-operated calcium influx and arachidonic acid release which inhibits malignant proliferation, invasion, and metastasis. The focus of this investigation was structural analysis of CAI and to determine if the inhibition of calcium influx and arachidonic acid release by CAI and its antiproliferative activity were mediated through the same chemical domains. Four families of molecular modifications of the CAI parent were synthesized: (I) modification or substitution of the triazole ring; (II) removal of the substituted benzophenone tail; (III) dehalogenation or partial truncation of the benzophenone moiety; and (IV) removal of the triazole and altered substitutions of the benzophenone tail. Compounds were tested for the inhibition of calcium influx and arachidonic acid release and inhibition of proliferation and colony formation in soft agar using the malignant CHO line transfected with the m5 muscarinic receptor and the A2058 human melanoma cell line. Only CAI and Group I compounds inhibited stimulated calcium influx, arachidonic acid release, and proliferation. Linear regression analysis of the relationship of the 50% inhibitory concentration values for all compounds in inhibition of calcium influx and arachidonate release was statistically significant (r2 = 0.993). Similarly, a linear relationship was demonstrated between inhibition of calcium influx and inhibition of tumor cell proliferation (r2 = 0.971). Groups II-IV had minimal or no signal or growth inhibitory activity. This investigation provides the first evidence for a coordinate link between calcium influx, calcium-mediated arachidonic acid release, and malignant proliferation and metastasis and constitutes the initial analysis of structurally important domains of the CAI molecule.",
        "Doc_title":"Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI.",
        "Journal":"Cancer research",
        "Do_id":"8313384",
        "Doc_ChemicalList":"Antineoplastic Agents;Triazoles;Arachidonic Acid;Aminoimidazole Carboxamide;carboxyamido-triazole;Calcium",
        "Doc_meshdescriptors":"Aminoimidazole Carboxamide;Animals;Antineoplastic Agents;Arachidonic Acid;CHO Cells;Calcium;Cell Division;Cricetinae;Cricetulus;Humans;Lung Neoplasms;Signal Transduction;Structure-Activity Relationship;Triazoles;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analogs & derivatives;pharmacology;pharmacology;metabolism;metabolism;drug effects;prevention & control;secondary;drug effects;pharmacology",
        "_version_":1605811278324957184},
      {
        "Doc_abstract":"Tumor-suppressor protein p53, the 'guardian of the genome', is critical in maintaining cellular homeostasis and genomic stability. Earlier, we have reported the discovery of internal ribosome entry sites (IRESs) within the p53 mRNA that regulate the translation of the full length and its N-terminal-truncated isoform, ÎN-p53. Polypyrimidine tract-binding protein (PTB) is an IRES trans-acting factor that positively regulates the IRES activities of both p53 isoforms by relocating from nucleus to the cytoplasm during stress conditions. Here we have demonstrated the putative contact points of PTB on the p53 IRES RNA. Studies on mutations that occur naturally in the 5' untranslated region (5' UTR) in p53 mRNA were lacking. We have investigated a naturally occurring C-to-T single-nucleotide polymorphism (SNP) first reported in human melanoma tumors. This SNP is at position 119 in the 5' UTR of p53 mRNA and we demonstrate that it has consequences on the translational control of p53. Introduction of this SNP has led to decrease in cap-independent translation from p53 5' UTR in bicistronic reporter assay. Further, the effects of this SNP on cap-independent translation have been studied in the context of p53 cDNA as well. Interestingly, the 5' UTR with this SNP has shown reduced binding to PTB that can be corroborated to its weaker IRES activity. Previously, it has been shown that G2-M checkpoint, DNA-damaging stress and oncogenic insult favor IRES-mediated translation. Under similar conditions, we demonstrate that this SNP interferes with the enhancement of the IRES activity of the 5' UTR. Taken together, the results demonstrate for the first time that SNP in the 5' UTR of the p53 mRNA might have a role in translational control of this critical tumor-suppressor gene.",
        "Doc_title":"Effect of a natural mutation in the 5' untranslated region on the translational control of p53 mRNA.",
        "Journal":"Oncogene",
        "Do_id":"23027126",
        "Doc_ChemicalList":"5' Untranslated Regions;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;RNA, Messenger;TP53 protein, human;Tumor Suppressor Protein p53;Polypyrimidine Tract-Binding Protein",
        "Doc_meshdescriptors":"5' Untranslated Regions;Animals;Binding Sites;Cyclin-Dependent Kinase Inhibitor p21;DNA Damage;Humans;Mutation;Polymorphism, Single Nucleotide;Polypyrimidine Tract-Binding Protein;Polyribosomes;Protein Biosynthesis;RNA, Messenger;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;analysis;genetics",
        "_version_":1605903619893231616},
      {
        "Doc_abstract":"The avian influenza virus H9N2 subtype has circulated in wild birds, is prevalent in domestic poultry, and has successfully crossed the species boundary to infect humans. Phylogenetic analyses showed that viruses of this subtype appear to have contributed to the generation of highly pathogenic H5N1 viruses. Little is known about the host responses to H9N2 viruses in human airway respiratory epithelium, the primary portal for viral infection. Using an apically differentiated primary human tracheobronchial epithelial (TBE) culture, we examined host immune responses to infection by an avian H9N2 virus, in comparison with a human H9N2 isolate. We found that IFN-Î² was the prominent antiviral component, whereas interferon gamma-induced protein 10 kDa (IP-10), chemokine (C-C motif) ligand (CCL)-5 and TNF-Î± may be critical in proinflammatory responses to H9N2 viruses. In contrast, proinflammatory IL-1Î², IL-8, and even IL-6 may only play a minor role in pathogenicity. Apparently Toll-like receptor (TLR)-3, TLR-7, and melanoma differentiation-associated gene 5 (MDA-5) contributed to the innate immunity against the H9N2 viruses, and MDA-5 was important in the induction of IFN-Î². We showed that the avian H9N2 virus induced apoptosis through the mitochondria/cytochrome c-mediated intrinsic pathway, in addition to the caspase 8-mediated extrinsic pathway, as evidenced by the cytosolic presence of active caspase 9 and cytochrome c, independent of truncated BH3 interacting domain death agonist (Bid) activation. Further, we demonstrated that FLICE-like inhibitory protein (FLIP), an apoptotic dual regulator, and the p53-dependent Bcl-2 family members, Bax and Bcl-x(s), appeared to be involved in the regulation of extrinsic and intrinsic apoptotic pathways, respectively. The findings in this study will further our understanding of host defense mechanisms and the pathogenesis of H9N2 influenza viruses in human respiratory epithelium.",
        "Doc_title":"Host immune and apoptotic responses to avian influenza virus H9N2 in human tracheobronchial epithelial cells.",
        "Journal":"American journal of respiratory cell and molecular biology",
        "Do_id":"20118223",
        "Doc_ChemicalList":"BAX protein, human;BCL2L1 protein, human;BH3 Interacting Domain Death Agonist Protein;BID protein, human;CASP8 and FADD-Like Apoptosis Regulating Protein;Cytokines;Inflammation Mediators;TP53 protein, human;Toll-Like Receptors;Tumor Suppressor Protein p53;bcl-2-Associated X Protein;bcl-X Protein;Caspases;IFIH1 protein, human;DEAD-box RNA Helicases;Interferon-Induced Helicase, IFIH1",
        "Doc_meshdescriptors":"Animals;Apoptosis;BH3 Interacting Domain Death Agonist Protein;Birds;Bronchi;CASP8 and FADD-Like Apoptosis Regulating Protein;Caspases;Cells, Cultured;Cytokines;Cytopathogenic Effect, Viral;DEAD-box RNA Helicases;Enzyme Activation;Epithelial Cells;Gene Expression Regulation;Humans;Immunity, Innate;Inflammation Mediators;Influenza A Virus, H9N2 Subtype;Influenza in Birds;Influenza, Human;Interferon-Induced Helicase, IFIH1;RNA Interference;Time Factors;Toll-Like Receptors;Trachea;Tumor Suppressor Protein p53;bcl-2-Associated X Protein;bcl-X Protein",
        "Doc_meshqualifiers":"genetics;metabolism;immunology;pathology;virology;metabolism;metabolism;genetics;metabolism;genetics;metabolism;immunology;pathology;virology;genetics;metabolism;growth & development;pathogenicity;immunology;pathology;virology;immunology;pathology;virology;genetics;metabolism;immunology;pathology;virology;metabolism;metabolism;metabolism",
        "_version_":1605903604671053824},
      {
        "Doc_abstract":"The neurofibromatoses (NF) are genetic disorders. Increased risks of some cancers in people with NF are well recognised, but there is no comprehensive enumeration of the risks across the whole range of site-specific cancers. Our aim was to provide this.;A linked data set of hospital admissions and deaths in England was used to compare rates of tumours in an NF cohort with rates in a comparison cohort, with results expressed as rate ratios (RR).;The RR for all cancers combined, in people with both types of NF combined, was 4.3 (95% confidence interval (CI): 4.0-4.6), based on 769 cases of cancer in 8003 people with NF. Considering only people with presumed NF1 (as defined in the main article), the RR for all cancers excluding nervous system malignancies remained elevated (2.7, 95% CI: 2.4-2.9); and risks were significantly high for cancer of the oesophagus (3.3), stomach (2.8), colon (2.0), liver (3.8), lung (3.0), bone (19.6), thyroid (4.9), malignant melanoma (3.6), non-Hodgkin's lymphoma (3.3), chronic myeloid leukaemia (6.7), female breast (2.3) and ovary (3.7).;Neurofibromatosis was associated with an increased risk of many individual cancers. The relationships between NF and cancers may hold clues to mechanisms of carcinogenesis more generally.",
        "Doc_title":"Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study.",
        "Journal":"British journal of cancer",
        "Do_id":"23257896",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Female;Humans;Male;Middle Aged;Neoplasms;Nervous System Neoplasms;Neurofibromatoses;Population Surveillance;Risk Factors",
        "Doc_meshqualifiers":"epidemiology;pathology;epidemiology;pathology;complications",
        "_version_":1605748176389668865},
      {
        "Doc_abstract":"Ocular albinism type 1 (OA1) is an X-linked recessive disorder characterized by a major impairment of visual acuity, nystagmus, strabismus, photophobia and retinal hypopigmentation. From the analysis of patients carrying deletions and translocations involving the distal short arm of the X chromosome (Xp22.3) we have identified a region of approximately 110 kb in which the OA1 gene must lie. We have extensively searched for genes in this region using a variety of techniques which included exon amplification, cDNA selection and direct hybridization of cosmid inserts to cDNA libraries. Putative exons identified by exon amplification were used to screen a human retina cDNA library and several cDNA clones corresponding to an approximately 7.5 kb transcript were isolated and characterized. Transcripts of this newly identified gene were found to be abundant in retina and melanoma and could also be detected in brain, placenta, lung, kidney and pancreas. Interestingly, sequence analysis revealed that this new gene encodes a 1616 amino acid protein sharing significant similarities with the Apical Protein from Xenopus laevis (APX) which is implicated in amiloride-sensitive sodium channel activity. The gene, termed APXL (APX-Like), spans approximately 160 kb, contains 10 exons and covers over 70% of the 110 kb critical region for OA1. A truncated pseudogene sharing very high levels of homology with the rat eIF-5 gene, a eukaryotic translation initiation factor, was found to lie in the middle of intron 1. APXL was found deleted in two patients with contiguous gene syndromes including OA1 and in one patient with isolated OA1. Mapping, expression and patient analysis data led us to consider the APXL gene a strong candidate for the OA1 gene. DNA from 57 unrelated patients with OA1 was, therefore, scanned for mutations in the coding region, using both SSCP analysis and direct sequencing. No functionally significant mutation was identified, suggesting that APXL is not directly involved in OA1. Further studies are needed to clarify the physiologic role of this highly conserved gene.",
        "Doc_title":"Cloning of a human homologue of the Xenopus laevis APX gene from the ocular albinism type 1 critical region.",
        "Journal":"Human molecular genetics",
        "Do_id":"7795590",
        "Doc_ChemicalList":"Apx protein, Xenopus;Membrane Proteins;SHROOM2 protein, human;Sodium Channels;Xenopus Proteins",
        "Doc_meshdescriptors":"Albinism, Ocular;Amino Acid Sequence;Animals;Base Sequence;Chromosome Deletion;Chromosome Mapping;Cloning, Molecular;Exons;Humans;Male;Membrane Proteins;Molecular Sequence Data;Pseudogenes;Rats;Sequence Analysis, DNA;Sequence Homology, Amino Acid;Sodium Channels;Tissue Distribution;X Chromosome;Xenopus Proteins;Xenopus laevis",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;genetics;genetics",
        "_version_":1605746409775038465},
      {
        "Doc_abstract":"Virion glycoproteins gB, gD, and gH/gL play essential roles for herpes simplex virus (HSV) entry. The function of gD is to interact with a cognate receptor, and soluble forms of gD block HSV entry by tying up cell surface receptors. Both gB and the nonessential gC interact with cell surface heparan sulfate proteoglycan (HSPG), promoting viral attachment. However, cells deficient in proteoglycan synthesis can still be infected by HSV. This suggests another function for gB. We found that a soluble truncated form of gB bound saturably to the surface of Vero, A431, HeLa, and BSC-1 cells, L-cells, and a mouse melanoma cell line expressing the gD receptor nectin-1. The HSPG analog heparin completely blocked attachment of the gC ectodomain to Vero cells. In contrast, heparin only partially blocked attachment of soluble gB, leaving 20% of the input gB still bound even at high concentrations of inhibitor. Moreover, heparin treatment removed soluble gC but not gB from the cell surface. These data suggest that a portion of gB binds to cells independently of HSPG. In addition, gB bound to two HSPG-deficient cell lines derived from L-cells. Gro2C cells are deficient in HSPG, and Sog9 cells are deficient in HSPG, as well as chondroitin sulfate proteoglycan (CSPG). To identify particular gB epitopes responsible for HSPG-independent binding, we used a panel of monoclonal antibodies (MAbs) to gB to block gB binding. Only those gB MAbs that neutralized virus blocked binding of soluble gB to the cells. HSV entry into Gro2C and Sog9 cells was reduced but still detectable relative to the parental L-cells, as previously reported. Importantly, entry into Gro2C cells was blocked by purified forms of either the gD or gB ectodomain. On a molar basis, the extent of inhibition by gB was similar to that seen with gD. Together, these results suggest that soluble gB binds specifically to the surface of different cell types independently of HSPG and CSPG and that by doing so, the protein inhibits entry. The results provide evidence for the existence of a cellular entry receptor for gB.",
        "Doc_title":"Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.",
        "Journal":"Journal of virology",
        "Do_id":"16140736",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Peptide Fragments;Proteoglycans;Receptors, Virus;Viral Envelope Proteins;glycoprotein B, Simplexvirus;glycoprotein gC, herpes simplex virus type 1;Heparin;Heparitin Sulfate",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Binding Sites;Cell Line;Cell Membrane;Cercopithecus aethiops;HeLa Cells;Heparin;Heparitin Sulfate;Herpesvirus 1, Human;Humans;L Cells (Cell Line);Mice;Peptide Fragments;Protein Structure, Tertiary;Proteoglycans;Receptors, Virus;Solubility;Vero Cells;Viral Envelope Proteins",
        "Doc_meshqualifiers":"metabolism;virology;pharmacology;metabolism;genetics;pathogenicity;physiology;chemistry;genetics;metabolism;metabolism;metabolism;chemistry;genetics;metabolism;physiology",
        "_version_":1605846967252942848},
      {
        "Doc_abstract":"Trends in overall age-standardized, truncated (35-64 years) and age-specific (40 to 49) cancer death certification rates in Switzerland from 1951 to 1984 were analysed. There was a substantial rise in lung cancer mortality in males, with an over 100% increase in overall rates. Thus, in the early 1980's, lung cancer alone accounted for 26% of all cancer deaths in Swiss males. However, male lung cancer rates tended to level off in subsequent cohorts starting from younger middle age in the late 1960's. In females, lung cancer mortality was approximately ten times lower than in males, but rates had been consistently rising since the late 1960's in all age groups. Declines were observed for several neoplasms of the digestive tract: besides stomach (overall decline 68% in males, 77% in females), trends were markedly downwards also for oesophageal cancer in males (-57%), and there was some moderate fall for intestinal sites in both sexes and gallbladder in females. Several trends for other common neoplasms were similar to those observed in other developed countries, such as the declines for (cervix) uteri, the general stability for breast cancer, or the increases in pancreatic cancer and (melanoma) of the skin. A peculiar feature of Swiss data, besides the marked decline in oesophageal cancer in males, was the consistent downward trend in thyroid cancer for both sexes. Thus, overall age-standardized total cancer mortality over the last three decades was moderately upwards in Swiss males, but consistently downwards in females. Male trends were more reassuring in middle age, chiefly in consequence of the flattening in lung cancer rises. Possible interpretations of these trends in terms of aetiological hypotheses (i.e., changes in alcohol drinking and improvements in diet for oesophageal cancer, or reduced prevalence of iodine deficiency for thyroid neoplasms) are discussed.;Trends in cancer mortality from 1951 to 1984 are analyzed by age, sex, and cancer site using official Swiss data.  A substantial rise in lung cancer mortality among males is noted, although a decline is seen among younger cohorts.  Mortality from lung cancer among females is 10 times lower than for males but shows signs of an increase. Declines in mortality from cancer of the digestive tract for both sexes were apparent.  Overall age-standardized cancer mortality was moderately up for males but consistently down for females.  Reasons for these trends are discussed.  Comparisons are then made with other developed countries.",
        "Doc_title":"Trends in cancer mortality in Switzerland, 1951-1984.",
        "Journal":"Revue d'epidemiologie et de sante publique",
        "Do_id":"3368605",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Diet;Digestive System Neoplasms;Female;Humans;Life Style;Lung Neoplasms;Male;Middle Aged;Neoplasms;Switzerland",
        "Doc_meshqualifiers":"mortality;mortality;mortality",
        "_version_":1605747533241384960},
      {
        "Doc_abstract":"The MICA gene encodes for major histocompatibility complex class I chain-related proteins (MIC), which belong to a recently identified new family of nonclassical major histocompatibility complex molecules. The general structure of the MICA molecule resembles that of major histocompatibility complex class I molecules. MIC molecules are considered to be stress-induced antigens that are recognized by cytotoxic T cells and natural killer cells, which play an important role in the surveillance of transformed infected and damaged cells. Associations of major histocompatibility complex class I molecules with skin cancer have been described before. To evaluate the possible association of MICA gene polymorphism with the risk for nonmelanoma skin cancer we evaluated 153 cases with squamous cell carcinoma, 261 cases with basal cell carcinoma, 111 controls with malignant melanoma, and 247 controls without a history of skin cancer. Five distinct MICA alleles A4, A5, A6, A9, and A5.1 were studied. As the MICA 5.1 variant gene contains a four-nucleotide insertion that causes a stop codon in the trans membrane region, the resulting truncated MICA molecule does not reside on the cellular membrane. In the case of individuals who are homozygous for MICA 5.1 this results in cells that are naked for the MICA molecule. We therefore specifically addressed the possible association between MICA 5.1 homozygosity and skin cancer, as these individuals are expected to be at the highest risk for skin cancer if the MICA gene plays a role in skin carcinogenesis. Viral proteins may serve as antigens for recognition of skin cancer by the immune system. Human papillomavirus is the most likely candidate virus to be involved in the carcinogenesis of cutaneous squamous cell carcinoma. Hence, we also assessed the association between MICA polymorphism and squamous cell carcinoma in human-papillomavirus-positive and human-papillomavirus-negative individuals as identified by the presence of human papillomavirus DNA in hairs plucked from their eyebrows. Our analyses did not reveal any significant differences regarding the MICA allele frequencies between cases and controls. Also homozygotes and heterozygotes for the MICA 5.1 variant gene were not at an increased risk for skin cancer compared to individuals without this variant gene and infection with human papillomavirus did not materially influence these findings. The same group of cases and controls was large enough to show an association between melanocortin 1 receptor gene polymorphism and skin cancer and to reasonably exclude an association between p53 codon 72 polymorphism and skin cancer. Therefore, we conclude that an association between MICA gene polymorphism and nonmelanoma skin cancer is not likely.",
        "Doc_title":"MICA gene polymorphism is not associated with an increased risk for skin cancer.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"11918717",
        "Doc_ChemicalList":"Histocompatibility Antigens Class I;MHC class I-related chain A",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Basal Cell;Carcinoma, Squamous Cell;Female;Gene Frequency;Genetic Predisposition to Disease;Histocompatibility Antigens Class I;Homozygote;Humans;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymorphism, Genetic;Risk Factors;Skin Neoplasms;Tumor Virus Infections",
        "Doc_meshqualifiers":"epidemiology;genetics;virology;epidemiology;genetics;virology;genetics;epidemiology;epidemiology;genetics;virology;epidemiology",
        "_version_":1605755846906609664},
      {
        "Doc_abstract":"Pheochromocytomas are tumors of the adrenal medulla originating in the chromaffin cells derived from the neural crest. Ten % of these tumors are associated with the familial cancer syndromes multiple endocrine neoplasia type 2, von Hippel-Lindau disease (VHL), and rarely, neurofibromatosis type 1, in which germ-line mutations have been identified in RET, VHL, and NF1, respectively. In both the sporadic and familial form of pheochromocytoma, allelic loss at 1p, 3p, 17p, and 22q has been reported, yet the molecular pathogenesis of these tumors is largely unknown. Allelic loss at chromosome 1p has also been reported in other endocrine tumors, such as medullary thyroid cancer and tumors of the parathyroid gland, as well as in tumors of neural crest origin including neuroblastoma and malignant melanoma. In this study, we performed fine structure mapping of deletions at chromosome 1p in familial and sporadic pheochromocytomas to identify discrete regions likely housing tumor suppressor genes involved in the development of these tumors. Ten microsatellite markers spanning a region of approximately 70 cM (1pter to 1p34.3) were used to screen 20 pheochromocytomas from 19 unrelated patients for loss of heterozygosity (LOH). LOH was detected at five or more loci in 8 of 13 (61%) sporadic samples and at five or more loci in four of five (80%) tumor samples from patients with multiple endocrine neoplasia type 2. No LOH at 1p was detected in pheochromocytomas from two VHL patients. Analysis of the combined sporadic and familial tumor data suggested three possible regions of common somatic loss, designated as PC1 (D1S243 to D1S244), PC2 (D1S228 to D1S507), and PC3 (D1S507 toward the centromere). We propose that chromosome 1p may be the site of at least three putative tumor suppressor loci involved in the tumorigenesis of pheochromocytomas. At least one of these loci, PC2 spanning an interval of <3.8 cM, is likely to have a broader role in the development of endocrine malignancies.",
        "Doc_title":"Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p.",
        "Journal":"Cancer research",
        "Do_id":"11156410",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adult;Aged;Alleles;Chromosome Deletion;Chromosome Mapping;Chromosomes, Human, Pair 1;Drosophila Proteins;Family Health;Female;Germ-Line Mutation;Humans;Loss of Heterozygosity;Male;Microsatellite Repeats;Middle Aged;Models, Genetic;Pheochromocytoma;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605766657622409216},
      {
        "Doc_abstract":"Individuals with inherited cancer syndromes are at significant risk of developing both benign and malignant tumours as a result of a germline mutation in a specific tumour suppressor gene. Tumours of familial origin are a rare event in the head and neck but despite this, they deserve a growing interest. Familial paragangliomas are most of the time limited to the paraganglionar system, but also may be part of different syndromic associations. Since early detection of paragangliomas reduces the incidence of morbidity and mortality, genotypic analysis in the search of SDHB, SDHC and SDHD mutations in families of affected patients plays a front-line diagnostic role, leading to more efficient patient management. Multiple endocrine neoplasias type 1 are characterized by the simultaneous occurrence of at least two of the three main related endocrine tumours: parathyroid, enteropancreatic and anterior pituitary. These tumours arise from inactivating germline mutations in the MEN-1 gene. No clear correlation of MEN-1 genotype with genotype has emerged to date, and MEN-1 mutation testing in tumours is not used clinically because it have not implications for tumour staging. Multiple endocrine neoplasia type 2 is due to a germline mutation in the RET proto-oncogene. Hallmarks of MEN-2A (the commonest phenotypic variant) include medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism. The most central clinical difference with MEN-1 is that the associated cancer can be prevented or cured by early thyroidectomy in mutation carriers. Individuals with neurofibomatosis type 1 present early in life with pigmentary abnormalities, skinfold freckling and iris hamartomas, as result of NF1 gene mutation. Neurofibromatosis 2 is caused by inactivating mutations of the NF2 gene, and is characterized by the development of nervous system tumours (mainly bilateral vestibular schwannomas), ocular abnormalities, and skin tumours. The molecular genetic basis of nasopharyngeal carcinomas remains unknown, but there is evidence for the linkage of these tumours to chromosome 3p. Finally, the high rate of p16 mutations in squamous cell carcinomas and the association of p16 with familial melanoma propose p16 as an ideal candidate gene predisposing to familial squamous cell carcinomas. The elucidation of the cellular processes affected by dysfunction in familial tumours of the head and neck may serve to identify potential targets for future therapeutic interventions.",
        "Doc_title":"Tumours of familial origin in the head and neck.",
        "Journal":"Oral oncology",
        "Do_id":"16857415",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Head and Neck Neoplasms;Humans;Multiple Endocrine Neoplasia;Nasopharyngeal Neoplasms;Neoplastic Syndromes, Hereditary;Neurofibromatoses;Paraganglioma",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605756203858657280},
      {
        "Doc_abstract":"Our specific aim in a 10-year prospective study of 772 Cincinnati firemen (predominantly aged 26 to 46 years) was to determine the prevalence, attributes, and etiology of persistent hypobetalipoproteinemia, defined by entry low-density lipoprotein cholesterol (LDLC) less than 75 mg/dL. A second specific aim was to cross-sectionally assess hypocholesterolemia (defined by total serum cholesterol [TC] < 130 mg/dL) in 1,314 white and 165 black men aged 26 to 46 years in the National Health and Nutrition Examination Survey (NHANES I). The 141 black and 631 white firemen had 4,973 person-years of follow-up time (median, 7.1 yr/man). Of 772 men, 44 (5.7%) had entry LDL levels less than 75 mg/dL; they had a mean follow-up time of 7.3 yr/man. Of these 44 men, there were 12 (1.8% of the cohort) with entry LDLC less than 75 mg/dL, and at least 67% of their follow-up LDLC levels were less than 75. Their mean entry TC and LDLC levels were low (130 and 58 mg/dL), mean triglyceride (TG) was low (63 mg/dL), and mean high-density lipoprotein cholesterol (HDLC) was high (60 mg/dL), LDLC remained at less than 75 mg/dL in 81% of their follow-up samples. Their mean entry and follow-up cholesterol and LDLC did not differ (P > .1, 130 v 133 mg/dL and 58 v 63 mg/dL). Compared with 32 men with entry LDLC less than 75 mg/dL but with less than 87% of follow-up LDLC less than 75 mg/dL, the 12 men with persistently low LDLC had lower mean Quetelet indices and diastolic blood pressure at entry (2.36 v 2.58, P = .056; 73 v 80 mm Hg, P = .03) and on follow-up study (2.45 v 2.69, P = .04; 72 v 79 mm Hg, P = .05). Of 12 men with persistently low LDLC, two had truncated apolipoprotein (apo) B (familial hypobetalipoproteinemia, two had the apo E genotype 2/3, and two had acquired hypobetalipoproteinemia that antedated mortality from melanoma by 9 years and from alcoholism by 2 years. Comparable to white and black firemen aged 26 to 46 years, 2.9% and 3.6% of whom had entry serum TC less than 130 mg/dL, of 1,314 white and 165 black men in the NHANES I study (aged 26 to 46), 1.8% and 3.6% had hypocholesterolemia (entry TC < 130 mg/dL). Daily mean calorie, fat, and protein intake (grams per day) did not differ (P > .05) in men with entry TC less than 130 mg/dL compared with those with TC 130 to 230 or greater than 230 mg/dL. Hypocholesterolemia in white and black men in NHANES I could not be attributed to hypocaloric intake or to protein, fat, or carbohydrate undernutrition. There appear to be racial differences in the prevalence of hypocholesterolemia. Blacks comprised 18% of the firemen's cohort but 42% of those with persistent hypobetalipoproteinemia; among NHANES I subjects, 3.6% of blacks were hypocholesterolemic versus 1.8% of whites. Unless persistent hypobetalipoproteinemia reflects an underlying disease, alcoholism, etc., it is often heritable, and may be associated with a reduced likelihood of coronary heart disease (CHD) and with increased longevity.",
        "Doc_title":"Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I.",
        "Journal":"Metabolism: clinical and experimental",
        "Do_id":"9186296",
        "Doc_ChemicalList":"Blood Glucose;Cholesterol, HDL;Cholesterol, LDL;Triglycerides;Cholesterol",
        "Doc_meshdescriptors":"Adult;African Continental Ancestry Group;Analysis of Variance;Blood Glucose;Blood Pressure;Cholesterol;Cholesterol, HDL;Cholesterol, LDL;Cohort Studies;Cross-Sectional Studies;Diet;European Continental Ancestry Group;Follow-Up Studies;Health Surveys;Humans;Hypobetalipoproteinemias;Male;Middle Aged;Occupations;Prospective Studies;Triglycerides;United States",
        "Doc_meshqualifiers":"metabolism;blood;blood;blood;blood;epidemiology;blood",
        "_version_":1605819502297088000}]
  }}
